---
document_datetime: 2023-09-21 17:10:25
document_pages: 84
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/cosentyx-h-c-3729-ii-0001-g-epar-assessment-report-variation_en.pdf
document_name: cosentyx-h-c-3729-ii-0001-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 131.0464155
conversion_datetime: 2025-12-15 01:28:21.940371
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 October 2015 EMA/CHMP/665427/2015 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Cosentyx

International non-proprietary name: SECUKINUMAB

Procedure No. EMEA/H/C/003729/II/0001/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                 | 5                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ....................................................................................5   |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                       | ........................................................6                                                 |
| 2. Scientific discussion................................................................................                 | 7                                                                                                         |
| 2.1. Introduction                                                                                                        | ........................................................................................................7 |
| 2.2. Non-clinical aspects..............................................................................................8 |                                                                                                           |
| 2.2.1. Pharmacology...................................................................................................8  |                                                                                                           |
| 2.2.2. Pharmacokinetics                                                                                                  | ..............................................................................................9           |
| 2.2.3. Toxicology......................................................................................................  | 11                                                                                                        |
| 2.2.4. Ecotoxicity/environmental risk assessment.........................................................                | 11                                                                                                        |
| 2.2.5. Discussion on non-clinical aspects .....................................................................          | 11                                                                                                        |
| 2.2.6. Conclusion on the non-clinical aspects                                                                            | ............................................................... 11                                        |
| 2.3. Clinical aspects .................................................................................................. | 11                                                                                                        |
| 2.3.1. Introduction....................................................................................................  | 11                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                  | ............................................................................................ 12           |
| 2.3.3. Pharmacodynamics..........................................................................................        | 16                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                   | ............................................................................................. 17          |
| 2.3.5. Discussion on clinical pharmacology...................................................................            | 18                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................             | 19                                                                                                        |
| 2.4. Clinical efficacy                                                                                                   | .................................................................................................. 19     |
| 2.4.1. Dose response studies                                                                                             | ..................................................................................... 19                  |
| 2.4.2. Main studies                                                                                                      | ................................................................................................... 20    |
| 2.4.3. Discussion on clinical efficacy............................................................................       | 53                                                                                                        |
| 2.4.1. Conclusions on the clinical efficacy ....................................................................         | 55                                                                                                        |
| 2.5. Clinical safety                                                                                                     | .................................................................................................... 56   |
| 2.6. Safety in special populations                                                                                       | ............................................................................... 69                        |
| 2.6.1. Discussion on clinical safety..............................................................................       | 74                                                                                                        |
| 2.6.2. Conclusions on clinical safety ............................................................................       | 76                                                                                                        |
| 2.6.3. PSUR cycle .....................................................................................................  | 77                                                                                                        |
| 2.7. Risk management plan                                                                                                | ....................................................................................... 77                |
| 2.8. Update of the Product information........................................................................           | 79                                                                                                        |
| 2.8.1. User consultation                                                                                                 | ............................................................................................ 79           |
| 3. Benefit-Risk Balance.............................................................................                     | 80                                                                                                        |
| 4. Recommendations.................................................................................                      | 83                                                                                                        |
| 5. EPAR changes                                                                                                          | ....................................................................................... 83                |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ACR

American College of Rheumatology

ADA

Anti-drug antibodies

ADR

Adverse drug reaction

AE

Adverse event

AI

Autoinjector /pen

AIN457

Secukinumab

ALP

Alkaline phosphatase

ALT

Alanine aminotransferase

AS

Ankylosing spondylitis

AST

Aspartate aminotransferase

AUC

Area under the curve

AUCinf

Area under the curve from time 0 to infinity

AUClast

Area under the curve from time 0 to last measurable timepoint

AUCtau

Area under the curve between time interval

BSA

Body surface area

CASPAR

Classification criteria for psoriatic arthritis

Cavg

Average concentration

CHD

Coronary heart disease

CL

Clearance

Cmax

Maximum concentration

Cmax,ss

Maximum concentration at steady-state

Cmin,ss

Minimum concentration at steady-state

CRP

C-reactive protein

CSR

Clinical study report

CTCAE

Common terminology criteria for adverse events

CV

Coefficient of variation

CYP

Cytochrome

DAS28

Disease activity score

DAS28-CRP

Disease activity score - C-reactive protein

DAS28-ESR

Disease activity score - erythrocyte sedimentation rate

DDI

Drug-drug interaction

DLQI

Dermatology life quality index

DMARD

Disease modifying anti-rheumatic drug

ECG

Electrocardiogram

EMA

European Medicines Agency

EU

European Union

EULAR-CRP

European league against rheumatism - C-reactive protein

FAS

Full analysis set

FDA

Food and Drug Administration

GCP

Good clinical practice

GI

Gastrointestinal

HAQ-DI

Health assessment questionnaire - disability index

hsCRP

High sensitivity C-reactive protein

HLT

High level term

IBD

Inflammatory bowel disease

IGA mod 2011

Investigator's global assessment modified 2011

IL-17

Interleukin 17

IR

Incidence rate

iv

Intravenous

LoQ

List of questions

LYO

Lyophilisate

MACE

Major adverse cardiovascular event

MedDRA

Medical dictionary for regulatory activities

MCID

Minimum clinically important difference

MTX

Methotrexate

NMQ

Novartis MedDRA Query

NSAID

Non-steroidal anti-inflammatory drug

PASI

Psoriasis area and severity index

PCS

Physical component summary

<div style=\"page-break-after: always\"></div>

| PFS         | Pre-filled syringe                                                                                      |
|-------------|---------------------------------------------------------------------------------------------------------|
| PD          | Pharmacodynamic                                                                                         |
| PK          | Pharmacokinetic                                                                                         |
| PoC         | Proof of concept                                                                                        |
| PPK         | Population pharmacokinetic                                                                              |
| PsA         | Psoriatic arthritis                                                                                     |
| PT          | Preferred term                                                                                          |
| q4w         | Once every 4 weeks                                                                                      |
| RA          | Rheumatoid arthritis                                                                                    |
| RMP         | Risk management plan                                                                                    |
| SAE         | Serious adverse event                                                                                   |
| sc          | Subcutaneous                                                                                            |
| SCE         | Summary of clinical efficacy                                                                            |
| SCP         | Summary of clinical pharmacology                                                                        |
| SCS         | Summary of clinical safety                                                                              |
| SD          | Standard deviation                                                                                      |
| SF-36       | Medical outcome short form (36) health survey                                                           |
| SmPC        | Summary of product characteristics                                                                      |
| SMQ         | Standardized MedDRA Query                                                                               |
| SOC         | System organ class                                                                                      |
| t max       | Time to maximum concentration                                                                           |
| t 1/2       | Terminal half-life                                                                                      |
| TNFα        | Tumour necrosis factor alpha                                                                            |
| TNFα-IR     | TNFα inhibitor inadequate responder                                                                     |
| ULN         | Upper limit of normal                                                                                   |
| URTI        | Upper respiratory tract infections                                                                      |
| US          | United States                                                                                           |
| vdH-mTSS    | van der Heijde-modified Total Sharp Score                                                               |
| VPC         | Visual predictive check                                                                                 |
| V z WPAI-GH | Volume of distribution during terminal phase Work productivity and activity impairment - general health |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Novartis Europharm Ltd submitted to the European Medicines Agency on 6 March 2015 an application for a group of variations.

The following variations were requested in the group:

| Variations requested   | Variations requested                                                                                                                          | Type    | Annexes affected   |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                | Type II | I and IIIB         |
| C.I.11.z               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | Type IB | None               |

Extension of Indication to include new indication for Cosentyx in the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate as monotherapy or in combination with methotrexate (MTX); as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, and 5.2 of the SmPC are updated in order to update the safety and efficacy information. The Package Leaflet is updated in accordance. Furthermore, minor editorial changes have been introduced throughout the PI and updated RMP has been also submitted. In addition, the MAH proposed to update the due date of the Psoriasis registry in the RMP (category 3 study).

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/0247/2014 on the agreement of a paediatric investigation plan (PIP) and the granting of a (productspecific) waiver.

At the time of submission of the application, the PIP EMEA-000380-PIP02-09-M02 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan  medicinal  products  because  there  is  no  authorised  orphan  medicinal  product  for  a  condition related to the proposed indication.

## MAH request for additional one year marketing protection

With this application, the MAH requested an additional one year marketing protection in accordance with Article 14(11) of Regulation (EC) No 726/2004. In view of a positive opinion on an additional year of marketing protection granted for the parallel extension of indication procedure

<div style=\"page-break-after: always\"></div>

(EMEA/H/C/0003729/II/02) the MAH withdrew the request.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Tuomo Lapveteläinen

Co-Rapporteur:

Kristina Dunder

| Timetable                                   | Actual dates      |
|---------------------------------------------|-------------------|
| Submission date                             | 6 March 2015      |
| Start of procedure:                         | 28 March 2015     |
| CHMP Rapporteur Assessment Report           | 26 May 2015       |
| CHMP Co-Rapporteur Assessment Report        | 26 May 2015       |
| PRAC Rapporteur Assessment Report           | 26 May 2015       |
| PRAC members comments                       | 4 June 2015       |
| PRAC Outcome                                | 11 June 2015      |
| Updated PRAC Rapporteur Assessment Report   | 16 June 2015      |
| CHMP members comments                       | 15 June 2015      |
| Updated CHMP Rapporteur Assessment Report   | 18 June 2015      |
| Request for supplementary information (RSI) | 25 June 2015      |
| CHMP Rapporteur Assessment Report           | 28 September 2015 |
| PRAC Rapporteur Assessment Report           | 28 September 2015 |
| PRAC members comments                       | 30 September 2015 |
| Updated PRAC Rapporteur Assessment Report   | 2 October 2015    |
| PRAC Outcome                                | 8 October 2015    |
| CHMP members comments                       | 12 October 2015   |
| Updated CHMP Rapporteur Assessment Report   | 16 October 2015   |
| Opinion                                     | 22 October 2015   |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Cosentyx (secukinumab, AIN457) belongs to the Pharmacotherapeutic group of Interleukin inhibitors (ATC Code: L04AC10).  Secukinumab is a first in class recombinant high-affinity, fully human monoclonal anti-human antibody of the IgG1/kappa isotype that selectively targets interleukin 17A (IL-17A). IL-17A, produced by a subset of T helper cells, named Th17, but also by other T cells, neutrophils and mast cells, promotes the expression of other pro-inflammatory cytokines as well as effector proteins. This cascade results in the activation of neutrophils and macrophages as well as epithelial cells and fibroblasts, and is considered to play an important role in the pathophysiology of many autoimmune diseases, including psoriasis and psoriatic arthritis (PsA). This new mechanism of action offers greater specificity and selectivity in targeting the specific downstream cytokine.

Cosentyx (secukinumab) was approved on 15 Jan 2015 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.  Cosentyx is available in three different pharmaceutical forms: 150 mg powder for solution for injection (also referred to as Lyo in vial), 150 mg solution for injection in pre-filled syringe (also referred to as PFS), and 150 mg solution for injection in pre-filled pen (also referred to as AI or Pen). The recommended dose in psoriasis is 300 mg of secukinumab by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg.

The current type II variation application was to register a new indication of psoriatic arthritis (PsA). PsA is a chronic debilitating disease which afflicts peripheral synovial, axial, and entheseal structures and is associated with nail involvement and skin psoriasis in up to 30 % of patients. Current therapies include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor alpha (TNFα) inhibitors. Although TNFα inhibitor therapy has dramatically improved the treatment, 30% to 40% of patients fail to respond to these therapies. There are new agents with alternate mechanisms of action such as ustekinumab and apremilast but there still remains an unmet need for agents with novel mechanism of action.

The PsA clinical development program for secukinumab included patients with active PsA disease despite current or previous NSAIDs, DMARDs, and/or TNFα inhibitor therapy. The proposed new indication was:

Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease- modifying anti- rheumatic drug (DMARD) therapy has been inadequate.

The proposed posology was:

For patients with concomitant moderate to severe plaque psoriasis or who are anti TNFα inadequate responders (TNFa-IR), the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg.

For other patients, the recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4.

The PsA clinical development program included two phase II studies (A2206 in PsA patients and F2201 in a related arthritic condition RA) and two pivotal phase III studies in the target indication and population (F2306 and F2312).

<div style=\"page-break-after: always\"></div>

The development of new products for the treatment of psoriatic arthritis is covered in the Guideline on clinical investigation of medicinal products indicated for the treatment of psoriatic arthritis (CHMP/EWP/438/04). Recommendations of this guideline were mostly taken into account.

## 2.2. Non-clinical aspects

## 2.2.1. Pharmacology

## Primary pharmacodynamic studies

Neutralization of human IL-17A-, IL-17AF-dependent production of MMP-3 by human synovial fibroblasts

The in  vitro neutralising  activity  of  secukinumab  for  IL-17-induced  metalloproteinase  production  was evaluated  by  studying  the  inhibition  of  human  MMP-3  release  from  primary  human  fibroblast-like synoviocytes  (FLS)  stimulated  with  either  human  IL-17A  or  IL-17AF  in  combination  with  a  fixed concentration of 60 pM of human TNFα.

FLS  were  costimulated  with  30  pM  IL17A  and  60  pM  TNFa.  Secukinumab  neutralised  the  induction  of MMP-3  secretion  potently  and  in  a  dose-dependent  manner  with  an  IC50  value  of  0.067  ±  0.004  nM (mean ± SEM, n=3; Figure 1 ). The heterodimer IL-17AF, which is less potent than IL-17A, was used at a 33-fold higher concentration (1 nM IL-17AF vs 30 pM IL-17A) to achieve comparable MMP-3 levels. Under these  conditions,  secukinumab  neutralized  IL-17AF-dependent  effects  in  the  nanomolar  range  with  an IC50 value of 4.471 ± 0.595 nM (mean ± SEM, n=3; Figure 2 ).

Figure 1. Inhibitory effect of secukinumab (AIN457) on MMP-3 secretion by human FLS costimulated with IL-17A/ TNFa

<!-- image -->

Primary  human  FLS  were  co-stimulated  overnight  with  IL-17A  (30pM)/  TNFa  (60pM)  in  the  presence  of  increasing concentration of secukinumab (AIN457) or control IgG1. MMP-3 release was measured by AlphaLISA.

Overall,  the  inhibition  of  MMP-3  release  by  secukinumab  is  in  the  similar  range  as  the  previously described inhibition of IL-6 release from FLS by the antibody, where an IC50 value of 0.14 ± 0.02 nM was determined for IL-17A (30 pM)/ TNFα co-stimulation, and an IC50 value of 3.30 ± 0.20 nM for IL-17AF (1 nM)/ TNFα-induced effects (RD-2013-00026). Therefore, sub-nanomolar or nanomolar concentrations of secukinumab were sufficient to neutralize human IL-17A- and IL-17AF-dependent release, respectively, of pro-inflammatory and tissue-degrading mediators from human primary FLS. Since MMP-3 plays a role in

<div style=\"page-break-after: always\"></div>

tissue degradation (Burrage et al , 2006), these data suggest that neutralization of the bioactivity of IL17A  and/or  IL-17AF  may  contribute  to  the  inhibition  of  the  structural  damage  in  inflammatory  and autoimmune diseases including rheumatoid arthritis and psoriatic arthritis.

Figure 2. Inhibitory effect of secukinumab (AIN457) on MMP-3 secretion by human FLS costimulated with IL-17AF/ TNFa

<!-- image -->

Primary  human  FLS  were  co-stimulated  overnight  with  IL-17AF  (1nM)/  TNFa  (60pM)  in  the  presence  of  increasing concentration of secukinumab (AIN457) or control IgG1. MMP-3 release was measured by AlphaLISA.

## 2.2.2. Pharmacokinetics

A comparison of PK parameters in cynomolgus monkeys and humans after intravenous administration is presented in Table 1 . The similar PK characteristics observed in the cynomolgus monkey and PsA and AS patients are in line with the comparable binding activities of secukinumab to cynomolgus monkey and human neonatal Fc receptor (FcRn).

## Human exposure multiples

Using a population PK model based on pharmacokinetic data from several i.v. and s.c. studies in PsA and AS patients, mean concentration-time profiles resulting from the dose regimens in the phase III program were simulated. This allowed the calculation of human exposure multiples for the 300 or 150 mg s.c. dosing regimens in PsA patients with loading doses at Weeks 0, 1, 2, and 3, followed by maintenance doses every four weeks (q4w) starting at Week 4 until week 48.

For the calculation of human exposure multiples, use was made of i) the experimental maximum concentration at steady-state, Cmax,ss, (5455 μg/mL) and ii) the experimental AUCtau at steady-state divided by the dosing interval tau to obtain the average steady-state concentration Cav,ss (4824 μg/mL) for the 13 week toxicology study in cynomolgus monkey with single weekly s.c. administration at the NOAEL of 150 mg/kg. Exposure data and exposure multiples for the loading and maintenance phases are given in Table 2 .

## Table 1. Comparative PK in cynomolgus and PsA and AS patients

<div style=\"page-break-after: always\"></div>

| Parameters             | Cynomolgus monkey   | Cynomolgus monkey   | PsA patients    | AS patients     |
|------------------------|---------------------|---------------------|-----------------|-----------------|
|                        | Sp2/0               | CHO b               | CHO             | CHO             |
| Dose                   | 10 mg/kg i.v.       | 10 mg/kg i.v.       | 2x10 mg/kg i.v. | 2x10 mg/kg i.v. |
| Cmax (μg/mL)           | 253 e               | 319 e               | 424             | 364             |
| CL (mL/day/kg)         | 2.76                | 1.8                 | 1.9             | 2.0             |
| Vz (mL/kg)             | n.a.                | n.a.                | 81.1            | 78.7            |
| Vss (mL/kg)            | 74.5                | 59.0                | n.a.            | n.a.            |
| T1/2 (day)             | 20.1                | 24.0                | 29.8            | 28.1            |
| F (%)                  | 94                  | 62                  | 85 f            | 79 f            |
| (s.c. bioavailability) | (15 mg/kg s.c)      | (15 mg/kg s.c.)     |                 |                 |

a) Parameters from [DMPK R0400373]

b) Parameters from [DMPK R0600743-1]

- c) Results from [Study CAIN457A2206] with CHO-derived material, clearance and distribution volume normalized for a typical PsA patient with a mean body weight of 84 kg
- d) Results from [Study CAIN457A2209] with CHO-derived material, clearance and distribution volume normalized for a typical AS patient with a mean body weight of 77 kg
- e) values are C(0) = extrapolated initial drug level after i.v. administration

f) Source: [SCP - section 1.2.1]

n.a.: not available

Table 2. Comparative systemic exposure in cynomolgus monkey and PsA patients

| Patients                                                         | Exposuremultiples   | Exposuremultiples            | Exposuremultiples                               | Exposuremultiples                                                     | Exposuremultiples                                |
|------------------------------------------------------------------|---------------------|------------------------------|-------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------------|
|                                                                  |                     |                              | Loading                                         | Maintenance                                                           | Maintenance                                      |
| Dose regimen                                                     | Cav,ss (μg/mL)a,e   | Cmax,ind/ Cmax,ss (μg/mL)b,e | Based on Cmax,ss of 5455 μg/mL at 150 mg/kg S.c | Based on AUC7d,ss/7d (Cav,ss) of 4824 μg/mL at NOAEL of 150 mg/kg s.c | Based on Cmax,ss of 5455 μg/mL at 150 mg/kg S.C. |
| 150 mg s.c. at w 0,1,2,3 then 150 mg s.c. q4w starting at week 4 | 25.1                | 61.2/ 31.8                   | 89                                              | 192                                                                   | 172                                              |
| 300 mg s.c. at w 0,1,2,3 then 300 mg s.c. q4w starting at week 4 | 50.3                | 122 / 63.6                   | 45                                              | 96                                                                    | 86                                               |

- a) Cav,ss is the average secukinumab concentration (=AUCtau/tau; tau = 28 days) during maintenance at steady-state.
- b)  Cmax,ind  is  the  maximum  secukinumab  concentration  after  the  5th  dose  in  the  loading  phase; Cmax,ss is the maximum secukinumab concentration during maintenance at steady state.
- c) Predicted Cmax,ind in patients were compared with Cav,ss and Cmax,ss, respectively, at the NOAEL of 150  mg/kg  s.c.  in  the  13  weeks  tox  study  in  cynomolgus  monkey  in  order  to  calculate  the  exposure multiple during loading; tau (dosing interval) is 7 days in the cynomolgus tox study and in the clinical studies in patients.
- d) Predicted Cav,ss and Cmax,ss in patients were compared with Cav,ss and Cmax,ss, respectively, at the NOAEL of 150 mg/kg s.c. in 13 weeks study in cynomolgus monkey in order to calculate the exposure multiple during maintenance; tau (dosing interval) is 7 days in the cynomolgus tox study and 28 days in patients in the maintenance phase.
- e) Derived PK characteristics for mean simulated human exposure profiles

<div style=\"page-break-after: always\"></div>

The average serum concentrations at steady-state observed in monkeys after 13 weekly s.c. doses were 192-  and  96-fold  higher  than  the  predicted  average  serum  concentrations  expected  in  PsA  patients treated  with  monthly  maintenance  s.c.  doses  of  150  mg  and  300  mg  respectively.  At  the  end  of  the loading  phase,  human  exposure  is  approximately  2-fold  higher  than  during  the  maintenance  phase. Therefore, exposure multiples are approximately half of those described above during the maintenance phase.

For  assessment  of  non-target  related  toxicity  the  species  difference  in  binding  affinity  to  the  IL-17A receptor is not important, therefore human exposure multiple calculations on the basis of the exposure in man and animals were considered valid.

## 2.2.3. Toxicology

No new toxicity data were submitted in this application, which was considered acceptable by the CHMP.

## 2.2.4. Ecotoxicity/environmental risk assessment

Secukinumab is a high-affinity fully human monoclonal anti-human Interleukin-17A antibody and in accordance with the CHMP guideline on the environmental risk assessment (EMEA/CHMP/SWP/4447/00) is exempted from testing because of its chemical structure.

## 2.2.1. Discussion on non-clinical aspects

One new pharmacodynamics study addressing the neutralising effect of secukinumab on IL-17A and IL17AF-dependent production of MMP-3 by human synovial fibroblasts was included. The new data support the role of secukinumab in prevention of cartilage damage in PsA, AS and RA patients.

The  CHMP  considered  that  the  comparison  of  PK  characteristics  and  systemic  exposure  to  humans demonstrate  significant  exposure  margin  to  PsA  and  AS  patients  and  that  the  nonclinical  safety  data generated to support the initial marketing authorisation of Cosentyx for treatment of psoriasis patients were adequate and sufficient to support the indication in PsA

## 2.2.2. Conclusion on the non-clinical aspects

Non clinical data submitted in this application, are sufficient to support the use of secukinumab in the new indication

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

## Summary of Phase 2 studies used for dose selection

| Study                | Description             | N                    | Treatments                                                                     | Key Efficacy         | Key Conclusions                                                                            |
|----------------------|-------------------------|----------------------|--------------------------------------------------------------------------------|----------------------|--------------------------------------------------------------------------------------------|
| Psoriatic Arthritis  | Psoriatic Arthritis     | Psoriatic Arthritis  | Psoriatic Arthritis                                                            | Psoriatic Arthritis  | Psoriatic Arthritis                                                                        |
| A2206                | PoC (iv) PsA            | in 42                | 10 mg/kg secukinumab iv at R, Day 22 PBO iv at R, Day 22                       | ACR20 (Wk 6)         | Secukinumab demonstrated preliminary evidence for therapeutic benefit in patients with PsA |
| Rheumatoid Arthritis | Rheumatoid Arthritis    | Rheumatoid Arthritis | Rheumatoid Arthritis                                                           | Rheumatoid Arthritis | Rheumatoid Arthritis                                                                       |
| F2201                | Dose-ranging (sc) in RA | 237                  | 25, 75, 150 or 300 mg secukinumab sc at R, Wks 4, 8, 12 PBO at R, Wks 4, 8, 12 | ACR20 (Wk 16)        | Secukinumab 75-300 mg sc showed efficacy in RA                                             |

## Summary of Phase 3 controlled, randomized, blinded trials

| Study             | Description                                                           | N Treatments                                                                                                                                                                         | Primary endpoint   |
|-------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| F2306 (PE: 24 Wk) | Efficacy/safety in target population (iv load / sc every 4 weeks) 606 | 10 mg/kg iv secukinumab, PBO at Wks 0, 2, 4, followed by 75, 150 mg sc q4w from Wk 8 to Wk 104 PBO iv at Wks 0, 2, 4, followed by sc q4w at Wks 8 and 12 a or Wks 8 to 20 b          | ACR20 at Wk 24     |
| F2312 (PE: 24 Wk) | Efficacy/safety in target population (sc load / sc every 4 weeks) 397 | 75, 150, 300 mg sc secukinumab in pre-filled syringe (PFS) at Wks 0, 1, 2 and 3, then q4w from Wk 4 to Wk 256 PBO sc at Wks 0, 1, 2 and 3 then q4w at Wks 4 to 12 c or Wks 4 to 20 d | ACR20 at Wk 24     |

ACR = American College of Rheumatology; iv =intravenous; N = number of patients included in efficacy analysis (Full Analysis Set); PBO = placebo; PE = Primary Endpoint  analysis  at Week  24;  PFS  =  pre-filled  syringe;  PoC  =proof  of  concept;  R  =  randomization (baseline); sc = subcutaneous; q4w = once every 4 weeks; Wks = weeks

a PBO non-responders (&lt;20% improvement from baseline in both tender and swollen joint counts) were re-randomized 1:1 to receive either secukinumab 75 or 150 mg sc q4w starting at Wk 16

b PBO responders (≥20% improvement from baseline in both tender and swollen joint counts) were re-randomized 1:1 to receive either secukinumab 75 or 150 mg sc q4w starting at Wk 24

c PBO non-responders (&lt;20% improvement from baseline in both tender and swollen joint counts) were re-randomized 1:1 to receive either secukinumab 150 or 300 mg sc q4w starting at Wk 16

d  PBO responders (≥20% improvement from baseline in both tender and swollen joint counts) were re-randomized 1:1 to receive either secukinumab 150 or 300 mg sc q4w starting at Wk 24

## 2.3.2. Pharmacokinetics

Secukinumab displays PK properties typical of a human IgG1-type immunoglobulin interacting with a soluble target, i.e. a low clearance and a low total volume of distribution. The PK properties of secukinumab in patients with PsA were described using population PK analysis. The studies included in the analysis are described in Table 3 .

## Table 3.  Studies included in the PPK analysis.

<div style=\"page-break-after: always\"></div>

| Study   | Description                                | Regimens                                                                                                                                                                                                                                                                                                      | Note                                                                                                                  |
|---------|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| A2206   | PoC PD study of efficacyof AIN457          | ·2 x 10 mg/kg i.v. q3w ·placebo                                                                                                                                                                                                                                                                               | PK samples taken pre- dose,2,3,4 and 24 hoursafterinfusion,and then atweeks1,2,3,4, 6,8,10,12,16,20and 24/end ofstudy |
| F2306*  | Phase IIl efficacy safety and tolerability | ●3 x 10 mg/kg i.v. q2w + 150 mg s.c.q4w from week 8 ●3x 10 mg/kg i.v.q2w + 75 mg s.c.q4w fromweek8 ·placebo+150mg s.c.q4wfrom week24 ·placebo +75mg s.c.q4wfrom week 24 ·placebo + 150 mg s.c.q4w from week 16 ·placebo+75 mg s.c.q4wfrom week 16 ·placebo                                                    | PKsamples at weeks 0, 4,16,24,52                                                                                      |
| F2312** | Phase III efficacy,safety and tolerability | ●4x300 mg s.c.q1w + 300 mg s.c.q4w from week 4 ·4x 150 mg s.c.q1w + 150 mg s.c.q4w fromweek4 ●4 x 75 mg s.c.q1w + 75mg s.c. q4w from week 4 ·placebo + 300 mg s.c. q4w from week 24 ·placebo + 150 mg s.c.q4w from week 24 ·placebo+300mg s.c.q4wfromweek16 · placebo + 150 mg s.c. q4w from week 16 ·placebo | PK samples at weeks 0, 4,16, 24                                                                                       |

*F2306:Week52interimlock

**F2312:Week24interimlock

Based on the final model and parameter estimates ( Table 4 ), PK profiles were simulated and secondary exposure metrics such as AUC, Cavg, Cmin, Cmax, Tmax, and t1/2 were derived.

Table 4. Parameters of the final PK model

| Name                              | Value        | %RSE   | Shrinkage (%)   |
|-----------------------------------|--------------|--------|-----------------|
| Structural parameters             |              |        |                 |
| CL [L/day]                        | 0.19         | 2      |                 |
| Vc[L]                             | 3.66         | 4      |                 |
| Q [L/day]                         | 0.54         | 10     |                 |
| Vp1 [L]                           | 2.45         | 5      |                 |
| ka [1/day]                        | 0.18 (fixed) |        |                 |
| Fabs1 (bioavailability)           | 85%          | 2      |                 |
| Covariate effect                  |              |        |                 |
| WTO on CL                         | 0.71         | 8      |                 |
| WTO on Vc                         | 0.44         | 37     |                 |
| WTO on Vp1                        | 0.72         | 25     |                 |
| Inter-individual variability(std) |              |        |                 |
| IIV on CL                         | 0.32         | 3      | 7.9             |
| IIV on Vc                         | 0.36         | 8      | 33              |
| IIV on Q1                         |              |        |                 |
| IIV on Vp1                        | 0.3          | 11     | 53              |
| IIV on ka                         |              |        |                 |

<div style=\"page-break-after: always\"></div>

| IIV on Fabs1                     |       |    |
|----------------------------------|-------|----|
| Covariance                       |       |    |
| CL-Vc (corr)                     | 0.66  | 8  |
| Residualvariability              |       |    |
| Additive error (std)             | 2.37  | 5  |
| Proportional error (std)         | 0.11  | 4  |
| Objective Function Value (BIC)   | 21604 |    |
| Objective Function Value (-2xLL) | 20511 |    |

A two-compartment model, with first-order absorption (for sc drug administration) and zero-order infusion (for iv drug administration) adequately described secukinumab PK profiles.

## Absorption

On the basis of the PPK model the mean maximum concentrations (Cmax) at steady-state following sc loading + 150 mg sc and 300 mg sc maintenance dose were estimated to be 31 µg/ml and 62.1 µg/ml and occurred at approximately 6 days after dose in PsA patients. The Cmax at steady-state is approximately 2 times higher than the Cmax after the single-dose.

## Bioavailability

On the basis of the PPK model, the bioavailability after sc administration is 85% in PsA patients.

## Distribution

Estimation from the PPK model indicated a low total volume of distribution (central compartment volume of 3.66 l (CV% 30.5) and peripheral compartment volume of 2.45 l (CV% 30.6) in a typical PsA patient weighing 84 kg.

## Elimination

Secukinumab has a terminal half-life (t1/2) averaging 25 days with an inter-patient variability of 27.5% and secukinumab has slow serum clearance (CL = 0.19 l/day, CV% 32.5%) on the basis of the PPK model.

Clearance and volumes of secukinumab vary with body weight in an allometric relationship. For CL and central volume of distribution the allometric exponents were estimated to be 0.8 and 0.4 respectively. CRP at baseline, race (non-Asian vs Asian), and anti-TNFα response status did not have a clinically relevant influence on CL (after adjusting for bodyweight).

## Excretion

No specific elimination studies have been performed and this is acceptable because secukinumab is not expected to be excreted in urine or secreted into the bile.

## Metabolism

The majority of IgG elimination occurs via intracellular catabolism, following fluid-phase or receptor mediated endocytosis.

## Dose proportionality and time dependencies

On the basis of the PPK model the PK of secukinumab is linear with no evidence of a time dependent change in the CL. There is also no evidence of a dose-dependence of CL. On the basis of the study

<div style=\"page-break-after: always\"></div>

CAIN457F2312 there was an evidence of dose-proportionality in exposure (mean concentrations at steady-state) across the 75 mg, 150 mg and 300 mg during the sc administration.

Dose-independency of secukinumab CL was demonstrated by plotting the individual estimates of CL from the PPK model against the treatment regimens ( Figure 3 ).

Figure 3. Relative CL by treatment group (after adjusting for bodyweight)

Relative CL indicates relative to the CL of 0.19 l/day in a 'typical subject' (e.g., a value of 0.1 indicates a 10% relative increase in CL).

<!-- image -->

The estimated CL in the clinical phase III studies CAIN457F2306 and CAIN457F2312 was generally consistent across the active study groups. In the study CAIN457A2206 the CLs were lower (exposures were higher) compared to the other phase III studies, but this was considered to be a chance finding.

## Exposure in target population

No clinically relevant differences in secukinumab PK were observed between the various autoimmune diseases studied (AS, PsA, PsO, RA, CD, AS, non-infectious uveitis). PK is also similar when compared between healthy volunteers, PsA and AS patients. Furthermore, PK similarity was observed between the lyophilisate formulation (LYO) and solution and between the three forms LYO, prefilled syringe (PFS) and auto-injector/pen (AI). The exposure profiles of a typical patient given the proposed dosing are illustrated in Figure 4 .

Figure 4. Simulated concentration profiles of s.c. loading + s.c. maintenance 300 mg, 150 mg and 75 mg phase III regimens

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Special populations

No clinical studies were performed in patients with impaired hepatic or renal function and that was considered acceptable because no great effect on exposure is anticipated on the assumption that secukinumab has typical IgG pharmacokinetic properties.

## Pharmacokinetic interaction studies

No in vitro or in vivo drug-drug interaction studies were performed.

The PPK results in PsA patients with secukinumab indicated that MTX had no impact on the disposition of secukinumab. However, as no data of concomitant use of MTX (and glucocorticoids) in PsA patients (or in AS patients) were available in the initial submission the MAH was requested to justify that MTX and glucocorticoids have no impact on the disposition of secukinumab. The MAH provided further analyses from the phase III studies for patients with and without concomitant methotrexate or glucocorticoid use which showed that there were no systematic trends, either downward or upward, in concentrations of one subgroup versus the other. Therefore, the following sentence was proposed to be added to the Cosentyx SmPC: 'No interaction was seen when Cosentyx was administered concomitantly with MTX and/or corticosteroids in arthritis studies (including in patients with PsA and AS)', which was accepted by the CHMP.

## 2.3.3. Pharmacodynamics

## Mechanism of action

The pharmacodynamic effect of secukinumab in binding to IL-17A, and inhibiting IL-17A signalling, is linked with the reduction of the inflammatory processes of PsA. Based on the data provided within the initial MAA, the engagement of IL-17A was seen as an increase in serum total IL-17A levels after secukinumab treatment, followed by a slow release of the IL-17A-secukinumab complex.

## Primary and secondary pharmacology

A meta-analysis entitled Total Interleukin 17A analysis report (Release date: 06-Feb-2015 was provided in order to assess the total IL-17A levels from eight phase I, IIb and phase III clinical trials which were either not part of the clinical study reports or only partly summarized in the CSR (Studies A1101, A2206, A2209, A2212, A2220, A2309, F2201 and F2208).

Pharmacodynamic blood samples for quantification of total IL-17A (i.e., the sum of free and secukinumab bound IL-17 in serum) were taken at the same time points as for pharmacokinetic. The MESO Scale Discovery electrochemiluminescence assay was used.

Study A2206 i.e., the Proof-of-Concept study in PsA was included in the meta-analysis. The median total IL-17A concentration-time profile after a dose of 10 mg/kg iv on Days 0 and 22 is shown in Figure 5 . The highest median concentration was 107 pg/mL, observed 2 weeks after the first dose, followed by slowly declining concentrations from 90 to 50 pg/mL during a half year time.

## Figure 5. Median total IL-17A serum concentration-time profiles (A2206)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Based on the meta-analysis, the increase in total IL-17A concentrations at post dose time points is due to binding to secukinumab to form an IL-17A-secukinumab complex which has slower clearance than that of uncomplexed IL-17A. The decrease after treatment reflects the decrease in secukinumab concentrations.

In  summary,  total  IL-17A  profiles  across  studies  in  both  healthy  subjects  and  patient  populations (psoriasis,  psoriatic  arthritis,  ankylosing  spondylitis,  rheumatoid  arthritis)  show  concentration-time patterns that are consistent with target engagement of secukinumab.

## 2.3.4. PK/PD modelling

The MAH provided a population PK (PPK) modelling report with the pooled PPK analysis of Cosentyx in PsA.  The data were collected l from the following studies: CAIN457A2206, CAIN457F2306 and CAIN457F2312. Graphical exploratory analysis of Cosentyx exposure -response of efficacy, adverse events (AEs) and radiographic assessments in PsA patients were also provided.  The focus was on describing exposure-response trend at a fixed time point, rather than through longitudinal PK/PD modelling.

The 2-compartment PK model adequately described the observed concentration-time profiles for sc and iv secukinumab in PsA patients.  The influence of covariates on the individual PK was explored. The following covariates were investigated: bodyweight, age, gender, race (non-Asian vs. Asian), disease activity assessed by the PASI score, DAS28 score and CRP level at baseline, previous use of biologics, response status to anti-TNFα therapy, concomitant use of methotrexate, and time since first diagnosis of psoriatic arthritis. They were tested using a full covariate modelling approach. Only the effect of bodyweight was considered clinically relevant based on an assumption that only changes in typical parameter estimates &gt;20% are clinically important. Dose dependency or time dependency was not seen. The PK properties were as expected for an IgG antibody and the PPK model parameters were similar to a previous PPK analysis of secukinumab in psoriasis patients.

In the graphical analysis, a comparison of Cmin concentrations between patients &lt; 90 kg and ≥ 90 kg showed that the heavier patient the lower exposure. This is in line with findings from the PPK analysis and the known impact of body weight on the PK of mAbs. Also in the clinical studies with psoriasis patients, the body weight of the patients was demonstrated to have an effect on the exposure.  The results of this exploratory analysis were limited to the sc loading regimen tested in study CAIN457F2312 (loading dose on weeks 0, 1, 2, 3, 4, followed by Q4W dosing).

Clear exposure-response relationships were observed in all efficacy parameters (ACR, PASI, DAS and HAQ-DI), with a trend for increased response with higher Cmin concentrations. The exposure-response relationship of endpoints reflecting the arthritic components of the disease (ACR20/50/70, DAS28-CRP) appeared to plateau at Cmin level higher than ca. 20 µg/ml. This concentration (20 µg/ml) generally corresponds to the typical steady-state Cmin achieved following a 150 mg sc Q4W dosing.

<div style=\"page-break-after: always\"></div>

Exposure-response relationships of PASI75/90 and HAQ-DI demonstrated a trend for a monotonous increase in response over the concentration range.

No evidence of an effect of Cmin was observed on AE rates for the following categories: any AE, infections and infestations, upper respiratory tract infections, nasopharyngitis, and urinary tract infection. There was an increasing trend with exposure for SAEs and oral herpes. However, its interpretation was complicated by the fact that it appeared to be driven by lower AE rates in the first two exposure categories ([0, 10] and [10, 20] µg/mL) and higher AE rate in the last exposure category (&gt;30 µg/mL) when compared to the placebo group (0 µg/mL). Also, the slope coefficients were not statistically significant at the 0.1 level for those AE categories. It was therefore difficult to conclude for a Cmin-related effect in both cases.

## 2.3.5. Discussion on clinical pharmacology

The PK data of secukinumab in PsA patients were provided from 3 clinical studies. In addition, simulated PK data from the PPK model and a graphical exploratory analysis of exposure-response of efficacy, AEs and radiographic assessments were presented.

In the clinical study CAIN457A2206, the studied secukinumab dose was 10 mg/kg as an iv infusion administered twice by 3 weeks interval (also placebo group). For evaluation of the PK of secukinumab, the chosen dosing regimen was not optimal because the 2nd dose was administered, while there were still substantial amounts of drug from the 1st dose. The reported PK parameters for secukinumab were quite similar as earlier seen in the study with similar dosing regimen and route with psoriasis patients.

In the extension study (CAIN457A2206E1), the studied secukinumab dose was 3 mg/kg administered as an iv infusion monthly up to 6 months (with a possible extension of a further 6 months).The steady-state was reached on the basis of the pre-dose and post-dose infusion serum concentrations after week 16. The Cmax,ss and Cmin,ss values of secukinumab were lower in the samples from patients, which received placebo in the study CAIN457A2206.

In the clinical study CAIN457F2306, the studied loading dose of secukinumab was 10 mg/kg iv at baseline, weeks 2 and 4, and thereafter the studied secukinumab doses were 75 mg and 150 mg s.c monthly (starting at week 8). At week 4, serum concentrations reflected the rise in exposure (the mean concentrations were about equal both after 75 mg and 150 mg sc). At week 16, mean concentrations declined due to the less-frequent sc dosing as the iv dosing. The mean secukinumab concentrations declined still at weeks 24 and 52. The mean secukinumab concentrations with 75 mg sc dose were 16.2 µg/ml and 10.2 µg/ml at weeks 24 and 52 and with 150 mg sc dose 24.4 µg/ml and 18.6 µg/ml, respectively. In this study, there were also patients who received placebo as the loading dose and at week 16 were classified as responder or non-responders. The non-responders received secukinumab 75 mg or 150 mg sc monthly and the responders remained on placebo until week 24 and thereafter received either secukinumab 75 mg or 150 mg sc. The mean secukinumab concentrations were at week 52 very close to those seen in the active secukinumab groups.

In the pivotal clinical study CAIN457F2312 the studied secukinumab doses were 75 mg or 150 mg or 300 mg sc weekly up to 4 week and thereafter monthly starting at week 4. In this study, there were also patients receiving placebo in the same study design as in the study CAIN457F2306, except the doses after the re-randomisation were 150 mg or 300 mg sc The dose-proportionality in the secukinumab concentrations was found at week 4 and also at steady-state (weeks 16 and 24). The mean secukinumab concentrations were in the expected range i.e., with 75 mg sc ~10 µg/ml , with 150 mg sc ~ 20 µg/ml and with 300 mg ~ 40 µg/ml.

<div style=\"page-break-after: always\"></div>

The inter-subject variation in the PK parameters of secukinumab after iv administration was low or moderate (16-33%). Based on the PPK model in PsA, the derived inter-subject variability for PK parameters such as Cmin,ss, Cmax,ss, Cavg,ss, AUCtau,ss for the 150 mg and 300 mg sc regimens was in the range of 31.4% and 45.0%. Estimates of intra-subject variability were not available from PsA patients. In the Cmin values the inter-subject variation was usually moderate (&gt; 30%).

On the basis of the PPK model, the PK of secukinumab is linear with no evidence of a time dependent change in the CL or dose-dependence of CL (CL = 0.19 l/day, CV% 32.5%).

On the basis of the PPK model, the bioavailability after sc administration was 85% in PsA patients being better than in psoriasis patients (66-77%).

The body weight of the patients was found to have an impact on secukinumab serum concentrations and also on efficacy. On the basis of the PPK model and graphical analysis the heavier the patient, the lower the Cmin concentrations were observed. There was also a trend that the higher the Cmin concentrations, the better response in efficacy. The Cmin,ss of secukinumab needed for the therapeutic effect was estimated to be about 20 µg/ml. This steady-state concentration is achieved for most patients with the proposed dosing regimen with 150 mg or 300 mg sc. The 75 mg sc was demonstrated to be not sufficiently effective. The applicant provided adequate secukinumab concentration data separately for patients &lt; 90 kg and ≥ 90 kg and discussion about the secukinumab concentrations and efficacy variables (i.e., ACR, PASI, DAS and HAQ-DI) in the pivotal clinical study CAIN457F2312. On the basis of the simulations etc. no consistent clinically meaningful benefit could be observed for the 300 mg dose over 150 mg in heavier patients.

Regarding the covariate effect in anti TNFa-IR patients, this appears to affect Emax rather than EC50 suggesting that these patients are likely to have a lower treatment effect even at the higher exposures. In contrast, the lower effect observed in patients in the upper weight category (&gt;90kg) appears to be attributed to a lower exposure as both EC50 and Emax are similar across weight groups.).

Age and gender do not appear to be significant predictors of secukinumab PK, why the tendency for age and gender related differences in response appear to be related to PD for these sub-groups.

In all clinical studies with PsA patients, there were pre-dose samples with quantifiable concentrations of secukinumab. The number of these samples; however, was relatively small and did not impact on interpretation of PK results.

## 2.3.6. Conclusions on clinical pharmacology

The pharmacokinetics of secukinumab in PsA patients was very similar as in the psoriatic patients.

## 2.4. Clinical efficacy

## 2.4.1. Dose response studies

## Study A2206

## A randomized, double-blind placebo-controlled multi-center proof-of-concept study to assess the efficacy of AIN457 in patients with psoriatic arthritis.

Study A2206 was a proof of concept study in patients with diagnosis of active psoriatic arthritis based on Classification Criteria or Psoriatic Arthritis (CASPAR). The patients received secukinumab 10 mg/kg iv or matching placebo on Days 1 and 22.

<div style=\"page-break-after: always\"></div>

ACR20 response rates on secukinumab and placebo at Week 6 did not differ significantly and the primary endpoint of the study was therefore not met.  However, preliminary evidence for therapeutic benefit of secukinumab in PsA patients was observed as numerically greater responses on secukinumab were seen.

## Study A2206E1

## An open label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with psoriatic arthritis.

Study A2206E1 was an open-label extension of the phase II proof of concept study A2206, with iv dosing 3 mg/kg q4w. The primary objective was to assess safety and tolerability of secukinumab. Patients previously treated with placebo in the core study achieved response rates similar to those initially treated with secukinumab, and the efficacy was maintained during the 52-week treatment period.

## Study F2201

A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous secukinumab (AIN457) followed by an extension phase up to a total of 60 weeks in patients with active rheumatoid arthritis despite stable treatment with methotrexate.

F2201 was a study in patients with active RA, with treatment up to Week 48 and a 12-week follow-up period.  Secukinumab was administered sc q4w with a dose range of 25 mg, 75 mg, 150 mg or 300 mg. No loading dose was given.

Although the primary efficacy endpoint (ACR20 response of secukinumab compared to placebo at Week 16) was not achieved, there was a clear numerical trend in favour of secukinumab 75-300 mg within the primary and the secondary efficacy variables.

Taken together, the initial doses and the dosing regimen in phase II studies were based on preclinical in vivo efficacy data in animal models from the initial MAA. The two phase II studies A2206 and F2201 provided preliminary evidence of efficacy in two arthritic disease models, PsA and RA. The posology carried forward to the phase III studies was mainly based on pK/PD modelling and simulation of different treatment regimens as well as data in psoriasis.

## 2.4.2. Main studies

## Study CAIN457F2306 ( also referred to as F2306)

A randomized, double-blind, placebo-controlled, multicentre study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active psoriatic arthritis.

## Methods

## Study participants

The main inclusion criteria are summarised below:

1. Male or non-pregnant, non-lactating female patients at least 18 years of age.
2. Diagnosis of PsA classified by CASPAR criteria  and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥ 3 tender joints out of 78 and ≥3 swollen joints out of 76 (dactylitis of a digit counts as one joint each).
3. RF and anti-CCP antibodies negative.

<div style=\"page-break-after: always\"></div>

4. Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥ 2 cm diameter (but not in intertriginous areas such as armpits, or chest between breasts, or groin) or nail changes consistent with psoriasis or a documented history of plaque psoriasis.
5. Patients with PsA should have been on NSAIDs for at least 4 weeks prior to randomization with inadequate control of symptoms or intolerant to NSAIDs.
6. Patients who were regularly taking NSAIDs as part of their PsA therapy were required to be on a stable dose for at least 2 weeks before study randomization and had to remain on a stable dose up to Week 24.
7. Patients taking corticosteroids were to be on a stable dose of ≤10 mg/day prednisone or equivalent for at least 2 weeks before randomization and had to remain on a stable dose up to Week 24.
8. Patients taking MTX (≤ 25 mg/week) were allowed to continue their medication if the dose was stable for at least 4 weeks.

The main exclusion criteria were:

1. Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or morphine)
2. Patients who had ever received biologic immunomodulating agents except for those targeting TNF alpha, investigational or approved.
3. Patients who had previously been treated with more than 3 different TNF alpha inhibitors (investigational or approved).
4. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or IL-17 receptor
5. Use of any investigational drug and/or devices within 4 weeks of randomization or 5 half lives of the investigational drug, whichever was longer.
6. Ongoing use of prohibited psoriasis treatments / medications (e.g., topical corticosteroids, UV therapy) at randomization. The following wash out periods were to be observed:
- a. Oral or topical retinoids 4 weeks
- b. Photochemotherapy (e.g. PUVA) 4 weeks
- c. Phototherapy (UVA or UVB) 2 weeks

d. Topical treatments (except in face, scalp and genital area during screening, only corticosteroids with mild to moderate potency) 2 weeks

7. Any intramuscular or i.v. corticosteroid treatment within 4 weeks before randomization

## Treatments

The study design is presented in Figure 6 .

At baseline, eligible patients were to be randomized to one of the following 3 treatment arms in a ratio of 1:1:1:

- Group 1: Secukinumab i.v. (10 mg/kg) at baseline, Weeks 2 and 4, then secukinumab 75 mg s.c. starting at Week 8 and injected every 4 weeks
- Group 2: Secukinumab i.v. (10 mg/kg) at baseline, Weeks 2 and 4, then secukinumab 150 mg s.c. starting at Week 8 and injected every 4 weeks

<div style=\"page-break-after: always\"></div>

- Group 3: Placebo i.v. at baseline, Weeks 2 and 4, then placebo s.c. starting at Week 8 and Week 12.

Figure 6.Schematic of Study F2306

<!-- image -->

At Week 16, all patients were to be classified as responders (≥20% improvement from baseline in both tender and swollen joint counts) or non-responders. Patients who were randomized to placebo at baseline were to be re-randomized by the IRT to receive double blind treatment up to two years, as follows:

- Patients on placebo (Group 3) who were responders remained on placebo until week 24. At Week 24,  these  patients  received  either  secukinumab  75  or  150  mg  every  4  weeks,  regardless  of responder status (as dictated by the re-randomization).
- Patients on placebo (Group 3) who were non-responders were to be re-randomized (1:1) at Week 16 to receive either secukinumab 75 mg or 150 mg sc every 4 weeks.

## Objectives

The primary objective was to demonstrate that the efficacy of secukinumab 75 or 150 mg at Week 24 was superior to placebo in patients with active psoriatic arthritis (PsA) based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.

The secondary objectives were to demonstrate that:

1. The efficacy  of  secukinumab  75  or  150  mg  at  Week  24  was  superior  to  placebo  based  on  the proportion of patients achieving a Psoriasis Area and Severity Index 75 (PASI75) response in the subgroup of patients who have ≥3% skin involvement with psoriasis.
2. The efficacy  of  secukinumab  75  or  150  mg  at  Week  24  was  superior  to  placebo  based  on  the proportion of patients achieving a PASI90 response in the subgroup of patients who have ≥3% skin involvement with psoriasis.

<div style=\"page-break-after: always\"></div>

3. The improvement (change) from baseline on secukinumab 75 or 150 mg was superior to placebo for the Disease Activity Score 28-CRP (DAS28-CRP) at Week 24.
4. The improvement (change) from baseline on secukinumab 75 or 150 mg was superior to placebo for the Short Form 36 (SF36)- Physical Component Summary (PCS) at Week 24.
5. The improvement (change) from baseline on secukinumab 75 or 150 mg was superior to placebo for the Health Assessment Questionnaire - Disability Index (HAQ-DI©) at Week 24.
6. The efficacy  of  secukinumab  75  or  150  mg  at  Week  24  was  superior  to  placebo  based  on  the proportion of patients achieving an ACR50 response.
7. The improvement (change) from baseline to Week 24 on secukinumab pooled regimen (75 mg and  150  mg  s.c.)  was  superior  to  placebo  for  joint/bone  structural  damage  (van  der  Heijde modified total Sharp score [vdH-mTSS]).
8. The efficacy of secukinumab pooled regimen (75 mg and 150 mg s.c.) at Week 24 was superior to placebo  based on  the  proportion  of  patients  with  dactylitis  in  the  subset  of  patients  who  have dactylitis at baseline.
9. The efficacy of secukinumab pooled regimen (75 mg and 150 mg s.c.) at Week 24 was superior to placebo based on the proportion of patients with enthesitis in the subset of patients who have enthesitis at baseline.
10. The improvement (change) from baseline to Week 24 on secukinumab 75 or 150 mg was superior to placebo for joint/bone structural damage (vdH-mTSS).
11. The overall safety and tolerability of each secukinumab regimen compared to placebo a assessed by  vital  signs,  clinical  laboratory  values,  electrocardiogram  (ECG)  and  adverse  events  (AEs) monitoring.

## Outcomes/endpoints

The primary efficacy endpoint was ACR20 response at Week 24.

The secondary efficacy endpoints were:

- PASI75 response at Week 24 in the subgroup of patients who had ≥3% skin involvement with psoriasis at baseline.
- PASI90 response at Week 24 in the subgroup of patients who had ≥3% skin involvement with psoriasis at baseline.
- Disease activity score DAS28-CRP at Week 24.
- SF36-PCS at Week 24.
- Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 24.
- ACR50 response at Week 24.
- Joint/bone structural damage (van der Heijde-modified total Sharp score [vdH-mTSS]).
- Proportion of patients with dactylitis at Week 24 in the subset of patients who have dactylitis at baseline.
- Proportion of patients with enthesitis at Week 24 in the subset of patients who have enthesitis at baseline.

<div style=\"page-break-after: always\"></div>

## Sample size

A 5% two-sided type I error rate was used to control for type I error. Two secukinumab doses were tested vs. placebo with respect to the primary endpoint (ACR20 response at Week 24), thus the type-Ierror was split to 2.5% two-sided for each comparison. Sample sizes were based on this type I error assumption.

For  the  primary  endpoint,  ACR20  in  the  overall  population,  200  patients  per  group  would  yield approximately  99%  power  to  detect  a  treatment  difference  in  the  response  rates  between  the secukinumab regimens and placebo with the above assumptions (Fisher's exact test, NQuery 7.0).

A total of 817 patients were screened and 606 patients were randomised to the treatment groups; 202 patients in each treatment group.

## Randomisation

At baseline (Visit 2), all eligible patients were randomized via the IRT (Interactive Response Technology) to one of the treatment arms ( 1:1:1 ratio) At Week 16 (Visit 8), all patients were classified as responders or non-responders. Patients who were randomized to placebo at baseline were re-randomized to receive double blind treatment up to 2 years.

Randomization was stratified according to being either TNFα inadequate responders (TNFa-IR) or TNFα inhibitor  naïve  patients.  30%  of  patients  were  to  be  TNFa-IR  to  ensure  a  representative  patient population for the assessment of efficacy and safety.

## Blinding (masking)

This was a double-blind study.

## Statistical methods

Summary statistics for continuous variables included N, mean, standard deviation minimum, lower quartile, median, upper quartile, and maximum. For binary or discrete variables the absolute number of patients in each category and relative frequencies were provided. If not otherwise specified, p-values and confidence intervals were two-sided and the level of significance was set to 5% (two-sided, family-wise type- I-error).

Statistical  analyses  of  efficacy  variables  were  performed  on  an  intent-to-treat  basis,  involving  all randomized  patients  who  were  assigned  to  study  treatment  (Full  analysis  set,  FAS).  A  sequentially rejective  testing  strategy  was  used  to  evaluate  the  study  hypotheses  for  the  primary  and  secondary variables (hypotheses H1 to H19) while retaining a family-wise type I error of 5%.

For  binary  variables  ( e.g., ACR20 response) a logistic regression model was  fitted with treatment and TNF-alpha inhibitor status as factors and baseline score (if appropriate) and weight as covariates. Missing responses were considered as non-responders. Continuous variables were evaluated using a mixed-effect model repeated measures (MMRM) which was valid under the missing at random (MAR) assumption.

The MAR assumption for missing data in MMRM analyses for continuous endpoints is questionable. It was defined that the data collected after the placebo patient switched to secukinumab at Week 16 was treated as missing. Thus the occurrence of these missing values at Week 24 is due to the study design and is not at  random.  The  MAH  conducted  additional  sensitivity  analyses  as  requested  and  confirmed  that  the conclusions of the clinical study report remain valid.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

A  total  of  817  patients  were  screened  and  606  were  randomized  to  the  3  treatment  groups.  Of  the randomized patients, 515 (85.0%) patients completed 52 weeks of treatment (86.1% in the secukinumab 10 mg/kg-75 mg group, 89.1% in the secukinumab 10 mg/kg-150 mg group and 79.7% in the placebo group ( Table 5 ).

Of  the  202  patients  in  the  placebo  group,  187  patients  were  re-randomized  (1:1).  Of  these  placebo patients,  4  patients  discontinued  before  receiving  secukinumab,  123  non-responding  patients  received secukinumab starting at Week 16 (75 mg: 62 patients and 150 mg: 61 patients) sc every 4 weeks, and 60  patients  continued  on  placebo  until  Week  24  and  then  received  either  secukinumab  75  mg  (28 patients) or 150 mg (32 patients) sc every 4 weeks. Overall, 161 patients in the placebo group completed Week 52.

For the 91 patients who  discontinued at Week  52, the most  common  reason  for premature discontinuation  was  lack  of  efficacy  which  occurred  at  a  higher  rate  in  the  placebo  group  (6.4%) compared to the secukinumab 10 mg/kg-75 mg group (3.0%) and the secukinumab 10 mg/kg-150 mg group (3.5%).

Similar percentages of patients reported having at least one protocol deviation up to Week 24 (28.7% vs. 23.8% vs. 29.7% in the secukinumab 10 mg/kg-75 mg, secukinumab 10 mg/kg-150 mg and placebo groups, respectively). The most common categories were 'key procedures not performed as per-protocol' and 'GCP-related deviation'. Percentages of patients reporting at least one protocol deviation during the entire treatment period were 34.7% in secukinumab 10 mg/kg-75 mg, 31.2% in secukinumab 10 mg/kg150 mg and 34.2% in placebo.

Table 5. Patient disposition-up to Week 52-Randomised set (Study F2306).

| Disposition IReason        | AIN457 10mg/kg -75mg N=202 n (%)   | AIN457 10mg/kg -150mg N=202 n (%)   | Placebo N=202 n (%)   | Placebo Non- responder -AIN457 75mg N=62 n (%)   | Placebo Non- responder -AIN457 150mg N=61 n (%)   | Placebo Responder -AIN457 75mg N=31 n (%)   | Placebo Responder -AIN457 150mg N=33 n (%)   |
|----------------------------|------------------------------------|-------------------------------------|-----------------------|--------------------------------------------------|---------------------------------------------------|---------------------------------------------|----------------------------------------------|
| Randomized                 | 202                                | 202                                 | 202                   | 82                                               | 81                                                | 31                                          | 33                                           |
| Completed Week52           | 174 (86.1)                         | 180 (89.1)                          | 161 (79.7)            | 55 (88.7)                                        | 51 (83.6)                                         | 27 (87.1)                                   | 28 (84.8)                                    |
| Discontinued Week52        | 28 (13.9)                          | 22 (10.9)                           | 41 (20.3)             | 7 (11.3)                                         | 10 (16.4)                                         | 4 (12.9)                                    | 5 (15.2)                                     |
| Adverseevent               | 6 (3.0)                            | 5(2.5)                              | 9 (4.5)               | 2 (3.2)                                          | 2 (3.3)                                           | 1 (3.2)                                     | 1(3.0)                                       |
| Lackof                     | 6(3.0)                             | 7(3.5)                              | 13 (6.4)              | 1. (1.6)                                         | 5(8.2)                                            | 1(3.2)                                      | 0(0.0)                                       |
| Lostto follow-up           | 1 (0.5)                            | 1 (0.5)                             | 4 (2.0)               | 0(0.0)                                           | 0(0.0)                                            | 1(3.2)                                      | 2(6.1)                                       |
| Physician                  | 6(3.0)                             | 4(2.0)                              | 2(1.0)                | 1(1.6)                                           | 0(0.0)                                            | 0 (0.0)                                     | 0(0.0)                                       |
| Pregnancy                  | 0 (0.0)                            | 0 (0.0)                             | 1 (0.5)               | 1(1.6)                                           | 0(0.0)                                            | 0 (0.0)                                     | 0(0.0)                                       |
| Protocol deviation         | 2(1.0)                             | 0(0.0)                              | 0 (0.0)               | 0.(0.0)                                          | 0(0.0)                                            | 0 (0.0)                                     | D (0.0)                                      |
| Subject Iguardian decision | 6(3.0)                             | 5 (2.5)                             | 12 (5.9)              | 2(3.2)                                           | 3 (4.9)                                           | 1(3.2)                                      | 2(6.1)                                       |
| Death                      | 1(0.5)                             | 0(0.0)                              | 0r0.01                | 0(0.01                                           | 010.01                                            | 010.0)                                      | 0(0.0)                                       |

Placebo patients who are not re-randomized are counted in the placebo total only.

## Recruitment

Study initiation date: 08 Sep 2011 (first patient first visit)

<div style=\"page-break-after: always\"></div>

Study completion date: Not applicable. Last Visit 17 / Week 52 for interim analysis was on 09 Oct 2013.

## Conduct of the study

The study protocol was amended 3 times. The amendments are considered minor and occurred prior to study un-blinding.

The following changes were made to the planned analysis:

- Prior to database lock, the baseline definition was revised in the statistical analysis plan to allow X-ray and MRI values collected within 30 days/7 days (respectively) after dosing to be considered as baseline values.

## Baseline data

The majority of patients were &lt; 65 years of age (89.1% in both the secukinumab 10 mg/kg-75 mg group and  secukinumab  10  mg/kg-150  mg  group  and  95.0%  in  the  placebo  group)  with  a  mean  age  of  49 years). More than half of the patients were female (54.5%) and more than two-thirds of patients (74.6%) were  non-  hispanic  or  latino.  Around  20%  were  smokers  at  baseline.  The  mean  BMI  (±SD)  was: 30.05±6.250  kg/m2,  in  the  secukinumab  10  mg/kg-75  mg  group,  29.86±6.828  kg/m2  in  the secukinumab 10 mg/kg-150 mg group and 28.67±6.476 kg/m2 in the placebo group.

Baseline demographics and disease characteristics are reported in Table 6 .

Table 6. Demographic and background characteristics by randomised Treatment (Randomised set, Study F2306)

| Demographicvariable              | AIN457 10mg/kg -75mg N=202   | AIN457 10mg/kg - 150 mg N=202   | Placebo N=202   |
|----------------------------------|------------------------------|---------------------------------|-----------------|
| Age group in years, n (%)        |                              |                                 |                 |
| <65                              | 180 (89.1)                   | 180 (89.1)                      | 192 (95.0)      |
| >= 65                            | 22 (10.9)                    | 22 (10.9)                       | 10 (5.0)        |
| >= 75                            | 1 (0.5)                      | 0 (0.0)                         | 1 (0.5)         |
| Age (Years)                      |                              |                                 |                 |
| N                                | 202                          | 202                             | 202             |
| Mean                             | 48.8                         | 49.6                            | 48.5            |
| SD                               | 12.23                        | 11.76                           | 11.19           |
| Median                           | 50.0                         | 51.0                            | 49.0            |
| Min - Max                        | 20 -76                       | 22-73                           | 21 -77          |
| Gender, n (%)                    |                              |                                 |                 |
| Female                           | 118 (58.4)                   | 106 (52.5)                      | 106 (52.5)      |
| Male                             | 84 (41.6)                    | 96 (47.5)                       | 96 (47.5)       |
| Race, n (%)                      |                              |                                 |                 |
| White                            | 165 (81.7)                   | 162 (80.2)                      | 154 (76.2)      |
| BlackofAfricanAmerican           | 2 (1.0)                      | 3 (1.5)                         | 0 (0.0)         |
| Asian                            | 33 (16.3)                    | 36 (17.8)                       | 46 (22.8)       |
| Native Hawaiian or other Pacific | 0 (0.0)                      | 0 (0.0)                         | 1 (0.5)         |
| Islander                         |                              |                                 |                 |
| Unknown                          | 1 (0.5)                      | 0 (0.0)                         | 0 (0.0)         |
| Other                            | 1 (0.5)                      | 1 (0.5)                         | 1 (0.5)         |

<div style=\"page-break-after: always\"></div>

| Ethnicity, n (%) Hispanic or Latino   | 15 (7.4)     | 16 (7.9)     | 14 (6.9)     |
|---------------------------------------|--------------|--------------|--------------|
| Not Hispanic or Latino                | 143 (70.8)   | 150 (74.3)   | 159 (78.7)   |
| Unknown                               | 23 (11.4)    | 19 (9.4)     | 10 (5.0)     |
| Not reported                          | 21 (10.4)    | 17 (8.4)     | 19 (9.4)     |
| Height (cm)                           |              |              |              |
| N                                     | 201          | 200          | 202          |
| Mean                                  | 167.51       | 167.94       | 166.54       |
| SD                                    | 10.127       | 10.286       | 10.143       |
| Median                                | 167.00       | 168.00       | 167.00       |
| Min - Max                             | 145.0 -201.0 | 143.0-200.0  | 144.0 -190.5 |
| Weight (kg)                           |              |              |              |
| N                                     | 202          | 202          | 202          |
| Mean                                  | 84.45        | 84.23        | 80.00        |
| SD                                    | 19.608       | 21.052       | 20.472       |
| Median                                | 82.00        | 83.00        | 79.85        |
| Min - Max                             | 44.0 - 155.1 | 50.0 - 163.3 | 32.0 - 152.4 |
| BMI (kg/m**2)                         |              |              |              |
| n                                     | 201          | 200          | 202          |
| Mean                                  | 30.05        | 29.86        | 28.67        |
| SD                                    | 6.250        | 6.828        | 6.476        |
| Median                                | 29.34        | 28.46        | 27.47        |
| Min -Max                              | 17.3-51.4    | 16.7-58.6    | 14.6-59.5    |
| Currentsmokeratbaseline,n(%)          |              |              |              |
| No                                    | 168 (83.2)   | 160 (79.2)   | 162 (80.2)   |
| Yes                                   | 34 (16.8)    | 42 (20.8)    | 40 (19.8)    |
| BaselineDAS28CRPscore                 |              |              |              |
| n                                     | 202          | 201          | 201          |
| Mean                                  | 4.891        | 4.782        | 4.929        |
| SD                                    | 1.1502       | 1.0941       | 1.0994       |
| Minimum                               | 1.52         | 1.83         | 2.28         |
| Q1                                    | 4.092        | 3.996        | 4.062        |
| Median                                | 4.815        | 4.664        | 4.844        |
| Q3                                    | 5.678        | 5.478        | 5.718        |
| Maximum                               | 8.12         | 7.86         | 7.54         |
| Presenceofenthesitisn (%)             |              |              |              |
| Yes                                   | 129 (63.9)   | 126 (62.4)   | 117 (57.9)   |
| No                                    | 73 (36.1)    | 76 (37.6)    | 85 (42.1)    |
| Presenceof dactylitisn (%)            |              |              |              |
| Yes                                   | 104 (51.5)   | 104 (51.5)   | 116 (57.4)   |
| No                                    | 98 (48.5)    | 98 (48.5)    | 86 (42.6)    |
| MTXuseatrandomization                 |              |              |              |
| Yes                                   | 122 (60.4)   | 121 (59.9)   | 125 (61.9)   |
| No                                    | 80 (39.6)    | 81 (40.1)    | 77 (38.1)    |

<div style=\"page-break-after: always\"></div>

## Doseofmethotrexateatrandomization(mg/week)

| Background Characteristics                      | AIN457 10mg/kg -75mg N=202                      | AIN457 10mg/kg -150mg N=202                     | Placebo N=202                                   |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| n                                               | 115                                             | 118                                             | 122                                             |
| Mean                                            | 15.26                                           | 14.56                                           | 14.41                                           |
| SD                                              | 5.004                                           | 5.267                                           | 5.417                                           |
| Minimum                                         | 2.5                                             | 2.5                                             | 2.5                                             |
| Q1                                              | 10.00                                           | 10.00                                           | 10.00                                           |
| Median                                          | 15.00                                           | 15.00                                           | 15.00                                           |
| Q3                                              | 20.00                                           | 20.00                                           | 20.00                                           |
| Maximum                                         | 30.0                                            | 25.0                                            | 25.0                                            |
| TenderjointtotalscoreforPsA78joints             | TenderjointtotalscoreforPsA78joints             | TenderjointtotalscoreforPsA78joints             | TenderjointtotalscoreforPsA78joints             |
| n                                               | 202                                             | 202                                             | 202                                             |
| Mean                                            | 23.4                                            | 23.8                                            | 25.1                                            |
| SD                                              | 17.19                                           | 16.40                                           | 18.41                                           |
| Minimum                                         | 3                                               | 3                                               | 1                                               |
| Q1                                              | 11.0                                            | 11.0                                            | 11.0                                            |
| Median                                          | 19.0                                            | 20.5                                            | 19.0                                            |
| Q3                                              | 32.0                                            | 31.0                                            | 35.0                                            |
| Maximum                                         | 75                                              | 78                                              | 78                                              |
| SwollenjointtotalscoreforPsA76joints            | SwollenjointtotalscoreforPsA76joints            | SwollenjointtotalscoreforPsA76joints            | SwollenjointtotalscoreforPsA76joints            |
| n                                               | 202                                             | 202                                             | 202                                             |
| Mean                                            | 12.7                                            | 12.5                                            | 14.9                                            |
| SD                                              | 11.11                                           | 9.38                                            | 13.06                                           |
| Minimum                                         | 3                                               | 3                                               | 2                                               |
| Q1                                              | 5.0                                             | 6.0                                             | 6.0                                             |
| Median                                          | 9.0                                             | 10.0                                            | 10.0                                            |
| Q3                                              | 16.0                                            | 16.0                                            | 18.0                                            |
| Maximum                                         | 68                                              | 56                                              | 66                                              |
| BaselineDAS28ESRscore                           | BaselineDAS28ESRscore                           | BaselineDAS28ESRscore                           | BaselineDAS28ESRscore                           |
| n                                               | 202                                             | 201                                             | 201                                             |
| Mean                                            | 5.434                                           | 5.373                                           | 5.501                                           |
| SD                                              | 1.3072                                          | 1.2098                                          | 1.2197                                          |
| Minimum                                         | 1.87                                            | 2.23                                            | 2.56                                            |
| Q1                                              | 4.487                                           | 4.704                                           | 4.576                                           |
| Median                                          | 5.426                                           | 5.274                                           | 5.401                                           |
| Q3                                              | 6.438                                           | 6.181                                           | 6.457                                           |
| Maximum                                         | 8.71                                            | 8.49                                            | 8.29                                            |
| Patientsglobalassessmentofdisease(PsA) activity | Patientsglobalassessmentofdisease(PsA) activity | Patientsglobalassessmentofdisease(PsA) activity | Patientsglobalassessmentofdisease(PsA) activity |
| n                                               | 202                                             | 201                                             | 201                                             |
| Mean                                            | 56.1                                            | 55.2                                            | 55.6                                            |
| SD                                              | 22.62                                           | 23.99                                           | 21.70                                           |
| Minimum                                         | 0                                               | 4                                               | 1                                               |
| Q1                                              | 42.0                                            | 39.0                                            | 44.0                                            |
| Median                                          | 55.0                                            | 53.0                                            | 57.0                                            |
| Q3                                              | 74.0                                            | 73.0                                            | 70.0                                            |
| Maximum                                         | 100                                             | 100                                             | 100                                             |

<div style=\"page-break-after: always\"></div>

| Background Characteristics                            | AIN457 10mg/kg -75mg N=202                            | AIN457 10mg/kg -150mg N=202                           | Placebo N=202                                         |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Physiciansglobalassessment                            | Physiciansglobalassessment                            | Physiciansglobalassessment                            | Physiciansglobalassessment                            |
| n                                                     | 198                                                   | 199                                                   | 200                                                   |
| Mean                                                  | 54.3                                                  | 58.3                                                  | 56.7                                                  |
| SD                                                    | 18.04                                                 | 18.88                                                 | 18.78                                                 |
| Minimum                                               | 0                                                     | 1                                                     | 1                                                     |
| Q1                                                    | 43.0                                                  | 46.0                                                  | 44.0                                                  |
| Median                                                | 56.0                                                  | 59.0                                                  | 57.0                                                  |
| Q3                                                    | 67.0                                                  | 71.0                                                  | 70.0                                                  |
| Maximum                                               | 100                                                   | 100                                                   | 100                                                   |
| Psoriatic arthritispain today                         | Psoriatic arthritispain today                         | Psoriatic arthritispain today                         | Psoriatic arthritispain today                         |
| n                                                     | 202                                                   | 200                                                   | 201                                                   |
| Mean                                                  | 55.1                                                  | 55.7                                                  | 56.7                                                  |
| SD                                                    | 22.07                                                 | 24.22                                                 | 21.06                                                 |
| Minimum                                               | 0                                                     | 4                                                     | 3                                                     |
| Q1                                                    | 41.0                                                  | 38.5                                                  | 45.0                                                  |
| Median                                                | 56.5                                                  | 58.0                                                  | 59.0                                                  |
| Q3                                                    | 70.0                                                  | 76.0                                                  | 71.0                                                  |
| Maximum                                               | 100                                                   | 100                                                   | 100                                                   |
| NaivetoTNFalphainhibitors                             | NaivetoTNFalphainhibitors                             | NaivetoTNFalphainhibitors                             | NaivetoTNFalphainhibitors                             |
| Yes                                                   | 142 (70.3)                                            | 143 (70.8)                                            | 143 (70.8)                                            |
| No                                                    | 60 (29.7)                                             | 59 (29.2)                                             | 59 (29.2)                                             |
| Proportionofpatientswithpsoriasisofhandsandfeet       | Proportionofpatientswithpsoriasisofhandsandfeet       | Proportionofpatientswithpsoriasisofhandsandfeet       | Proportionofpatientswithpsoriasisofhandsandfeet       |
| Yes                                                   | 102 (50.5)                                            | 103 (51.0)                                            | 108 (53.5)                                            |
| No                                                    | 100 (49.5)                                            | 99 (49.0)                                             | 93 (46.0)                                             |
| Proportionofpatientswithpsoriasisofthenail            | Proportionofpatientswithpsoriasisofthenail            | Proportionofpatientswithpsoriasisofthenail            | Proportionofpatientswithpsoriasisofthenail            |
| Yes                                                   | 136 (67.3)                                            | 145 (71.8)                                            | 154 (76.2)                                            |
| No                                                    | 66 (32.7)                                             | 57 (28.2)                                             | 47 (23.3)                                             |
| Time sincefirst diagnosisofpsoriatic arthritis(years) | Time sincefirst diagnosisofpsoriatic arthritis(years) | Time sincefirst diagnosisofpsoriatic arthritis(years) | Time sincefirst diagnosisofpsoriatic arthritis(years) |
| n                                                     | 200                                                   | 201                                                   | 201                                                   |
| Mean                                                  | 7.830                                                 | 8.337                                                 | 7.437                                                 |
| SD                                                    | 8.5695                                                | 8.5338                                                | 8.0881                                                |
| Minimum                                               | 0.04                                                  | 0.04                                                  | 0.02                                                  |
| Q1                                                    | 2.082                                                 | 2.045                                                 | 1.747                                                 |
| Median                                                | 5.101                                                 | 5.342                                                 | 4.375                                                 |
| Q3                                                    | 9.900                                                 | 11.855                                                | 11.190                                                |
| Maximum                                               | 49.30                                                 | 45.68                                                 | 48.27                                                 |
| CASPAR TotalScore                                     | CASPAR TotalScore                                     | CASPAR TotalScore                                     | CASPAR TotalScore                                     |
| n                                                     | 202                                                   | 202                                                   | 202                                                   |
| Mean                                                  | 4.361                                                 | 4.381                                                 | 4.391                                                 |
| SD                                                    | 0.8364                                                | 0.9023                                                | 0.8584                                                |
| Minimum                                               | 3.00                                                  | 2.00                                                  | 3.00                                                  |
| Q1                                                    | 4.000                                                 | 4.000                                                 | 4.000                                                 |
| Median                                                | 4.000                                                 | 4.000                                                 | 5.000                                                 |
| Q3                                                    | 5.000                                                 | 5.000                                                 | 5.000                                                 |

<div style=\"page-break-after: always\"></div>

| Background Characteristics                            | AIN457 10mg/kg -75mg N=202                            | AIN457 10mg/kg -150mg N=202                           | Placebo N=202                                         |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Maximum                                               | 6.00                                                  | 6.00                                                  | 6.00                                                  |
| TargetLesionDiameter                                  | TargetLesionDiameter                                  | TargetLesionDiameter                                  | TargetLesionDiameter                                  |
| n                                                     | 182                                                   | 186                                                   | 183                                                   |
| Mean                                                  | 8.45                                                  | 8.12                                                  | 8.02                                                  |
| SD                                                    | 11.460                                                | 10.017                                                | 8.080                                                 |
| Minimum                                               | 0.0                                                   | 0.0                                                   | 0.0                                                   |
| Q1                                                    | 3.00                                                  | 3.00                                                  | 3.00                                                  |
| Median                                                | 5.00                                                  | 5.00                                                  | 5.00                                                  |
| Q3                                                    | 9.00                                                  | 9.00                                                  | 10.00                                                 |
| Maximum                                               | 90.0                                                  | 70.0                                                  | 50.0                                                  |
| HealthAssessmentQuestionnaire-DisabilityIndex(HAQ-DI) | HealthAssessmentQuestionnaire-DisabilityIndex(HAQ-DI) | HealthAssessmentQuestionnaire-DisabilityIndex(HAQ-DI) | HealthAssessmentQuestionnaire-DisabilityIndex(HAQ-DI) |
| n                                                     | 201                                                   | 200                                                   | 201                                                   |
| Mean                                                  | 1.2512                                                | 1.2313                                                | 1.1884                                                |
| SD                                                    | 0.66568                                               | 0.68175                                               | 0.64410                                               |
| Minimum                                               | 0.000                                                 | 0.000                                                 | 0.000                                                 |
| Q1                                                    | 0.7500                                                | 0.7500                                                | 0.7500                                                |
| Median                                                | 1.2500                                                | 1.2500                                                | 1.1250                                                |
| Q3                                                    | 1.7500                                                | 1.7500                                                | 1.7500                                                |
| Maximum                                               | 2.875                                                 | 3.000                                                 | 2.750                                                 |
| Systemicglucocorticoidsuseatrandomization             | Systemicglucocorticoidsuseatrandomization             | Systemicglucocorticoidsuseatrandomization             | Systemicglucocorticoidsuseatrandomization             |
| Yes                                                   | 34 (16.8)                                             | 34 (16.8)                                             | 27 (13.4)                                             |
| No                                                    | 168 (83.2)                                            | 168 (83.2)                                            | 175 (86.6)                                            |
| Numberofprioranti-TNFPsA therapies*                   | Numberofprioranti-TNFPsA therapies*                   | Numberofprioranti-TNFPsA therapies*                   | Numberofprioranti-TNFPsA therapies*                   |
| 0                                                     | 142 (70.3)                                            | 143 (70.8)                                            | 142 (70.3)                                            |
| 1                                                     | 35 (17.3)                                             | 39 (19.3)                                             | 36 (17.8)                                             |
| >=2                                                   | 25 (12.4)                                             | 20 (9.9)                                              | 24 (11.9)                                             |
| Patientswithpsoriasis>=3%ofBSA                        | Patientswithpsoriasis>=3%ofBSA                        | Patientswithpsoriasis>=3%ofBSA                        | Patientswithpsoriasis>=3%ofBSA                        |
| Yes                                                   | 108 (53.5)                                            | 108 (53.5)                                            | 109 (54.0)                                            |
| No                                                    | 94 (46.5)                                             | 94 (46.5)                                             | 93 (46.0)                                             |
| BaselinePASlscore                                     | BaselinePASlscore                                     | BaselinePASlscore                                     | BaselinePASlscore                                     |
| n                                                     | 108                                                   | 108                                                   | 109                                                   |
| Mean                                                  | 10.67                                                 | 15.62                                                 | 15.10                                                 |
| SD                                                    | 8.833                                                 | 13.888                                                | 11.633                                                |
| Minimum                                               | 0.8                                                   | 2.4                                                   | 0.8                                                   |
| Q1                                                    | 4.60                                                  | 6.25                                                  | 7.00                                                  |
| Median                                                | 8.20                                                  | 11.25                                                 | 11.80                                                 |
| Q3                                                    | 15.45                                                 | 19.35                                                 | 19.20                                                 |
| Maximum                                               | 59.1                                                  | 72.0                                                  | 62.8                                                  |
| Baseline PASl,n (%)                                   | Baseline PASl,n (%)                                   | Baseline PASl,n (%)                                   | Baseline PASl,n (%)                                   |
| <=10                                                  | 64 (59.3)                                             | 50 (46.3)                                             | 46 (42.2)                                             |
| >10                                                   | 44 (40.7)                                             | 58 (53.7)                                             | 63 (57.8)                                             |

BaselineIGAmod2011score,n (%)

<div style=\"page-break-after: always\"></div>

| Background Characteristics   | AIN457 10mg/kg -75mg N=202   | AIN457 10mg/kg -150mg N=202   | Placebo N=202   |
|------------------------------|------------------------------|-------------------------------|-----------------|
| 0=Clear                      | 0 (0.0)                      | 0 (0.0)                       | 1 (0.9)         |
| 1=Almostclear                | 1 (0.9)                      | 0 (0.0)                       | 1 (0.9)         |
| 2=Milddisease                | 26 (24.1)                    | 22 (20.4)                     | 20 (18.3)       |
| 3=Moderate disease           | 65 (60.2)                    | 64 (59.3)                     | 67 (61.5)       |
| 4=Severedisease              | 15 (13.9)                    | 21 (19.4)                     | 20 (18.3)       |
| 5=Verysevere disease         | 0 (0.0)                      | 0 (0.0)                       | 0 (0.0)         |

*Startedbeforethefirstdosingofstudytreatment

## Numbers analysed

The following analysis sets were used for the data analysis: Randomized set; Full analysis set (FAS); and Safety set.  The  total  number  of  patients  in  each  analysis  set  was  606  and  the  number  of  patients  by treatment group was 202. Efficacy analyses were performed on an intent-to-treat basis, involving all 606 randomized patients who were assigned to study treatment ( Table 7 ).

Table 7. Analysis sets by treatment sequence (Randomised set, Study F2306)

| Analysis Set                             | AIN457 10mg/kg -75mg N   | AIN457 10mg/kg -150mg N   |   Placebo N |   Placebo Non- responder -AIN457 75mg N |   Placebo Non- responder -AIN457 150mg N |   Placebo -AIN457 75mg N |   Placebo ResponderResponder -AIN457 150mg N |
|------------------------------------------|--------------------------|---------------------------|-------------|-----------------------------------------|------------------------------------------|--------------------------|----------------------------------------------|
| Randomizedset                            | 202                      | 202                       |         202 |                                      62 |                                       81 |                       31 |                                           33 |
| Full analysisset                         | 202                      | 202                       |         202 |                                      62 |                                       61 |                       31 |                                           33 |
| Safety set                               | 202                      | 202                       |         202 |                                      62 |                                       61 |                       31 |                                           33 |
| Treatedwith AIN457afterre- randomization |                          |                           |         183 |                                      62 |                                       61 |                       28 |                                           32 |

Placebocolumnincludepalientsrandomizedtoplaceboatthebeginning andre-randomized toAlN457later.as wellasthoseprematurelydiscontinuedwithouttakingAlN457.

-Placebopatientswhoarenotre-randomizedarecounted in theplacebototal only.

## Outcomes and estimation

The results of the primary efficacy variable ACR20 response using non-responder imputation for the FAS at Week 24 is shown in Table 8 and Figure 7 .

Secukinumab  at  both  doses  (10  mg/kg-75  mg  and  10  mg/kg-150  mg)  was  statistically  significantly superior to placebo for ACR20 response at Week 24 (p&lt;0.0001). At Week 24, the ACR20 response rate was 50.5% for secukinumab 10 mg/kg-75 mg, 50.0% for secukinumab 10 mg/kg-150 mg and 17.3% for placebo.

Table 8. ACR20 response using non-responder imputation - up to Week 24 (Full analysis set)

| Analysis visit   | TreatmentGroup             | n/M (%)      | Comparison   | Oddsratio   | 95% Confidence Interval   | p-value   |
|------------------|----------------------------|--------------|--------------|-------------|---------------------------|-----------|
| Week1            | AIN45710mg/kg 75mg（N=202）  | 41/202（20.3) | vs.Placebo   | 4.46        | (2.21,8.97)               | <.0001    |
|                  | AIN45710mg/kg 150mg（N=202） | 42/202(20.8) | vs.Placebo   | 4.59        | (2.28,9.22)               | <.0001    |
|                  | Placebo（N=202)             | 11/202（5.4)  |              |             |                           |           |
| Week2            | AIN45710mg/kg-             | 67/202(33.2) | Vs.Placebo   | 3.81        | (2.26,6.42)               | <.0001    |

<div style=\"page-break-after: always\"></div>

|        | 75mg（N=202)                   |               |            |      |              |        |
|--------|-------------------------------|---------------|------------|------|--------------|--------|
|        | AIN457 10 mg/kg- 150mg(N=202) | 61/202(30.2)  | vs.Placebo | 3.30 | (1.95,5.58)  | <.0001 |
|        | Placebo(N=202)                | 24/202(11.9)  |            |      |              |        |
| Week4  | AIN45710mg/kg- 75mg(N=202)    | 87/202(43.1)  | vs.Placebo | 2.96 | (1.90,4.61)  | <.0001 |
|        | AIN45710mg/kg- 150mg（N=202)   | 88/202(43.6)  | vs.Placebo | 3.00 | (1.93, 4.68) | <.0001 |
|        | Placebo(N=202)                | 44/202(21.8)  |            |      |              |        |
| Week8  | AIN457 10 mg/kg - 75mg(N=202) | 100/202(49.5) | vs.Placebo | 3.65 | (2.36,5.85)  | <.0001 |
|        | AIN45710mg/kg- 150mg(N=202)   | 102/202(50.5) | vs.Placebo | 3.78 | (2.44,5.88)  | <.0001 |
|        | Placebo(N=202)                | 45/202(22.3)  |            |      |              |        |
| Week12 | AIN45710mg/kg- 75mg(N=202)    | 104/202(51.5) | vs.Placebo | 3.57 | (2.31,5.50)  | <.0001 |
|        | AIN45710mg/kg- 150mg（N=202)   | 113/202(55.9) | vs.Placebo | 4.27 | (2.77,6.60)  | <.0001 |
|        | Placebo(N=202)                | 50/202(24.8)  |            |      |              |        |
| Week16 | AIN45710mg/kg- 75mg(N=202)    | 106/202(52.5) | vs.Placebo | 4.43 | (2.84,6.91)  | <.0001 |
|        | AIN45710mg/kg- 150mg（N=202）   | 115/202(56.9) | vs.Placebo | 5.31 | (3.39,8.31)  | <.0001 |
|        | Placebo（N=202)                | 43/202(21.3)  |            |      |              |        |
| Week20 | AIN45710mg/kg- 75 mg (N= 202) | 107/202(53.0) | vs.Placebo | 6.90 | (4.25,11.17) | <.0001 |
|        | AIN45710mg/kg- 150mg（N=202)   | 100/202(49.5) | vs.Placebo | 5.93 | (3.66,9.60)  | <.0001 |
|        | Placebo (N=202)               | 32/202(15.8)  |            |      |              |        |
| Week24 | AIN45710mg/kg- 75mg(N=202)    | 102/202(50.5) | vs.Placebo | 5.53 | (3.46, 8.85) | <.0001 |
|        | AIN45710mg/kg- 150mg(N=202)   | 101/202（50.0) | vs.Placebo | 5.39 | (3.37,8.62)  | <.0001 |
|        | Placebo（N=202)                | 35/202(17.3)  |            |      |              |        |

Oddsratio,95%confidenceinterval,andp-valuearefroma logisticregressionmodelwith treatmentand randomizationstratum(TNFastatus-naiveorIR)asfactorsandbaselineweightasacovariate. Oddsratio&gt;1favorsAlN457.

M:Numberofpatientsinthetreatmentgroup.

n:ThenumberofpatientswhoareACR20responderswiththecorrespondingimputationapproachinthe treatmentarouo.

Figure 7. ACR20 response using non-responder imputation - up to Week 24 (Full analysis set)

<!-- image -->

*P-value&lt;0.05

<div style=\"page-break-after: always\"></div>

## Secondary efficacy results

The results of the hypothesis tests within the testing strategy are shown in Table 9 .  Secukinumab 10 mg/kg-75 mg and 10 mg/kg-150 mg were superior to placebo at Week 24 for all endpoints in the testing hierarchy. All p-values except that for the vdH-mTSS were &lt;0.0001.

Table 9. Results for primary and secondary endpoints based on hierarchical testing sequence

| Endpoint                                | Secukinumab10 mg/kg-75mg (N=202)   | Secukinumab10 mg/kg-150mg (N=202)   | Pooled Secukinumab (N=404)   | Placebo (N=202)   |
|-----------------------------------------|------------------------------------|-------------------------------------|------------------------------|-------------------|
| Primary                                 |                                    |                                     |                              |                   |
| Endpoint: ACR20                         | 50.5% p<0.0001                     | 50.0% p<0.0001                      |                              | 17.3%             |
| PASI75                                  | 64.8% p<0.0001                     | 61.1% p<0.0001                      |                              | 8.3%              |
| PASI90                                  | 49.1% p<0.0001                     | 45.4% p<0.0001                      |                              | 3.7%              |
| DAS28-CRP                               | -1.67 p＜0.0001                     | -1.62 p<0.0001                      |                              | -0.77             |
| SF-36PCS                                | 5.41 p＜0.0001                      | 5.91 p＜0.0001                       |                              | 1.82              |
| HAQ-DI                                  | -0.41 P<0.0001                     | -0.40 p<0.0001                      |                              | -0.17             |
| ACR50                                   | 30.7% p<0.0001                     | 34.7% p＜0.0001                      |                              | 7.4%              |
| vanderHeijde modifiedtotal Sharpscore** | 0.02 p=0.0132                      | 0.13 p=0.0212                       | 0.08 p=0.0113                | 0.57              |
| Presenceof Dactylitis**                 | 43.3% p＜0.0001                     | 51.9% p<0.0001                      | 47.6% p＜0.0001               | 84.5%             |
| Presenceof Enthesitis**                 | 51.2% P<0.0001                     | 54.0% p＜0.0001                      | 52.5% p<0.0001               | 87.2%             |

hierarchyorderisfirstpooledvanderHeijdemodifiedtotalSharpscore,followedbypooled dactylitisandenthesitisscores,lastlyvanderHeijdemodifiedtotalSharpscoreforindividualdoses. Individualdosesfordactvlitisandenthesitisarenotinthehierarchv

## Study CAIN457F2312 (also referred to as F2312)

A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety and tolerability up to 5 years in patients with Active Psoriatic Arthritis

## Methods

## Study participants

There were 76 study centres in 10 countries (Australia 4 centres, Belgium 3 centres, Canada 6 centres, Czech Republic 4 centres, Germany 9 centres, Poland 6 centres, Russia Federation 10 centres, Thailand 2 centres, United Kingdom 10 centres, United States of America 22 centres).

Inclusion and exclusion criteria were identical to those of Study F2306, with the addition of the following exclusion  criterion:  History  of  hypersensitivity  to  the  study  drug  or  its  excipient  or  to  drugs  of  similar chemical classes.

## Treatments

The study design is presented in Figure 8 .

<div style=\"page-break-after: always\"></div>

Figure 8. Schematic of Study F2312 design

<!-- image -->

At baseline, patients were randomized to one of the following 4 treatment arms in a ratio of 1:1:1:1:

- Group 1: Secukinumab 75 mg (0.5 mL) plus placebo (2 x 1.0 mL) at BSL, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks starting at Week 4.
- Group 2: Secukinumab 150 mg (1.0 mL) plus placebo (0.5 mL and 1.0 mL) at BSL, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks starting at Week 4.
- Group 3: Secukinumab 300 mg (2 × 1.0 mL) plus placebo (0.5 mL) at BSL, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks starting at Week 4.
- Group 4: Placebo (2 × 1.0 mL and 1× 0.5 mL) at BSL, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks starting at Week 4.

At  Week  16,  patients  were  classified  as  responders  (ACR20  response  defined  as  ≥  20%  improvement from baseline in both tender and swollen joint counts) or non-responders. Patients who were randomized to Groups 1, 2, and 3 continued to receive study treatment as described above regardless of responder status.  Patients  who  were  randomized  to  placebo  at  baseline  were  re-randomized  by  the  Interactive Response Technology (IRT) to receive double-blind treatment up to 52 weeks, as follows:

- Group 4: Placebo patients who were non-responders were re-randomized in a 1:1 ratio to receive secukinumab 150 mg sc or 300 mg sc every 4 weeks.
- Group 4: Placebo patients who were responders continued to receive placebo every 4 weeks until Week 24. Starting at Week 24, these patients received secukinumab 150 mg sc or 300 mg sc (1:1) every 4 weeks regardless of responder status (as dictated by the re-randomization).

<div style=\"page-break-after: always\"></div>

All study treatments were self-administered by the patients at the study site up to Week 104. After Week 104,  the  patients  were  allowed  to  self-administer  the  PFS  at  home  during  the  optional  visits  in  which there were no scheduled site assessments.

At Week 24, efficacy of secukinumab treatment was assessed based on an ACR20 response.

According  to  the  investigational  plan,  response  to  study  treatment  was  also  assessed  at  the  Week  52 visit. Un-blinding is planned after the Week 52 analysis was conducted in order to eliminate the placebo injection.  Responders  (ACR20  response)  patients  continued  in  the  post  Week  52  open-label  long-term treatment period on the same treatment dose and regimen (secukinumab 75 mg, 150 mg or 300 mg every 4 weeks) until Week 256 and non-responder patients will be discontinued the study.

## Objectives, Outcomes/endpoints

The objectives, primary and secondary endpoints of the study were similar to those of study F2306 with an additional comparison between the 300 mg dose and placebo while no assessment of joint/bone structural damage was performed.

## Sample size

A 5% two-sided type I error rate was used to control for type I error. Three secukinumab doses were tested versus placebo with respect to the primary endpoint (ACR20 response at Week 24), thus the typeI-error was split to 1.7% two-sided for each comparison. Sample sizes were based on this type I error assumption.

The overall placebo rate was expected to be 21% and the overall rate on a dose of secukinumab was expected to be 47%. For the primary endpoint of ACR20 response in the FAS population, 100 patients per group would yield approximately 92% power to detect a treatment difference of 26% (Fisher's exact test, NQuery 7.0).

## Randomisation

At baseline, all eligible  patients  were  randomized via IRT to one of four treatment arms. At Week 16, patients were classified as responders or non-responders. Patients who were randomised to placebo at baseline were re-randomised to receive double-blind treatment up to 52 weeks.

The patients were stratified at randomization according to either TNFα-IR or TNFα inhibitor naïve patients. Approximately  40%  of  randomized  patients  should  be  TNFα-IR  to  ensure  a  representative  patient population for the assessment of efficacy and safety.

## Blinding (masking)

This was a double-blind, double-dummy study.

## Statistical methods

See the methods described for study F2306.

For  binary  variables  ( e.g., ACR20 response) a logistic regression model was  fitted with treatment and TNFα-inhibitor  status  as  factors  and  baseline  score  (if  appropriate)  and  weight  as  covariates.  In  cases where  separation  was  a  concern  at  Week  24  time-point, e.g., 0%  response  in  one  treatment  (sub)-

<div style=\"page-break-after: always\"></div>

group, an exact logistic regression model was applied. Fisher's exact test was applied for situations where separation issues caused both logistic regression and exact logistic regression to fail.

## Results

## Participant flow

A total of 397 patients were randomized to 4 treatment groups: secukinumab 75 mg, 150 mg, 300 mg, and  placebo.  Of  the  total  randomized,  373  (94.0%)  patients  completed  24  weeks  of  treatment.  More patients  in  the  placebo  group  (10.2%)  discontinued  treatment  compared  with  all  of  the  secukinumab groups (range: 3.0%-6.1%). Of the 98 patients in the placebo group, 88 patients completed Week 24 and were re-randomized (1:1) (Table 10 ).

For the 24 patients who  discontinued at Week  24, the most  common  reason  for premature discontinuation  was  AEs,  which  occurred  at  a  higher  rate  in  the  placebo  group  compared  with secukinumab groups.

The  number  of  patients  who  reported  at  least  1  protocol  deviation  up  to  Week  24  was  lower  in  the secukinumab 75 mg group compared with the rest of the treatment groups (13.1% vs 15.0-18.4%). The most common categories for protocol deviations up to Week 24 were Good Clinical Practices (GCP) related deviations, followed by prohibited concomitant medication and selection criteria not met.

Table 10. Study design Patient disposition - up to Week 24 (Randomised set, Study F2312)

| Disposition/Reason      | AIN457 75mg N=99 n (%)   | AIN457 150mg N=100 n (%)   | AIN457 300mg N=100 n (%)   | Placebo N=98 n (%)   |
|-------------------------|--------------------------|----------------------------|----------------------------|----------------------|
| Randomized              | 99                       | 100                        | 100                        | 98                   |
| CompletedWeek24         | 93 (93.9)                | 95 (95.0)                  | 97 (97.0)                  | 88 (89.8)            |
| DiscontinuedWeek24      | 6 (6.1)                  | 5 (5.0)                    | 3 (3.0)                    | 10 (10.2)            |
| Adverseevent            | 3 (3.0)                  | 0 (0.0)                    | 2 (2.0)                    | 4 (4.1)              |
| Lackofefficacy          | 2 (2.0)                  | 3 (3.0)                    | 0 (0.0)                    | 3 (3.1)              |
| Physiciandecision       | 0 (0.0)                  | 1 (1.0)                    | 0 (0.0)                    | 0 (0.0)              |
| Subjectguardiandecision | 1 (1.0)                  | 1 (1.0)                    | 1(1.0)                     | 3 (3.1)              |

Placebopatientswhoarenotre-randomizedarecountedintheplacebototalonly.

## Recruitment

Study initiation date: 14-Apr-2013 (first patient first visit)

Study completion date: Not applicable (last patient Visit 12/ Week 24 for interim analysis was on 12-May2014)

The primary endpoint analysis (Week 24 analysis) was performed after all patients had completed Week 24 visit. Additional analyses are planned for regulatory submission and/or publication purposes after all patients have completed year 1, 2, 3, 4 and 5.

## Conduct of the study

The original study protocol (dated 15-Oct-2012) was amended once (25-Feb-2014).

There were no changes to study conduct. The following changes were made in the planned analysis:

<div style=\"page-break-after: always\"></div>

- Prior  to  database  lock,  logistic  regression  was  planned  for  binary  endpoints.  However,  low response rates due to small sample sizes for a few subgroup analyses ( e.g., by TNFα-IR status or concomitant  MTX  use)  caused  separation  (ie,  convergence)  issues  when  applying  logistic regression.  The  planned  alternative  method,  exact  logistic  regression,  was  applied  but  also  did not  converge.  A  second  alternative  method,  Fisher's  exact  test,  was  therefore  proposed  and applied for situations where separation issues caused both logistic regression and exact logistic regression to fail.
- An  additional  data-driven  analysis  was  explored  to  determine  the  effect  of  weight  on  ACR20 response with a &lt;100 kg and ≥ 100 kg cutoff. Interactions between treatment and other baseline covariates  for  ACR20  response  at  Week  24  show  weight  may  have  a  possible  association  with ACR20  response.  Therefore,  both  a  table  and  a  figure  were  created  showing  ACR20  response through Week 24 by the 100 kg weight cutoff.

## Baseline data

Baseline  demographics were generally balanced across the treatment groups. The majority of patients were &lt; 65 years of age with a mean age of approximately 48 years. More than half of the population were female (51.6%). Overall, the female to male ratio was equal in the groups except for the placebo group which had 60.2% female and 39.8% male patients. Over 90% of patients were white and more than 80% were not Hispanic or Latino. Around 20% were smokers at baseline.

Disease history and baseline characteristics are reported in Table 11.

Table 11. Disease history and baseline characteristics by randomized treatment (Randomised set, Study F2312)

| Demographic variable     | AIN457 75mg N=99   | AIN457 150mg N=100   | AIN457 300mg N=100   | Placebo N=98   |
|--------------------------|--------------------|----------------------|----------------------|----------------|
| Age group in years, n(%) |                    |                      |                      |                |
| <65                      | 93 (93.9)          | 94 (84.0)            | 90 (90.0)            | 87 (88.8)      |
| 65-74                    | 6 (6.1)            | 6 (6.0)              | 9 (9.0)              | 9 (9.2)        |
| 275                      | 0 (0.0)            | 0 (0.0)              | 1(1.0)               | 2 (2.0)        |
| Age (Years)              |                    |                      |                      |                |
| n                        | 90                 | 100                  | 100                  | 98             |
| Mean                     | 48.6               | 46.5                 | 46.9                 | 48.9           |
| SD                       | 11.42              | 11.72                | 12.57                | 12.53          |
| Median                   | 51.0               | 46.5                 | 46.5                 | 51.0           |
| Min-Max                  | 21-71              | 20-87                | 23-77                | 20-77          |
| Gender, n(%)             |                    |                      |                      |                |
| Female                   | 52 (52.5)          | 45 (45.0)            | 49 (49.0)            | 59 (60.2)      |
| Male                     | 47 (47.5)          | 55 (55.0)            | 51 (51.0)            | 39 (39.8)      |

<div style=\"page-break-after: always\"></div>

| Race, n(%)                       |             |             |             |             |
|----------------------------------|-------------|-------------|-------------|-------------|
| AmercanIndianorAlaskaNative      | 0 (0.0)     | 2 (2.0)     | 0 (0.0)     | 0 (0.0)     |
| Asian                            | 5 (5.1)     | 6 (6.0)     | 2 (2.0)     | 1 (1.0)     |
| Black or Afnican American        | 0 (0.0)     | 0 (0.0)     | 1(1.0)      | 0 (0.0)     |
| NativeHawalianorotherPacific     | 1 (1.0)     | 1 (1.0)     | 0 (0.0)     | 0 (0.0)     |
| Islander                         |             |             |             |             |
| White                            | 90 (90.9)   | 90 (90.0)   | 96 (96.0)   | 94 (95.9)   |
| Unknown                          | 1 (1.0)     | 0 (0.0)     | 0 (0.0)     | 0 (0.0)     |
| Other                            | 2 (2.0)     | 1(1.0)      | 1(1.0)      | 3 (3.1)     |
| Ethnicity, n(%)                  |             |             |             |             |
| Hispanic or Latino               | 2 (2.0)     | 5 (5.0)     | 4 (4.0)     | 4 (4.1)     |
| Not Hispanic or Latino           | 84 (84.8)   | 82 (82.0)   | 80 (80.0)   | 79 (80.8)   |
| Not reported                     | 6 (6.1)     | 9 (9.0)     | 9 (9.0)     | 6 (8.1)     |
| Unknown                          | 7 (7.1)     | 4 (4.0)     | 7 (7.0)     | 9 (9.2)     |
| Height (cm)                      |             |             |             |             |
| Mean                             | 188.47      | 170.70      | 170.46      | 168.90      |
| SD                               | 9.803       | 9.847       | 9.601       | 9.630       |
| Median                           | 167.00      | 170.80      | 169.30      | 168.50      |
| Min-Max                          | 146.0-193.0 | 152.5-203.2 | 142.2-198.0 | 148.0-189.2 |
| Weight (kg)                      |             |             |             |             |
| Mean                             | 85.82       | 91.22       | 85.37       | 86.19       |
| SD                               | 20.558      | 19.814      | 18.429      | 19.802      |
| Median                           | 87.40       | 91.35       | 83.00       | 85.55       |
| Min-Max                          | 47.5-132.4  | 47.3-148.5  | 52.2-161.0  | 54.2-147.3  |
| BMI (kg/m)                       |             |             |             |             |
| Mean                             | 30.12       | 31.18       | 29.38       | 30.10       |
| SD                               | 6.958       | 5.802       | 5.800       | 5.963       |
| Median                           | 29.51       | 30.47       | 28.26       | 29.33       |
| Min-Max                          | 18.6-59.0   | 20.1-48.1   | 19.0-48.3   | 19.6-50.3   |
| Current smoker at baseline,n (%) |             |             |             |             |
| No                               | 79 (79.8)   | 79 (79.0)   | 81 (81.0)   | 81 (82.7)   |
| Yes                              | 20 (20.2)   | 21 (21.0)   | 19 (19.0)   | 17 (17.3)   |

<div style=\"page-break-after: always\"></div>

| BackgroundCharacteristics                     | AIN45775mg N=99   | N=100     | AIN457150mgAIN457300mg N=100   | Placebo N=98   |
|-----------------------------------------------|-------------------|-----------|--------------------------------|----------------|
| Baseline DAS28CRPscore                        |                   |           |                                |                |
| n                                             | 98                | 100       | 99                             | 98             |
| Mean                                          | 4.709             | 4.899     | 4.763                          | 4.712          |
| SD                                            | 1.0022            | 1.1206    | 1.0061                         | 1.0467         |
| Median                                        | 4.610             | 4.888     | 4.744                          | 4.627          |
| Presence of enthesitis, n (%)                 |                   |           |                                |                |
| Yes                                           | 68 (68.7)         | 84 (84.0) | 56 (56.0)                      | 65 (66.3)      |
| No                                            | 30 (30.3)         | 38 (36.0) | 44 (44.0)                      | 33 (33.7)      |
| Presence of dactylitis, n (%)                 |                   |           |                                |                |
| Yes                                           | 33 (33.3)         | 32 (32.0) | 46 (46.0)                      | 27 (27.6)      |
| No                                            | 65 (85.7)         | 68 (68.0) | 54 (54.0)                      | 71 (72.4)      |
| MTX use at randomization, n (%)               |                   |           |                                |                |
| Yes                                           | 47 (47.5)         | 44 (44.0) | 44 (44.0)                      | 50 (51.0)      |
| No                                            | 52 (52.5)         | 58 (56.0) | 56 (58.0)                      | 48 (49.0)      |
| Dose of methotrexate atrandomization(mg/week) |                   |           |                                |                |
| n                                             | 47                | 44        | 43                             | 50             |
| Mean                                          | 18.032            | 17.188    | 16.105                         | 17.600         |
| SD                                            | 7.2220            | 5.1371    | 5.3258                         | 11.2141        |
| Median                                        | 17.500            | 18.750    | 15.000                         | 15.000         |
| Tenderjointtotal scoreforPsA78joints          |                   |           |                                |                |
| n                                             | 99                | 100       | 100                            | 98             |
| Mean                                          | 22.2              | 24.1      | 20.2                           | 23.4           |
| SD                                            | 16.32             | 19.38     | 13.33                          | 18.97          |
| Median                                        | 18.0              | 18.0      | 17.0                           | 17.0           |
| Swollenjointtotal scoreforPsA76joints         |                   |           |                                |                |
| n                                             | 99                | 100       | 100                            | 98             |
| Mean                                          | 10.8              | 11.9      | 11.2                           | 12.1           |
| SD                                            | 9.17              | 10.05     | 7.77                           | 10.85          |
| Median                                        | 8.0               | 8.0       | 9.0                            | 8.5            |
| BaselineDAS28ESRscore                         |                   |           |                                |                |
| n                                             | 98                | 100       | 99                             | 98             |
| Mean                                          | 5.129             | 5.268     | 5.180                          | 5.188          |
| SD                                            | 1.2165            | 1.3003    | 1.2230                         | 1.1927         |
| Median                                        | 5.054             | 5.219     | 5.131                          | 5.151          |
| Subjects global assessment                    |                   |           |                                |                |
| n                                             | 98                | 100       | 99                             | 98             |
| Mean                                          | 59.0              | 62.0      | 60.7                           | 57.6           |
| SD                                            | 19.09             | 19.53     | 18.93                          | 19.77          |
| Median                                        | 60.5              | 65.5      | 64.0                           | 58.0           |
| Physicians globalassessment                   |                   |           |                                |                |
| n                                             | 98                | 100       | 99                             | 98             |
| Mean                                          | 59.0              | 58.7      | 55.0                           | 55.0           |
| SD                                            | 17.86             | 16.59     | 14.72                          | 15.98          |

<div style=\"page-break-after: always\"></div>

| BackgroundCharacteristics                               | AIN45775mg N=99                                         | N=100                                                   | AIN457150mgAIN457300mg N=100                      | Placebo N=98                                      |
|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Median                                                  | 60.0                                                    | 58.5                                                    | 55.0                                              | 57.5                                              |
| Psoriatic arthritispain today                           |                                                         |                                                         |                                                   |                                                   |
| n                                                       | 98                                                      | 100                                                     | 99                                                | 98                                                |
| Mean                                                    | 56.7                                                    | 58.9                                                    | 57.7                                              | 55.4                                              |
| SD                                                      | 21.11                                                   | 19.76                                                   | 18.02                                             | 22.11                                             |
| Median                                                  | 60.0                                                    | 61.0                                                    | 58.0                                              | 57.0                                              |
| Naive to TNF alphainhibitors,n (%)                      |                                                         |                                                         |                                                   |                                                   |
| Yes                                                     | 65 (65.7)                                               | 63 (03.0)                                               | 67 (67.0)                                         | 63 (64.3)                                         |
| No                                                      | 34 (34.3)                                               | 37 (37.0)                                               | 33 (33.0)                                         | 35 (35.7)                                         |
| Proportionof palientswithpsoriasisof hands andfeet,n(%) | Proportionof palientswithpsoriasisof hands andfeet,n(%) | Proportionof palientswithpsoriasisof hands andfeet,n(%) |                                                   |                                                   |
| Yes                                                     | 43 (43.4)                                               | 62 (62.0)                                               | 39 (30.0)                                         | 40 (40.8)                                         |
| No                                                      | 58 (56.6)                                               | 38 (38.0)                                               | 81 (81.0)                                         | 58 (59.2)                                         |
| Proportion of patientswithpsoriasis of the nail,n (%)   | Proportion of patientswithpsoriasis of the nail,n (%)   | Proportion of patientswithpsoriasis of the nail,n (%)   |                                                   |                                                   |
| Yes                                                     | 76 (76.8)                                               | 75 (75.0)                                               | 63 (83.0)                                         | 65 (66.3)                                         |
| No                                                      | 23 (23.2)                                               | 25 (25.0)                                               | 37 (37.0)                                         | 33 (33.7)                                         |
| Time sincefirstdiagnosisofpsoriatic arthritis(years)    | Time sincefirstdiagnosisofpsoriatic arthritis(years)    | Time sincefirstdiagnosisofpsoriatic arthritis(years)    |                                                   |                                                   |
| n                                                       | 99                                                      | 100                                                     | 100                                               | 98                                                |
| Mean                                                    | 6.484                                                   | 6.512                                                   | 7.381                                             | 7.318                                             |
| SD                                                      | 7.1775                                                  | 8.1728                                                  | 7.4798                                            | 7.7610                                            |
| Medien                                                  | 3.934                                                   | 4.297                                                   | 4.705                                             | 4.951                                             |
| CASPARTotal Score                                       |                                                         |                                                         |                                                   |                                                   |
| n                                                       | 99                                                      | 100                                                     | 100                                               | 98                                                |
| Mean                                                    | 4.222                                                   | 4.270                                                   | 4.220                                             | 4.031                                             |
| SD                                                      | 0.8398                                                  | 0.8022                                                  | 0.8713                                            | 0.8550                                            |
| Medien                                                  | 4.000                                                   | 4.000                                                   | 4.000                                             | 4.000                                             |
| Disabiityindexscore(HAQ-DI)                             |                                                         |                                                         |                                                   |                                                   |
| n                                                       | 08                                                      | 100                                                     | 99                                                | 98                                                |
| Mean                                                    | 1.1620                                                  | 1.2200                                                  | 1.2828                                            | 1.1684                                            |
| SD                                                      | 0.63261                                                 | 0.60174                                                 | 0.58346                                           | 0.66486                                           |
| Median                                                  | 1.2500                                                  | 1.2500                                                  | 1.2500                                            | 1.2500                                            |
| Systemic glucocorlicoids use atrandomization,n(%)       | Systemic glucocorlicoids use atrandomization,n(%)       | Systemic glucocorlicoids use atrandomization,n(%)       | Systemic glucocorlicoids use atrandomization,n(%) | Systemic glucocorlicoids use atrandomization,n(%) |
| Yes                                                     | 19 (19.2)                                               | 23 (23.0)                                               | 18 (18.0)                                         | 21 (21.4)                                         |
| No                                                      | 80 (80.8)                                               | 77 (77.0)                                               | 82 (82.0)                                         | 77 (78.8)                                         |
| Numberof prior anti-TNF PsA therapies*,n(%)             | Numberof prior anti-TNF PsA therapies*,n(%)             | Numberof prior anti-TNF PsA therapies*,n(%)             | Numberof prior anti-TNF PsA therapies*,n(%)       | Numberof prior anti-TNF PsA therapies*,n(%)       |
| 0=                                                      | 65 (65.7)                                               | 63 (63.0)                                               | 67 (67.0)                                         | 63 (64.3)                                         |
| =1                                                      | 21 (21.2)                                               | 28 (26.0)                                               | 18 (18.0)                                         | 16 (16.3)                                         |
| >=2                                                     | 13 (13.1)                                               | 11 (11.0)                                               | 17 (17.0)                                         | 19 (19.4)                                         |
| Patients with psoriasis≥3%of BSA,n (%)                  | Patients with psoriasis≥3%of BSA,n (%)                  | Patients with psoriasis≥3%of BSA,n (%)                  | Patients with psoriasis≥3%of BSA,n (%)            | Patients with psoriasis≥3%of BSA,n (%)            |
| Yes                                                     | 50 (50.5)                                               | 58 (58.0)                                               | 41 (41.0)                                         | 43 (43.9)                                         |
| No                                                      | 49 (49.5)                                               | 42 (42.0)                                               | 59 (59.0)                                         | 55 (56.1)                                         |
| Distalinterphalangealjointarthrilis,n(%)                | Distalinterphalangealjointarthrilis,n(%)                | Distalinterphalangealjointarthrilis,n(%)                | Distalinterphalangealjointarthrilis,n(%)          | Distalinterphalangealjointarthrilis,n(%)          |
| Yes                                                     | 62 (62.6)                                               | 57 (57.0                                                | 82 (62.0)                                         | 49 (50.0)                                         |
| No                                                      | 37 (37.4)                                               | 43 (43.0)                                               | 38 (38.0)                                         | 48 (49.0)                                         |
| Presenceof arthritismutilans,n (%)                      |                                                         |                                                         |                                                   |                                                   |
| Yes                                                     | 7 (7.1)                                                 | 7 (7.0)                                                 | 5 (5.0)                                           | 6 (6.1)                                           |

<div style=\"page-break-after: always\"></div>

| BackgroundCharacteristics          | AIN45775mg N=99   | N=100     | AIN457150mgAIN457300mg N=100   | Placebo N=98   |
|------------------------------------|-------------------|-----------|--------------------------------|----------------|
| No                                 | 91(91.9)          | 93 (93.0) | 95 (95.0)                      | 92 (93.9)      |
| Asymetricperipheral arthritis,n(%) |                   |           |                                |                |
| Yes                                | 61 (61.6)         | 64 (64.0) | 68 (68.0)                      | 61 (62.2)      |
| No                                 | 38 (38.4)         | 38 (36.0) | 32 (32.0)                      | 37 (37.8)      |
| Polyarticular arthrilis,n (%)      |                   |           |                                |                |
| Yes                                | 89 (89.9)         | 88 (86.0) | 85 (85.0)                      | 81 (82.7)      |
| No                                 | 10 (10.1)         | 14 (14.0) | 15 (15.0)                      | 17 (17.3)      |
| Spondylitis, n (%)                 |                   |           |                                |                |
| Yes                                | 21 (21.2)         | 23 (23.0) | 24 (24.0)                      | 18 (18.4)      |
| No                                 | 77 (77.8)         | 77 (77.0) | 76 (76.0)                      | 80 (81.6)      |

Startedbefore thefirstdosing ofstudytreatmentCASPAR=CIASsificationcriteriaforPsoriatic;

MTX=Methotrexate:PsA=PsoriaticArthritis;Arthritis:HAQ-Dl=HealthAssessment Questionnaire-Disability Index: TNF=Tumornecrosisfactor:BSA=Bodysurfacearea

## Numbers analysed

The following analysis sets were used for the data analysis: Randomised set; Full analysis set (FAS); and Safety  set.  The  total  number  of  patients  in  each  analysis  set  was  397.  The  number  of  patients  by treatment group was 99 in the secukinumab 75 mg group, 100 in the secukinumab 150 mg group, 100 in the secukinumab 300 mg group, and 98 in the placebo group ( Table 12 ). Among the 98 placebo-treated subjects, 88 were treated with secukinumab after re-randomization.

Efficacy analyses were performed on an intent-to-treat basis, involving all 397 randomized patients who were assigned to study treatment (FAS).

Table 12. Analysis sets by treatment sequence (Randomised set, Study F2312)

| AnalysisSet                             | AIN457 75mg   | AIN457 150mg   | AIN457 300mg   |   Placebo |   Placebo Non- responder -AIN457 150mg |   Placebo Non- responder -AIN457 300mg |   Placebo Responder -AIN457 150mg |   Placebo Responder -AIN457 300mg |
|-----------------------------------------|---------------|----------------|----------------|-----------|----------------------------------------|----------------------------------------|-----------------------------------|-----------------------------------|
| Randomizedset                           | 66            | 100            | 100            |        98 |                                     27 |                                     28 |                                16 |                                17 |
| Fullanalysisset                         | 99            | 100            | 100            |        98 |                                     27 |                                     28 |                                16 |                                17 |
| Safety set                              | 99            | 100            | 100            |        98 |                                     27 |                                     28 |                                16 |                                17 |
| TreatedwithAlN457 afterre-randomization |               |                |                |        88 |                                     27 |                                     28 |                                16 |                                17 |

Placebocolumnincludepatientsrandomizedtoplaceboatthebeginningandre-randomizedtoAlN457later,aswellasthoseprematurelydiscontinuedwithout takingAIN457.

PlaceboDatientswhoarenotre-randomizedarecountedintheplacebototalonly.

## Outcomes and estimation

The primary efficacy variable ACR20 response using non-responder imputation for the FAS at Week 24 is shown in Table 13 and Figure 9 . Secukinumab 75 mg, 150 mg and 300 mg were statistically superior to placebo at Week 24 using the pre-defined statistical testing hierarchy. Thus, the primary endpoint of this study was met. The ACR20 response rates at Week 24 were 29.3% for secukinumab 75 mg (p=0.0399; adjusted  p-value),  51.0%  for  secukinumab  150  mg  (p&lt;0.0001),  and  54.0% for  secukinumab  300  mg (p&lt;0.0001) compared with 15.3% for placebo. The magnitude of the treatment effect vs placebo was similar between the secukinumab 150 mg and 300 mg dose groups.

<div style=\"page-break-after: always\"></div>

Table 13. ACR20 response using non-responder imputation - up to Week 24 (Full analysis set, Study F2312)

| Analysis visit   | TreatmentGroup     | n/M    | (%)    | Comparison   | Odds ratio   | 95% Confidence Interval   | p-value (unadjusted)   |
|------------------|--------------------|--------|--------|--------------|--------------|---------------------------|------------------------|
| Week1            | AIN45775mg（N=99)   | 10/99  | (10.1) | vsPlacebo    | 1.46         | (0.53,4.01)               | 0.4633                 |
| Week1            | AIN457150mg（N=100) | 11/100 | (11.0) | vsPlacebo    | 1.55         | (0.57,4.19)               | 0.3903                 |
| Week1            | AIN457300mg(N=100) | 12/100 | (12.0) | vsPlacebo    | 1.77         | (0.66,4.71)               | 0.2534                 |
| Week1            | Placebo (86=N)     | 7/98   | (7.1)  |              |              |                           |                        |
| Week2            | AIN45775mg(N=99)   | 13/99  | (13.1) | vsPlacebo    | 0.90         | (0.40,2.04)               | 0.8025                 |
| Week2            | AIN457150mg(N=100) | 25/100 | (25.0) | vsPlacebo    | 1.90         | (0.92,3.96)               | 0.0850                 |
| Week2            | AIN457300mg(N=100) | 24/100 | (24.0) | vsPlacebo    | 1.90         | (0.91,3.96)               | 0.0876                 |
| Week2            | Placebo (N =98)    | 14/98  | (14.3) |              |              |                           |                        |
| Week3            | AIN45775mg(N=99)   | 23/99  | (23.2) | vsPlacebo    | 1.67         | (0.81,3.45)               | 0.1651                 |
| Week3            | AIN457150mg(N=100) | 42/100 | (42.0) | vsPlacebo    | 4.10         | (2.06,8.15)               | <.0001                 |
| Week3            | AIN457300mg（N=100) | 37/100 | (37.0) | vsPlacebo    | 3.26         | (1.64,6.48)               | 0.0008                 |
| Week3            | Placebo (N =98)    | 15/98  | (15.3) |              |              |                           |                        |
| Week4            | AIN45775mg(N=99)   | 28/99  | (28.3) | vsPlacebo    | 2.02         | (1.01,4.04)               | 0.0474                 |
| Week4            | AIN457150mg(N=100) | 49/100 | (49.0) | vsPlacebo    | 5.17         | (2.64,10.12)              | <.0001                 |
| Week4            | AIN457300mg(N=100) | 46/100 | (46.0) | vsPlacebo    | 4.37         | (2.24,8.52)               | <.0001                 |
| Week4            | Placebo (N=98)     | 16/98  | (16.3) |              |              |                           |                        |
| Week8            | AIN45775mg (N=99)  | 35/99  | (35.4) | vs Placebo   | 2.01         | (1.06,3.82)               | 0.0322                 |
| Week8            | AIN457150mg（N=100) | 60/100 | (60.0) | vsPlacebo    | 5.83         | (3.08,11.05)              | <.0001                 |
| Week8            | AIN457300mg(N=100) | 47/100 | (47.0) | vsPlacebo    | 3.27         | (1.75,6.14)               | 0.0002                 |
| Week8            | Placebo (N=98)     | 21/98  | (21.4) |              |              |                           |                        |
| Week 12          | AIN45775mg（N=99)   | 33/99  | (33.3) | vsPlacebo    | 1.47         | (0.78,2.75)               | 0.2353                 |
| Week 12          | AIN457150mg（N=100) | 56/100 | (56.0) | vsPlacebo    | 4.17         | (2.23,7.80)               | <.0001                 |
| Week 12          | AIN457300mg(N=100) | 57/100 | (57.0) | vsPlacebo    | 4.04         | (2.18,7.51)               | <.0001                 |
| Week 12          | Placebo (N =98)    | 25/98  | (25.5) |              |              |                           |                        |
| Week16           | AIN45775mg (N=99)  | 33/99  | (33.3) | vsPlacebo    | 2.25         | (1.15,4.41)               | 0.0176                 |
| Week16           | AIN457150mg（N=100) | 60/100 | (60.0) | vsPlacebo    | 7.76         | (3.96,15.22)              | <.0001                 |
| Week16           | AIN457300mg(N=100) | 57/100 | (57.0) | vsPlacebo    | 6.14         | (3.18,11.86)              | <.0001                 |
| Week16           | Placebo (N=98)     | 18/98  | (18.4) |              |              |                           |                        |
| Week20           | AIN45775mg(N=99)   | 29/99  | (29.3) | vsPlacebo    | 2.13         | (1.06,4.28)               | 0.0327                 |
| Week20           | AIN457150mg（N=100) | 53/100 | (53.0) | vsPlacebo    | 6.42         | (3.25,12.67)              | <.0001                 |
| Week20           | AIN457300mg（N=100) | 59/100 | (59.0) | vsPlacebo    | 7.60         | (3.86,14.94)              | <.0001                 |
| Week20           | Placebo (N=98)     | 16/98  | (16.3) |              |              |                           |                        |
| Week24           | AIN45775mg(N=99)   | 29/99  | (29.3) | vsPlacebo    | 2.32         | (1.14,4.73)               | 0.0200                 |
| Week24           | AIN457150mg（N=100） | 51/100 | (51.0) | vsPlacebo    | 6.52         | (3.25,13.08)              | <.0001                 |
| Week24           | AIN457300mg（N=100) | 54/100 | (54.0) | vsPlacebo    | 6.81         | (3.42,13.56)              | <.0001                 |
| Week24           | Placebo (N=98)     | 15/98  | (15.3) |              |              |                           |                        |

Oddsratio,95%confidenceinterval,andp-valuearefromalogisticregressionmodelwithtreatmentand Oddsratio&gt;1favorsAlN457.

M:Numberofsubjectsinthetreaimentgroup.

n:ThenumberofsubjectswhoareACR20responderswiththecorrespondingimputationapproachinthe treatmentgroup.

Figure 9. ACR20 response using non-responder imputation - up to Week 24 (Full analysis set, Study F2312)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Secondary efficacy results

The results of the hypothesis tests within the testing strategy are shown in Table 14 . Based on adjusted p-values,  all  secondary  endpoints  at  Week  24  were  met  with  the  secukinumab  300  mg  dose  group compared  with  placebo.  For  secukinumab  150  mg  dose  group  compared  with  placebo,  all  secondary endpoints  were  met  with  the  exception  of  HAQ-DI  and  ACR50.  The  ACR50  treatment  effect  for secukinumab 150 mg vs placebo was similar to that of the secukinumab 300 mg, but it was not tested because the ACR50 was placed after HAQ-DI in the hierarchy and the HAQ-DI did not achieve statistical significance  (p=0.0555).    None  of  the  secondary  endpoints  were  met  with  secukinumab  75  mg  dose group  compared  with  placebo.  The  pooled  hypotheses  for  dactylitis  and  enthesitis  were  not  tested; however, the nominal p-values for the 150mg and 300mg showed a benefit for secukinumab vs placebo.

Table 14. Results for primary and secondary endpoints based on hierarchical testing sequence (Full Analysis Set - Study F2312)

p-value

<!-- image -->

| Hypothesis   | Endpoint              | Comparison             | unadjusted   | adjusted   | Statistically significant?   |
|--------------|-----------------------|------------------------|--------------|------------|------------------------------|
| H1           | ACR20atWeek24         | AIN45775mgvsPlacebo    | 0.0200       | 0.0399     | Yes                          |
| H2           | ACR20 atWeek24        | AIN457150mgvsPlacebo   | <0.0001      | <0.0001    | Yes                          |
| H3           | ACR20 atWeek24        | AIN457300mgvsPlacebo   | <0.0001      | <0.0001    | Yes                          |
| H4           | PASI75atWeek24        | AIN45775mgvsPlacebo    | 0.1650       | 0.1650     | No                           |
| H5           | PASI75 atWeelk 24     | AIN457150mgVsPlacebo   | 0.0006       | 0.0017     | Yes                          |
| HB           | PASI75at Week24       | AIN457300mgvsPlacebo   | 0.0001       | <0.0001    | Yes                          |
| H7           | PASI90 atWeek24       | AIN45775mgvsPlacebo    | 0.6421       | 0.6421     | No                           |
| H8           | PASI90atWeek24        | AIN457150mgVsPlacebo   | 0.0029       | 0.0057     | Yes                          |
| H9           | PASI90atWeek24        | AIN457300mgvsPlacebo   | 0.0002       | 9000'0     | Yes                          |
| H10          | DAS28CRPatWeek24      | AIN45775mgvsPlacebo    | 0.3763       | 0.6421     | No                           |
| H11          | DAS28CRPatWeek24      | AIN457150mgvsPlacebo   | 0.0008       | 0.0057     | Yes                          |
| H12          | DAS28CRPatWeek24      | AIN457300mgvsPlacebo   | 0.0004       | 0.0013     | Yes                          |
| H13          | SF36-PCSatWeek24      | AIN45775mgvsPlacebo    | 0.0482       | 0.6421     | No                           |
| H14          | SF36-FCSat Week24     | AIN457150mgvsPlacebo   | 0.0003       | 0.0057     | Yes                          |
| H15          | SF36-PCSaltWeek24     | AIN457300mgvsP1acebo   | <0.0001      | 0.0013     | Yes                          |
| H16          | HAQ-DIatWeek24        | AIN45775mgvsPlacebo    | 0.9195       | 0.9195     | Mo                           |
| H17          | HAQ-DI atWeek24       | AIN457150mgvsPlacebo   | 0.0278       | 0.0555     | No                           |
| H18          | HAQ-DIat Week24       | AIN457300mgvsPlacebo   | 0.0013       | 0.0040     | Yes                          |
| H19          | ACR50atWeek24         | AIN45775mgvsPlacebo    | 0.0245       | 0.9195     | No                           |
| H20          | ACR50 atWeek24        | AIN457150mgvsPlacebo   | <0.0001      | 0.0555     | No                           |
| H21          | ACR50alWeek24         | AIN457300mgvsP1acebo   | <0.0001      | 0.0040     | Yes                          |
| H22          | Dactylitis at Week 24 | AIN457pooledvs Placebo | 0.0114       | 0.9195     | No                           |
| H23          | Enthesitis at Week24  | AIN457pooledysPlacebo  | 0.0060       | 0.9105     | No                           |

PASI75 and PASI90 response was assessed in the subgroup of patients who had ≥ 3% of body surface area (BSA) affected by psoriatic skin involvement at baseline. For both PASI75 and PASI90 response, the difference compared with placebo at Week 24 was statistically significant for the secukinumab 150 mg and 300 mg treatment (PASI75: 48.3%, p=0.0006 and 63.4%, p&lt;0.0001; PASI90: 32.8%, p=0.0029 and 48.8%, p=0.0002, respectively).

For  DAS28-CRP  change  from  baseline,  a  statistically  significant  difference  relative  to  placebo  was observed for the secukinumab 150 mg and 300 mg doses at Week 24 (p=0.0008 and p=0.0004) and response for these 2 dose levels were similar (-1,58 and -1.61, respectively, compared to placebo -0.96).

For SF-36 PCS scores, a clear dose-response rate was observed for the 150 mg and 300 mg dose groups relative to placebo at most visits, including the Week 24 visit. Changes in the secukinumab 75 mg, 150 mg and 300 mg groups at Week 24 were 4.38, 6.39 and 7.25, respectively, and 1.95 in the placebo group. Differences in mean change from baseline were statistically significant for all the 3 secukinumab dose levels (p=0.0482, p=0.0003, and p&lt;0.0001, respectively).

The changes from baseline for the HAQ-DI score were higher in the 150 mg and 300 mg dose groups compared  with  placebo  at  most  visits  including  the  Week  24  visit  (-0.48  and  -0.56,  respectively; p=0.0278 and p=0.0013, respectively).

<div style=\"page-break-after: always\"></div>

ACR50  responder  rates  were  highest  in  the  secukinumab  150  mg  and  300  mg  group  compared  with placebo (p&lt;0.0001 for both 150 mg and 300 mg) and Week 24 responder rates for these 2 dose levels were similar. ACR50 responder rates were also higher in the 75 mg compared with placebo at Week 24 (p=0.0245).

Placebo had a greater percentage of patients without dactylitis resolution compared with secukinumab pooled dose in the dactylitis subset (i.e., patients who had dactylitis at baseline) at Week 24 (p=0.0114). Overall,  the  percentage  of  patients  without  resolution  of  dactylitis  at  Week  24  was  69.7%,  50.0%, 43.5%, 53.2%, and 85.2% for secukinumab 75 mg, 150 mg, 300 mg, secukinumab pooled, and placebo groups, respectively. These differences vs placebo were also greater for the comparison of the 150 mg and 300 mg dose groups vs placebo (p=0.0056 and p=0.0021, respectively).

Placebo had a greater percentage of patients without resolution of enthesitis compared with secukinumab pooled  dose  in  the  enthesitis  subset  (i.e.,  patients  who  had  enthesitis  at  baseline)  at  Week  24 (p=0.0060). Overall, the percentage of patients without resolution of enthesitis at Week 24 was 67.6%, 57.8%, 51.8%, 59.6%, and 78.5% for secukinumab 75 mg, 150 mg, 300 mg, secukinumab pooled, and placebo groups, respectively. At Week 24, these differences vs placebo were also greater for the 150 mg and  300  mg  dose  groups  vs  placebo  (p=0.0108  and  p=0.0025,  respectively).  P-values  quoted  for enthesitis and dactylitis are unadjusted for multiplicity.

## Summary of main efficacy results

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table 15. Summary of Efficacy for trial CAIN457F2306

Title: A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active psoriatic arthritis (Interim analyses at Week 52)

| Study identifier          | CAIN457F2306                                                        | CAIN457F2306                                                                                                                                                                             |
|---------------------------|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | Randomized, double-blind, parallel-group, placebo controlled design | Randomized, double-blind, parallel-group, placebo controlled design                                                                                                                      |
| Design                    | Duration of main phase:                                             | 52 weeks (interim analyses of a 2-year trial) Primary Efficacy analysis at Week 24                                                                                                       |
| Hypothesis                | Superiority                                                         | Superiority                                                                                                                                                                              |
| Treatments groups         | Secukinumab 10 mg/kg-75 mg                                          | Secukinumab 10 mg/kg iv at baseline and Weeks 2 and 4, then secukinumab 75 mg sc q4w. Number randomized 202.                                                                             |
| Treatments groups         | Secukinumab 10 mg/kg-150 mg                                         | Secukinumab 10 mg/kg iv at baseline and Weeks 2 and 4, then secukinumab 150 mg sc q4w. Number randomized 202.                                                                            |
| Treatments groups         | Placebo                                                             | Placebo. Number randomized 202.                                                                                                                                                          |
| Endpoints and definitions | Primary endpoint ACR20 response at Week 24                          | To demonstrate that the efficacy of secukinumab 75 or 150 mg at Week 24 was superior to placebo in patients with active PsA based on the proportion of patients achieving ACR20 response |

<div style=\"page-break-after: always\"></div>

|               | Secondary endpoint                                             | PASI75 response at Week 24                                     | To demonstrate that the efficacy of secukinumab 75 or 150 mg at Week 24 was superior to placebo based on the proportion of patients achieving a PASI75 response in the subgroup of patients who have ≥3% skin involvement with psoriasis   |
|---------------|----------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|               | Secondary endpoint                                             | PASI90 response at Week 24                                     | To demonstrate that the efficacy of secukinumab 75 or 150 mg at Week 24 was superior to placebo based on the proportion of patients achieving a PASI90 response in the subgroup of patients who have ≥3% skin involvement with psoriasis   |
|               | Secondary endpoint                                             | DAS28-CRP at Week 24                                           | To demonstrate that the improvement (change) from baseline on secukinumab 75 or 150 mg was superior to placebo for the DAS28-CRP at Week 24                                                                                                |
| Database lock | 09 October 2013 (last Visit 17 / Week 52 for interim analysis) | 09 October 2013 (last Visit 17 / Week 52 for interim analysis) | 09 October 2013 (last Visit 17 / Week 52 for interim analysis)                                                                                                                                                                             |

## Results and Analysis

| Analysis description                                        | Primary Analysis                                                      | Primary Analysis                     | Primary Analysis                     | Primary Analysis                         | Primary Analysis                         |
|-------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------|--------------------------------------|------------------------------------------|------------------------------------------|
| Analysis population and time point                          | Intent to treat 24 weeks                                              | Intent to treat 24 weeks             | Intent to treat 24 weeks             | Intent to treat 24 weeks                 | Intent to treat 24 weeks                 |
| description Descriptive statistics and estimate variability | Treatment group                                                       | Secukinumab 10 mg/kg-75 mg           | Secukinumab 10 mg/kg-150 mg          | Secukinumab 10 mg/kg-150 mg              | Placebo                                  |
| description Descriptive statistics and estimate variability | Number of subject                                                     | 202                                  | 202                                  | 202                                      | 202                                      |
| description Descriptive statistics and estimate variability | ACR20                                                                 | 50.5%                                | 50.0%                                | 50.0%                                    | 17.3%                                    |
| description Descriptive statistics and estimate variability | DAS28-CRP                                                             | -1.67                                | -1.62                                | -1.62                                    | -0.77                                    |
| description Descriptive statistics and estimate variability | Number of subjects with ≥3% BSA psorasis skin involvement at baseline | 108                                  | 108                                  | 108                                      | 109                                      |
| description Descriptive statistics and estimate variability | PASI75                                                                | 64.8%                                | 61.1%                                | 61.1%                                    | 8.3%                                     |
| description Descriptive statistics and estimate variability | PASI90                                                                | 49.1%                                | 45.4%                                | 45.4%                                    | 3.7%                                     |
| Effect estimate per comparison                              | ACR20                                                                 | Comparison groups                    | Comparison groups                    | Secukinumab 10 mg/kg-75                  | Secukinumab 10 mg/kg-75                  |
| Effect estimate per comparison                              | ACR20                                                                 | Logistic regression model            | Logistic regression model            | mg vs. Placebo 5.53                      | mg vs. Placebo 5.53                      |
| Effect estimate per comparison                              | ACR20                                                                 | Odds ratio 95% CI                    | Odds ratio 95% CI                    | 3.46, 8.85                               | 3.46, 8.85                               |
| Effect estimate per comparison                              | ACR20                                                                 | P-value                              | P-value                              | p<0.0001                                 | p<0.0001                                 |
| Effect estimate per comparison                              | ACR20                                                                 | Comparison groups                    | Comparison groups                    | Secukinumab 10 mg/kg- 150 mg vs. Placebo | Secukinumab 10 mg/kg- 150 mg vs. Placebo |
| Effect estimate per comparison                              | ACR20                                                                 | Logistic regression model Odds ratio | Logistic regression model Odds ratio | 5.39                                     | 5.39                                     |

<div style=\"page-break-after: always\"></div>

|       |                                                                    | 95% CI                                                             | 3.37, 8.62                                                         |
|-------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|       |                                                                    | P-value                                                            | p<0.0001                                                           |
|       | PASI75                                                             | Comparison groups                                                  | Secukinumab 10 mg/kg-75 mg vs. Placebo                             |
|       |                                                                    | P-value                                                            | p<0.0001                                                           |
|       | PASI75                                                             | Comparison groups                                                  | Secukinumab 10 mg/kg- 150 mg vs. Placebo                           |
|       |                                                                    | P-value                                                            | p<0.0001                                                           |
|       | PASI90                                                             | Comparison groups                                                  | Secukinumab 10 mg/kg-75 mg vs. Placebo                             |
|       |                                                                    | P-value                                                            | p<0.0001                                                           |
|       | PASI90                                                             | Comparison groups                                                  | Secukinumab 10 mg/kg- 150 mg vs. Placebo                           |
|       |                                                                    | P-value                                                            | p<0.0001                                                           |
|       | DAS28-CRP                                                          | Comparison groups                                                  | Secukinumab 10 mg/kg-75 mg vs. Placebo                             |
|       |                                                                    | P-value                                                            | p<0.0001                                                           |
|       | DAS28-CRP                                                          | Comparison groups                                                  | Secukinumab 10 mg/kg- 150 mg vs. Placebo                           |
|       |                                                                    | P-value                                                            | p<0.0001                                                           |
| Notes | Results of the primary endpoint as well as the secondary endpoints | Results of the primary endpoint as well as the secondary endpoints | Results of the primary endpoint as well as the secondary endpoints |

## Table 16. Summary of Efficacy for trial CAIN457F2312

Title:  A  Phase  III  randomized,  double-blind,  placebo-controlled  multicenter  study  of  subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety and tolerability up to 5 years in patients with Active Psoriatic Arthritis (Interim analyses at Week 24)

| Study identifier          | CAIN457F2312                                                        | CAIN457F2312                                                        | CAIN457F2312                                                                                                                                                                                 |
|---------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | Randomized, double-blind, parallel-group, placebo controlled design | Randomized, double-blind, parallel-group, placebo controlled design | Randomized, double-blind, parallel-group, placebo controlled design                                                                                                                          |
| Design                    | Duration of main phase:                                             | Duration of main phase:                                             | 24 weeks (interim analyses of a 5-year trial) Primary Efficacy analysis at Week 24                                                                                                           |
| Hypothesis                | Superiority                                                         | Superiority                                                         | Superiority                                                                                                                                                                                  |
| Treatments groups         | Secukinumab 75 mg                                                   | Secukinumab 75 mg                                                   | Secukinumab 75 mg sc at baseline, Weeks 1, 2, 3 and 4, followed by 75 mg sc q4w. Number randomized 99.                                                                                       |
|                           | Secukinumab 150 mg                                                  | Secukinumab 150 mg                                                  | Secukinumab 150 mg sc at baseline, Weeks 1, 2, 3 and 4, followed by 150 mg sc q4w.. Number randomized 100.                                                                                   |
|                           | Secukinumab 300 mg                                                  | Secukinumab 300 mg                                                  | Secukinumab 300 mg sc at baseline, Weeks 1, 2, 3 and 4, followed by 300 mg sc q4w. Number randomized 100.                                                                                    |
|                           | Placebo                                                             | Placebo                                                             | Placebo. Number randomized 98.                                                                                                                                                               |
| Endpoints and definitions | Primary endpoint                                                    | ACR20 response at Week 24                                           | To demonstrate that the efficacy of secukinumab 75, 150 or 300 mg at Week 24 is superior to placebo in patients with active PsA based on the proportion of patients achieving ACR20 response |

<div style=\"page-break-after: always\"></div>

Secondary endpoint

Secondary endpoint

Secondary endpoint

Database lock

## Results and Analysis

| Analysis description                                        | Primary Analysis                                                      | Primary Analysis                     | Primary Analysis                     | Primary Analysis          | Primary Analysis          | Primary Analysis          | Primary Analysis         |
|-------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------|--------------------------------------|---------------------------|---------------------------|---------------------------|--------------------------|
| Analysis population and time point                          | Intent to treat 24 weeks                                              | Intent to treat 24 weeks             | Intent to treat 24 weeks             | Intent to treat 24 weeks  | Intent to treat 24 weeks  | Intent to treat 24 weeks  | Intent to treat 24 weeks |
| description Descriptive statistics and estimate variability | Treatment group                                                       | Secukinumab 75 mg                    | Secukinuma b 150 mg                  | Secukinuma b 150 mg       | Secukinuma b 300 mg       | Placebo                   | Placebo                  |
| description Descriptive statistics and estimate variability | Number of subject                                                     | 99                                   | 100                                  | 100                       | 100                       | 98                        | 98                       |
| description Descriptive statistics and estimate variability | ACR20                                                                 | 29.3%                                | 51.0%                                | 51.0%                     | 54.0%                     | 15.3%                     | 15.3%                    |
| description Descriptive statistics and estimate variability | DAS28-CRP                                                             | -1.12                                | -1.58                                | -1.58                     | -1.61                     | -0.96                     | -0.96                    |
| description Descriptive statistics and estimate variability | Number of subjects with ≥3% BSA psorasis skin involvement at baseline | 43                                   | 50                                   | 50                        | 58                        | 41                        | 41                       |
| description Descriptive statistics and estimate variability | PASI75                                                                | 28.0%                                | 48.3%                                | 48.3%                     | 63.4%                     | 16.3%                     | 16.3%                    |
| description Descriptive statistics and estimate variability | PASI90                                                                | 12.0%                                | 32.8%                                | 32.8%                     | 48.8%                     | 9.3%                      | 9.3%                     |
| Effect estimate per comparison                              | ACR20                                                                 | Comparison groups                    | Comparison groups                    | Secukinumab 75 mg Placebo | Secukinumab 75 mg Placebo | Secukinumab 75 mg Placebo | vs.                      |
| Effect estimate per comparison                              | ACR20                                                                 | Logistic regression model Odds ratio | Logistic regression model Odds ratio | 2.32                      | 2.32                      | 2.32                      | 2.32                     |
| Effect estimate per comparison                              | ACR20                                                                 | 95% CI                               | 95% CI                               | 1.14, 4,73                | 1.14, 4,73                | 1.14, 4,73                | 1.14, 4,73               |
| Effect estimate per comparison                              | ACR20                                                                 | P-value                              | P-value                              | p=0.0200                  | p=0.0200                  | p=0.0200                  | p=0.0200                 |
| Effect estimate per comparison                              | ACR20                                                                 | Comparison groups                    | Comparison groups                    | Secukinumab Placebo       | 150 mg                    | 150 mg                    | vs.                      |
| Effect estimate per comparison                              | ACR20                                                                 | Logistic regression model Odds ratio | Logistic regression model Odds ratio | 6.52                      | 6.52                      | 6.52                      | 6.52                     |
| Effect estimate per comparison                              | ACR20                                                                 | 95% CI                               | 95% CI                               | 3.25, 13.08               | 3.25, 13.08               | 3.25, 13.08               | 3.25, 13.08              |
| Effect estimate per comparison                              | ACR20                                                                 | P-value                              | P-value                              | p<0.0001                  | p<0.0001                  | p<0.0001                  | p<0.0001                 |

PASI75

response  at

Week 24

PASI90

response  at

Week 24

DAS28-CRP

at Week 24

To demonstrate

that the

efficacy of

secukinumab 75, 150 or 300 mg at Week 24

is superior to placebo based on the proportion of  patients  achieving  a  PASI75  response  in

the subgroup of patients who have ≥3% skin involvement with psoriasis

To demonstrate

that the

efficacy of

secukinumab 75, 150 or 300 mg at Week 24

is superior to placebo based on the proportion of  patients  achieving  a  PASI90  response  in

the subgroup of patients who have ≥3% skin involvement with psoriasis

To demonstrate

that the

improvement

(change)  from  baseline  on  secukinumab  75,

150 or 300 mg is superior to placebo for the

DAS28-CRP at Week 24

12 May 2014 (last patient Visit 12/ Week 24 for interim analysis)

<div style=\"page-break-after: always\"></div>

|       | ACR20                                                              | Comparison groups                                                  | Secukinumab 300 Placebo                                            |                                                                    | mg                                                                 | vs.                                                                |
|-------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|       | ACR20                                                              | Logistic regression model Odds ratio                               | 6.81                                                               |                                                                    |                                                                    |                                                                    |
|       | ACR20                                                              | 95% CI                                                             | 3.42, 13.56                                                        |                                                                    |                                                                    |                                                                    |
|       | ACR20                                                              | P-value                                                            | p<0.0001                                                           |                                                                    |                                                                    |                                                                    |
|       | PASI75                                                             | Comparison groups                                                  | Secukinumab Placebo                                                | 75                                                                 | mg                                                                 | vs.                                                                |
|       | PASI75                                                             | P-value                                                            | p=0.1650                                                           |                                                                    |                                                                    |                                                                    |
|       | PASI75                                                             | Comparison groups                                                  | Secukinumab Placebo                                                | 150                                                                | mg                                                                 | vs.                                                                |
|       | PASI75                                                             | P-value                                                            | p=0.0006                                                           |                                                                    |                                                                    |                                                                    |
|       | PASI75                                                             | Comparison groups                                                  | Secukinumab Placebo                                                | 300                                                                | mg                                                                 | vs.                                                                |
|       | PASI75                                                             | P-value                                                            | p<0.0001                                                           |                                                                    |                                                                    |                                                                    |
|       | PASI90                                                             | Comparison groups                                                  | Secukinumab Placebo                                                | 75                                                                 | mg                                                                 | vs.                                                                |
|       | PASI90                                                             | P-value                                                            | p=0.6421                                                           |                                                                    |                                                                    |                                                                    |
|       | PASI90                                                             | Comparison groups                                                  | Secukinumab Placebo                                                | 150                                                                | mg                                                                 | vs.                                                                |
|       | PASI90                                                             | P-value                                                            | p=0.0029                                                           |                                                                    |                                                                    |                                                                    |
|       | PASI90                                                             | Comparison groups                                                  | Secukinumab Placebo                                                | 300                                                                | mg                                                                 | vs.                                                                |
|       | PASI90                                                             | P-value                                                            | p=0.0002                                                           |                                                                    |                                                                    |                                                                    |
|       | DAS28-CRP                                                          | Comparison groups                                                  | Secukinumab Placebo                                                | 75                                                                 | mg                                                                 | vs.                                                                |
|       | DAS28-CRP                                                          | P-value                                                            | p=0.3763                                                           |                                                                    |                                                                    |                                                                    |
|       | DAS28-CRP                                                          | Comparison groups                                                  | Secukinumab Placebo                                                | 150                                                                | mg                                                                 | vs.                                                                |
|       | DAS28-CRP                                                          | P-value                                                            | p=0.0008                                                           |                                                                    |                                                                    |                                                                    |
|       | DAS28-CRP                                                          | Comparison groups                                                  | Secukinumab Placebo                                                | 300                                                                | mg                                                                 | vs.                                                                |
|       | DAS28-CRP                                                          | P-value                                                            | p=0.0004                                                           |                                                                    |                                                                    |                                                                    |
| Notes | Results of the primary endpoint as well as the secondary endpoints | Results of the primary endpoint as well as the secondary endpoints | Results of the primary endpoint as well as the secondary endpoints | Results of the primary endpoint as well as the secondary endpoints | Results of the primary endpoint as well as the secondary endpoints | Results of the primary endpoint as well as the secondary endpoints |

## Analysis performed across trials

The data from the 2 Phase 3 trials (F2306 and F2312) were pooled to evaluate the primary and secondary treatment effect across subgroups. Subgroups examined were age, gender, race, region, weight, TNFα inhibitor status, number of prior TNFα inhibitors, reasons for stopping TNFα inhibitors, baseline DAS28 status, concomitant corticosteroid use, concomitant methotrexate use, baseline HAQ-DI; baseline CRP, baseline BSA. When pooling was performed the 'AIN457 Pooled' group constituted of iv-75 mg, iv-150 mg, 150 mg sc and 300 mg sc, and the 75 mg sc dose from Study CAIN457F2312 was excluded. The MAH justified the pooling of the iv-75 mg, iv-150 mg, 150 mg sc, and 300 mg sc dose groups (while leaving out 75 mg sc) by the similarity in response rates for the primary and key secondary endpoints for these groups.

The results from the pooling approach are briefly summarized in the Forest plots below.

<div style=\"page-break-after: always\"></div>

Figure 10. Treatment difference between secukinumab and placebo for ACR20 response at  Week 24 stratified by age, gender and race (FAS, for Studies F2306 and F2312)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 11. Treatment difference between secukinumab and placebo for ACR20 response at Week 24 stratified by region, body weight and TNF alpha inhibitor status (FAS, for Studies F2306 and F2312)

<!-- image -->

N=sample size

NA&amp;AUS=NorthAmericaandAustralia

IR=inadenuateresnonder

<div style=\"page-break-after: always\"></div>

Figure 12. Treatment difference between secukinumab and placebo for ACR20 response at  Week 24 stratified by baseline DAS28-CRP, concomitant corticosteroid use and concomitant methotrexate use (FAS, for Studies F2306 and F2312)

<!-- image -->

&lt;..-FavorsPlacebo.....-FavorsAlN457..-&gt;

AIN457300mg

AIN457150mg

AIN457Pooled

<div style=\"page-break-after: always\"></div>

Figure 13. Treatment difference between secukinumab and placebo for ACR20 response at  Week 24 stratified by baseline HAQ - DI, baseline hsCRP and number of prior TNF alpha inhibitors (FAS, for Studies F2306 and F2312)

<!-- image -->

## Supportive studies

A subset of 363 (18%) patients with moderate to severe plaque psoriasis and concomitant PsA from 2 phase 3 moderate to severe plaque psoriasis trials (Study CAIN457A2302 and CAIN457A2303) was pooled to provide additional information on selected endpoints (HAQ-DI, PASI75 and PASI90) for secukinumab 150 mg sc and 300 mg sc dose regimens.

Among moderate to severe plaque psoriasis patients with concomitant PsA, greater improvements in physical functioning, as measured by the mean change in HAQ-DI score from baseline (comparison with placebo up to Week 12), were observed with secukinumab 300 mg from both studies A2302 and A2303. For both studies, the mean HAQ-DI score at baseline was comparable across the treatment groups. In Study A2302, the mean change in HAQ-DI score at Week 12 was -0.18, and -0.35 for those patients treated with secukinumab 150 mg and 300 mg, respectively, compared with -0.08 for placebo. In Study A2303, the mean change in HAQ-DI score at Week 12 was -0.19, and -0.41 for those patients treated with secukinumab 150 mg and 300 mg, respectively.

<div style=\"page-break-after: always\"></div>

## Table 17. Week 12 data for moderate to severe plaque psoriasis patients with concomitant PsA from Study A2302 and Study A2303

|             | CAIN457A2302             | CAIN457A2302             | CAIN457A2302            | CAIN457A2302                                     | CAIN457A2303             | CAIN457A2303             | CAIN457A2303             | CAIN457A2303                                     |
|-------------|--------------------------|--------------------------|-------------------------|--------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------------------------------|
|             | Response rate of PASI 75 | Response rate of PASI 90 | Mean change in HAQ-DI © | %of patients with change of ≥0.3 HAQ-DI © (MCID) | Response rate of PASI 75 | Response rate of PASI 90 | Mean change in HAQ- DI © | %of patients with change of ≥0.3 HAQ-DI © (MCID) |
| 150 mg      | 70%                      | 44%                      | -0.18                   | 26.7%                                            | 59%                      | 39%                      | -0.19                    | 31.7%                                            |
| 300 mg      | 68%                      | 53%                      | -0.35                   | 47.1%                                            | 72%                      | 44%                      | -0.41                    | 45.5%                                            |
| Placebo     | 4%                       | 0%                       | -0.08                   | 21.5%                                            | 2%                       | 2%                       | 0.02                     | 12.8%                                            |
| Etanercept* | -                        | -                        | -                       | -                                                | 39%                      | 18%                      | -0.29                    | 38.2%                                            |

* EU Sourced

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The PsA clinical development program includes two phase II studies (A2206 in PsA patients and F2201 in a related arthritic indication with RA patients) and two pivotal phase III studies PsA (F2306 and F2312). Pivotal  efficacy  data  up  to  Week  24  (Study  F2312)  and  up  to  Week  52  (Study  F2306)  have  been provided.  In  addition,  data  on  a  subset  of  363  psoriasis  patients  with  concomitant  PsA  from  psoriasis Studies A2302 and A2303 have been pooled to obtain information on selected endpoints (HAQ-DI, PASI 75/90; the latter study also included active comparator etanercept). In addition, follow-up data from five phase III psoriasis studies have been provided with the target secukinumab doses of 150 mg and 300 mg.

Recommendations of the EMA clinical guidance for psoriatic arthritis (Guideline on clinical investigation of medicinal  products  indicated  for  the  treatment  of  psoriatic  arthritis,  CHMP/EWP/438/04)  have  mostly been taken into account in the clinical development programme.

The initial doses and the dosing regimen in phase II studies were based on preclinical in vivo efficacy data in animal models which were evaluated during the initial MAA for Cosentyx.

The  two  phase  II  studies  A2206  and  F2201  provided  preliminary  evidence  of  efficacy  in  two  arthritic disease models, PsA and RA. The posology carried forward to the phase III studies was mainly based on PK/PD modelling and simulation of different treatment regimens as well as data in psoriasis.

The study population in phase III studies consisted of adults with active moderate to severe PsA. They fulfilled the CASPAR diagnostic criteria for PsA and the disease activity was based on 3 or more tender joints and 3 or more swollen joints.

Study  F2306  was  a  double-blind,  randomized,  parallel-group,  placebo-controlled  study.  The  52-week interim analyses of the 2-year study was provided, with the assessment of the primary efficacy variable of ACR20 response at Week 24. Loading regimen was secukinumab 10 mg/kg iv at baseline and at Weeks 2 and 4, followed by maintenance treatment with 75 mg or 150 mg sc q4w. The efficacy variables chosen covered relevant aspects of the disease except for the lack of dedicated assessment of axial involvement. The MAH was requested to discuss this issue and present any efficacy data available with respect to axial arthritis or  any  evidence that efficacy can be extrapolated to this sub-group of PsA patients. The MAH noted that only a small number of PsA patients within the studies had axial involvement, and therefore

<div style=\"page-break-after: always\"></div>

assessments of axial involvement would have been difficult to demonstrate meaningful data. However, the  MAH  considered  that  data  from  the  AS  studies  which  show  a  clear  effect  of  secukinumab  on  key measures of efficacy related to axial involvement and overall physical function could be extrapolated to the  PsA  patients.  The  CHMP  agreed  that  PsA  and  AS  represent  spondyloarthritides  with  some  clinical overlap and therefore considering the overall weight of evidence on the efficacy of secukinumab in both PsA  and  AS,  such  extrapolation  was  considered  meaningful.  A  statement  on  the  low  number  of  PsA patients with axial involvement was included in Section 5.1 of the SmPC.

The design of Study F2312 was identical to that of Study F2306, but the iv loading regimen in the latter study  was  replaced  by  a  sc  loading  regimen  that  is  similar  to  the  one  approved  for  the  treatment  of psoriasis (sc dosing at baseline, Weeks 1, 2, 3 and 4 and then q4w). Also, an additional 300 mg sc dose arm was included. No assessment of progression of structural damage was performed in this study.

## Efficacy data and additional analyses

For  Study  F2306,  202  patients  were  randomized  to  each  of  the  3  treatment  groups  (secukinumab  10 mg/kg-75 mg, secukinumab 10 mg/kg-150 mg and placebo). Baseline  disease  activity  was  consistent with moderate to severe PsA and generally comparable across the treatment groups.

The primary efficacy endpoint was achieved as secukinumab at both 10 mg/kg-75 mg and 10 mg/kg-150 mg doses was statistically significantly superior to placebo for ACR20 response at Week 24 (p&lt;0.0001). The ACR20 response rates at Week 24 were 50.5% for secukinumab 75 mg, 50.0% for secukinumab 150 mg and 17.3% for placebo. Superior response rates compared to placebo were seen as early as from Week 1 onwards, with p-values &lt;0.0001 at each time point.

For Study F2312, a total of 397 patients were randomized to 4 treatment groups: secukinumab 75 mg, 150 mg, 300 mg, and placebo. The primary efficacy endpoint was achieved as secukinumab at all doses was  statistically  significantly  superior  to  placebo  for  ACR20  response  at  Week  24  (p&lt;0.0001  for secukinumab  150  mg  and  300  mg  vs.  placebo,  p=0.0200  for  secukinumab  75  mg  vs.  placebo).  The ACR20 response rates at Week 24 were 29.3% for secukinumab 75 mg, 51.0% for secukinumab 150 mg, 54.0 for secukinumab 300 mg and 15.3% for placebo. For the 150 mg and 300 mg doses, statistically superior response rates compared to placebo were seen from Week 3 onwards.

All secondary endpoints at Week 24 were met with the 300 mg dose group compared with placebo. For the 150 mg dose group, secondary endpoints within the testing hierarchy were met until HAQ-DI. For ACR50 (placed after HAQ-DI in the hierarchy), the treatment effect was however similar to that of the 300 mg dose. Among exploratory endpoints, relevant improvements in quality of life  were  noted  with both secukinumab 150 mg and 300 mg doses.

ACR20,  ACR50  and  ACR70  response  rates  at  Week  24  were  higher  in  TNFα  inhibitor  naïve  patients compared with TNFα-IR patients. This is consistent with secukinumab data in psoriasis and also a general phenomenon in biological therapies. The subgroup analysis by TNFα inhibitor status at Week 24 provided evidence  that  the  ACR20  response  rates  in  TNFα-IR  patients  are  better  with  the  300  mg  dose.  The updated Week  52 efficacy data confirmed these results. Therefore, for TNFα-IR patients the recommended dose is 300 mg sc.

Based  on  temporal  efficacy  data,  a  time  point  earlier  than  24  weeks  could  have  been  chosen  for  the assessment  of  the  primary  endpoint.  55  placebo  patients  were  re-randomized  at  Week  16  and  were treated as MAR at Week 24 in the MMRM analyses. The MAH was requested to discuss the validity of the time point chosen for the primary endpoint analysis.

The MAH responded that the time point for the assessment of the primary endpoint at 24 weeks was based  on  the  EMA  guideline  and  the  need  to  harmonize  the  efficacy  and  the  structural  damage assessments. In addition, it was considered that the more stringent endpoints like ACR70 and DAS-28

<div style=\"page-break-after: always\"></div>

remission need longer time to become evident. As the placebo escape for non-responders at Week 16 may have resulted in potential bias, further sensitivity analyses were performed at Week 24 where the actual data from patients who were switched from placebo to active treatment at week 16 were analysed as placebo. In these analyses the conclusions of the clinical study report remained valid.

The MAH proposed a time point of 16 weeks for consideration to discontinue treatment in patients who have shown no response and this was agreed by the CHMP and is reflected in Section 4.2 of the SmPC.

Within  analyses  performed  across  trials,  similar  efficacy  at  Week  24  based  on  ACR  20,  50  and  70 responses was seen for both iv-75 mg and iv-150 mg dose groups in Study F2306. These results suggest a significant contribution of the iv loading dose to ACR response at Week 24. However, the doses began to separate around Week 32, and by Week 52, the ACR 20, 50 and 70 responses were approximately 3%, 10% and 3% higher in the iv-150 mg dose group. Similar separation at Week 32 was also seen in PASI 75 and 90 responses. In Study F2312, a clear difference in efficacy between the 75 mg sc regimen and the higher 150/300 mg sc dose regimens was evident. The 75 mg dose was statistically not significantly different to placebo, and it was clinically inferior to the 150 mg and 300 mg doses. The MAH was asked to provide an explanation for these observations. The MAH provided a simulated secukinumab concentration profile,  illustrating  the  overriding  contribution  of  the  iv  loading  regimen  towards  exposure  for  the respective 75 mg and 150 mg sc dosing regimens over the first 24 weeks of the study (although minor differences in exposure resulting from these regimens are predicted starting from Week 8). The CHMP agreed that this obscured the possibility to observe a dose-response during this period of time.

Several analyses were done in subpopulations across secukinumab 150 mg (n=100), secukinumab 300 mg (n=100), secukinumab pooled (n=604) and placebo pooled (n=300) groups.

In  the  analysis  by  weight,  ACR20  response  was  decreased  in  patients  weighing  ≥90  kg.  However,  it seemed that other endpoints including the more clinically relevant and more stringent ACR 50 and 70 responses were similar between the doses of 150 mg and 300 mg. The MAH provided further data based on  weight  groups,  stratified  by  TNF-a  status  from  study  F2312.  For  the  TNF-alpha  inhibitor  naïve subgroup of patients ≥ 90 kg, there was a difference in ACR 20 response at Week 24 in the 150 mg and 300 mg dose groups (50.0% and 65.0%, respectively) but not in the more stringent endpoint ACR50 (43.3%  and  40.0%,  respectively).  In  the  TNFa-IR  group  at  Week  24,  the  ACR  50  response  rate  was higher in the ≥ 90 kg weight group with the 300 mg dose, in line with the proposed posology.  At Week 52 the ACR 50 responses with both 150 mg and 300 mg dose continued to be similar within each weight group. According to the MAH, the most clinically relevant factor for stratification was considered to be TNF-alpha  response  status  and  stratification  by  body  weight  was  discounted  due  to  the  resulting  very small  sample  sizes  per  subset.  The  MAH´s  justifications  were  accepted  by  the  CHMP  as  no  consistent clinically  meaningful  benefit  of  the  300  mg  dose  over  the  150  mg  dose  in  heavier  patients  could  be observed.  The  CHMP  therefore  concluded  that  no  dose  adjustment  based  on  body  weight  would  be needed.  The  higher  efficacy  observed  with  the  300  mg  dose  in  the  TNFα-IR  patients  &gt;90kg  was consistent with the proposed 300 mg dose for these patients.

Among PsA  patients  with  psoriasis  (BSA  ≥3%),  higher  PASI75  and  PASI90  rates  were  observed  with secukinumab 300 mg dose compared to the 150 mg dose. This is consistent with the phase III psoriasis program. The difference was particularly evident in patients with moderate to severe psoriasis. Therefore the  dosing  proposed  for  patients  with  concomitant  moderate  to  severe  plaque  psoriasis, i.e., 300  mg secukinumab by sc injection, was considered justified.

## 2.4.1. Conclusions on the clinical efficacy

Both phase III studies met the primary endpoint as ACR20 response rates with all secukinumab doses tested  were  statistically  significantly  higher  compared  to  placebo  at  Week  24.  With  the  proposed  sc

<div style=\"page-break-after: always\"></div>

induction and maintenance regimen, the 150 mg dose provided clinically more relevant level of efficacy compared to the 75 mg dose, in particular in the long-term treatment up to Week 52. Based on subgroup analyses, the 300 mg dose was considered more appropriate for patients with concomitant moderate to severe plaque psoriasis and for TNFα-IR patients.

Other  endpoints  related  to  joint  and  skin  disease,  physical  function,  health-related  quality  of  life  and prevention of progression of structural damage  consistently show  clinically relevant efficacy of secukinumab in the treatment of PsA.

## 2.5. Clinical safety

## Introduction

The secukinumab development program studied 7048 patients, including 6200 patients exposed to at least one dose of secukinumab in any indication, and 6267 patient-years of secukinumab exposure, are included in the safety pooling ( Table 18 ). The safety data in the present submission provide an additional 2679 patient-years of secukinumab exposure (75% increase), including 955 patient-years of exposure in PsA patients and 691 patient-years of exposure in AS patients, beyond the 3588 patientyears of exposure reported previously for the psoriasis development program.

## Patient exposure

## Table 18. Exposure to secukinumab across Pools A, B1, B and C in the entire treatment period

|               | Pool A           | Pool A            | Pool A            | Pool A                  | Pool B1   | Pool B1           | Pool B1           | Pool B1                  | Pool B   | Pool B             | Pool B             | Pool B                 | Pool C                   |
|---------------|------------------|-------------------|-------------------|-------------------------|-----------|-------------------|-------------------|--------------------------|----------|--------------------|--------------------|------------------------|--------------------------|
|               | Any 75 mg N=39 1 | Any 150 mg N=43 8 | Any 300 mg N=14 5 | Any AIN4 57 dose N=97 4 |           | Any 150 mg N=68 1 | Any 300 mg N=40 0 | Any AIN4 57 dose N=14 72 |          | Any 150 mg N=19 19 | Any 300 mg N=16 18 | Any AIN457 dose N=3928 | Any AIN4 57 dose N=62 00 |
| ≥ 8 wk        | 382              | 431               | 140               | 953                     |           | 671               | 394               | 1447                     |          | 1888               | 1585               | 3855                   | 6031                     |
| ≥ 16 wk       | 373              | 410               | 128               | 911                     |           | 581               | 323               | 1277                     |          | 1572               | 1303               | 3248                   | 5287                     |
| ≥ 24 wk       | 367              | 388               | 110               | 865                     |           | 556               | 298               | 1221                     |          | 1521               | 1250               | 3138                   | 4964                     |
| ≥ 52 wk       | 225              | 226               | 2                 | 453                     |           | 317               | 101               | 643                      |          | 869                | 667                | 1761                   | 3671                     |
| Total pt- yrs | 420.0            | 444.9             | 90.1              | 955.0                   |           | 616.5             | 278.6             | 1315. 1                  |          | 1572. 1            | 1232. 3            | 3224.5                 | 6266. 6                  |

Pool A consisted of 2 pivotal placebo-controlled Phase 3 trials (F2306 and F2312) in PsA with placebo and dose  comparisons  that  allow  risks  to  be  evaluated  in  the  PsA  population  during  the  first  16  weeks  of treatment, which was the placebo-controlled phase, and during the entire treatment period (median 48 weeks of exposure to secukinumab, interim analyses on week 52 in study F2306 and on week 24 in study F2312).

Pool B1 included an expanded PsA population with PsA patients from the 2 Phase 3 PsA trials, F2306 and F2312, and psoriasis patients with concomitant PsA from 3 Phase 3 psoriasis trials, A2302, A2303, and A2304).

Pool B (a mixed population of PsA patients from the 2 Phase 3 PsA trials, F2306 and F2312, and psoriasis patients  from  the  5  Phase  3  psoriasis  trials  A2302,  A2303,  A2304,  A2308,  and  A2309)  increased  the

<div style=\"page-break-after: always\"></div>

probability of observing less common events over long-term treatment for the target doses of 150 mg sc and 300 mg sc.

Pool C, the largest data pool, includes all patients treated with secukinumab in 42 studies and maximised the probability of observing rare events in patients receiving secukinumab.

## Induction and placebo-controlled study period of Pool A

The overall incidence of AEs during the loading period from Weeks 0 to 8 did not indicate differences in tolerability across the secukinumab 75 mg, 150 mg and 300 mg sc and pooled 10 mg/kg iv loading group or to placebo. A similar AE profile was observed for Weeks 0 to 16 ( Table 19 ).

Table 19. Most frequent AEs by preferred term (&gt; 2% in any group) - Short-term period (16 weeks) (Pool A: Phase 3 PsA trials - Safety set)

| PreferredTerm                   | AIN457 75mg 66=N n (%)   | AIN457 150mg N=100 n (%)   | AIN457 300mg N=100 n (%)   | AIN457 10mg/kg -75mg N=202 n (%)   | AIN457 10mg/kg -150mg N=202 n (%)   | Any AIN457 N=703 n (%)   | Placebo N=300 n (%)   |
|---------------------------------|--------------------------|----------------------------|----------------------------|------------------------------------|-------------------------------------|--------------------------|-----------------------|
| -AnyAE                          | 48 (48.5)                | 57 (57.0)                  | 56 (56.0)                  | 122 (60.4)                         | 131 (64.9)                          | 414(58.9)                | 175(58.3)             |
| Nasopharyngitis                 | 6 (6.1)                  | 4 (4.0)                    | 6 (6.0)                    | 14 (6.9)                           | 19. (9.4)                           | 49 (7.0)                 | 17 (5.7)              |
| Upperrespiratorytract infection | 10 (10.1)                | 8(8.0)                     | 4 (4.0)                    | 9 (4.5)                            | 13(6.4)                             | 44(6.3)                  | 17(5.7)               |
| Headache                        | 2 (2.0)                  | 4 (4.0)                    | 7 (7.0)                    | 11 (5.4)                           | 11 (5.4)                            | 35 (5.0)                 | 10 (3.3)              |
| Nausea                          | 4 (4.0)                  | 4 (4.0)                    | 3(3.0)                     | 5(2.5)                             | 4 (2.0)                             | 20 (2.8)                 | 6(2.0)                |
| Diarrhoea                       | 3 (3.0)                  | 2 (2.0)                    | 2 (2.0)                    | 4 (2.0)                            | 6(3.0)                              | 17 (2.4)                 | 9 (3.0)               |
| Hypercholesterolaemia           | 1 (1.0)                  | 2 (2.0)                    | 0                          | 8 (4.0)                            | 6 (3.0)                             | 17 (2.4)                 | 6 (2.0)               |
| Hypertension                    | 0                        | 0                          | 3 (3.0)                    | 7 (3.5)                            | 3 (1.5)                             | 13 (1.8)                 | 8 (2.7)               |
| Urinarytractinfection           | 1 (1.0)                  | 4 (4.0)                    | 2 (2.0)                    | 2 (1.0)                            | 4 (2.0)                             | 13 (1.8)                 | 6 (2.0)               |
| Backpain                        | 3 (3.0)                  | 1 (1.0)                    | 0                          | 5 (2.5)                            | 3 (1.5)                             | 12 (1.7)                 | 5 (1.7)               |
| Pruritus                        | 1 (1.0)                  | 2 (2.0)                    | 2 (2.0)                    | 0                                  | 6 (3.0)                             | 11 (1.6)                 | 4 (1.3)               |
| Fatigue                         | 2 (2.0)                  | 1 (1.0)                    | 1 (1.0)                    | 5 (2.5)                            | 1 (0.5)                             | 10 (1.4)                 | 7 (2.3)               |
| Oralherpes                      | 1 (1.0)                  | 0                          | 4 (4.0)                    | 0                                  | 5 (2.5)                             | 10 (1.4)                 | 3 (1.0)               |
| Oropharyngealpain               | 0                        | 1 (1.0)                    | 2 (2.0)                    | 4 (2.0)                            | 3 (1.5)                             | 10 (1.4)                 | 7 (2.3)               |
| Cough                           | 0                        | 1 (1.0)                    | 3 (3.0)                    | 1 (0.5)                            | 4 (2.0)                             | 9 (1.3)                  | 8 (2.7)               |
| Dizziness                       | 0                        | 1 (1.0)                    | 2 (2.0)                    | 2 (1.0)                            | 4 (2.0)                             | 9 (1.3)                  | 3 (1.0)               |
| Dyslipidaemia                   | 0                        | 2 (2.0)                    | 0                          | 3 (1.5)                            | 4 (2.0)                             | 9 (1.3)                  | 7 (2.3)               |
| Gastroenteritis                 | 2 (2.0)                  | 1 (1.0)                    | 1 (1.0)                    | 2 (1.0)                            | 3 (1.5)                             | 9 (1.3)                  | 3 (1.0)               |
| Haematuria                      | 1 (1.0)                  | 3 (3.0)                    | 2 (2.0)                    | 3 (1.5)                            | 0                                   | 9 (1.3)                  | 1 (0.3)               |
| Vomiting                        | 2 (2.0)                  | 2 (2.0)                    | 2 (2.0)                    | 3 (1.5)                            | 0                                   | 9 (1.3)                  | 2 (0.7)               |
| Alanineaminotransferase         | 0                        | 1 (1.0)                    | 2 (2.0)                    | 2 (1.0)                            | 3 (1.5)                             | 8 (1.1)                  | 3(1.0)                |
| Arthralgia                      | 1 (1.0)                  | 0                          | 2 (2.0)                    | 3(1.5)                             | 2 (1.0)                             | 8 (1.1)                  | 4 (1.3)               |
| Bronchitis                      | 0                        | 2 (2.0)                    | 0                          | 3 (1.5)                            | 3 (1.5)                             | 8 (1.1)                  | 7 (2.3)               |
| Oedemaperipheral                | 3 (3.0)                  | 2 (2.0)                    | 0                          | 1 (0.5)                            | 2 (1.0)                             | 8 (1.1)                  | 0                     |
| Paininextremity                 | 3 (3.0)                  | 1 (1.0)                    | 0                          | 3 (1.5)                            | 1 (0.5)                             | 8 (1.1)                  | 5 (1.7)               |
| Rhinitis                        | 3 (3.0)                  | 2 (2.0)                    | 0                          | 3 (1.5)                            | 0                                   | 8 (1.1)                  | 0                     |
| Depression                      | 0                        | 0                          | 1 (1.0)                    | 4 (2.0)                            | 2 (1.0)                             | 7 (1.0)                  | 8 (2.7)               |
| Dyspepsia                       | 0                        | 3 (3.0)                    | 1 (1.0)                    | 2 (1.0)                            | 1 (0.5)                             | 7 (1.0)                  | 4 (1.3)               |
| Excoriation                     | 0                        | 1(1.0)                     | 0                          | 1 (0.5)                            | 5 (2.5)                             | 7 (1.0)                  | 1 (0.3)               |
| Gastrooesophagealreflux disease | 0                        | 0                          | 1 (1.0)                    | 5 (2.5)                            | 1 (0.5)                             | 7 (1.0)                  | 2 (0.7)               |
| Psoriasis                       | 1 (1.0)                  | 0                          | 2 (2.0)                    | 4 (2.0)                            | 0                                   | 7 (1.0)                  | 5 (1.7)               |
| Rash                            | 0                        | 2 (2.0)                    | 0                          | 2 (1.0)                            | 3 (1.5)                             | 7 (1.0)                  | 11 (3.7)              |
| Sinusitis                       | 0                        | 2 (2.0)                    | 1 (1.0)                    | 2 (1.0)                            | 2 (1.0)                             | 7 (1.0)                  | 5 (1.7)               |
| Conjunctivitis                  | 0                        | 2 (2.0)                    | 0                          | 1 (0.5)                            | 3 (1.5)                             | 6 (0.9)                  | 0                     |
| Mouthulceration                 | 0                        | 1 (1.0)                    | 2 (2.0)                    | 1(0.5)                             | 2 (1.0)                             | 6 (0.9)                  | 0                     |
| Cellulitis                      | 2 (2.0)                  | 0                          | 0                          | 2 (1.0)                            | 1 (0.5)                             | 5 (0.7)                  | 1 (0.3)               |
| Insomnia                        | 0                        | 1 (1.0)                    | 2 (2.0)                    | 2 (1.0)                            | 0                                   | 5 (0.7)                  | 5 (1.7)               |
| Lowerrespiratorytract           | 0                        | 2 (2.0)                    | 1 (1.0)                    | 0                                  | 2 (1.0)                             | 5 (0.7)                  | 2 (0.7)               |

infection

<div style=\"page-break-after: always\"></div>

| Migraine                                | 0       | 2 (2.0)   | 1 (1.0)   | 1 (0.5)   | 1 (0.5)   | 5 (0.7)   | 1 (0.3)   |
|-----------------------------------------|---------|-----------|-----------|-----------|-----------|-----------|-----------|
| Urticaria                               | 1 (1.0) | 0         | 2 (2.0)   | 1 (0.5)   | 1 (0.5)   | 5 (0.7)   | 0         |
| Hyperlipidaemia                         | 1 (1.0) | 2 (2.0)   | 0         | 1 (0.5)   | 0         | 4 (0.6)   | 5 (1.7)   |
| Muscle spasms                           | 0       | 2 (2.0)   | 0         | 1 (0.5)   | 1 (0.5)   | 4 (0.6)   | 4 (1.3)   |
| Psoriatic arthropathy                   | 1 (1.0) | 3 (3.0)   | 0         | 0         | 0         | 4 (0.6)   | 3 (1.0)   |
| Abdominal pain upper                    | 0       | 2 (2.0)   | 0         | 1 (0.5)   | 0         | 3 (0.4)   | 2 (0.7)   |
| Contusion                               | 0       | 3 (3.0)   | 0         | 0         | 0         | 3 (0.4)   | 2 (0.7)   |
| Hypokalaemia                            | 0       | 0         | 2 (2.0)   | 0         | 1 (0.5)   | 3 (0.4)   | 2 (0.7)   |
| Pruritus generalised                    | 0       | 0         | 2 (2.0)   | 1 (0.5)   | 0         | 3 (0.4)   | 1 (0.3)   |
| Injection site erythema                 | 2 (2.0) | 0         | 0         | 0         | 0         | 2 (0.3)   | 0         |
| Proteinuria                             | 2 (2.0) | 0         | 0         | 0         | 0         | 2 (0.3)   | 0         |
| Respiratory tract infection             | 0       | 0         | 2 (2.0)   | 0         | 0         | 2 (0.3)   | 0         |
| Wound                                   | 0       | 2 (2.0)   | 0         | 0         | 0         | 2 (0.3)   | 0         |
| Anaemia                                 | 0       | 0         | 0         | 1 (0.5)   | 0         | 1 (0.1)   | 7 (2.3)   |
| Viral upper respiratory tract infection | 0       | 0         | 0         | 0         | 0         | 0         | 7 (2.3)   |

Preferred terms are sorted in descending order of frequency in the Any AlN457 column.

## Entire studies

The  overall  exposure-adjusted  incidence  of  AEs  in  the  entire  treatment  period  of  Pool  A  was  similar between the any 300 mg and any 150 mg secukinumab groups and lower in the any 75 mg group ( Table 20 ). The exposure-adjusted AE rate for the placebo group was higher, reflecting the shorter duration of exposure for the placebo group in presence of decreasing reported rates over time. Taking account of the differences in duration of exposure over the entire treatment period, the general profile of AEs over the entire treatment period was similar to the initial 16-week treatment period, with no new involvement of SOCs over long-term treatment than was seen in the first 16 weeks of treatment. For many events, the rates for the any 300 mg group were comparable to or lower than for placebo, indicating no clinically meaningful increase in risk was observed for 300 mg over the entire treatment period.

Apparent small dose-related increases were seen for infections (URTI, bronchitis, sinusitis, pharyngitis, oral herpes, conjunctivitis), and ruritus, rash, increased ALT, gastroesophageal reflux disease, alopecia, palpitations, and epistaxis. In many cases rates for the 300 mg group were comparable to or lower than for placebo.

There were no meaningful differences between secukinumab groups in the distribution of AEs over time. AEs overall and most infection AEs and gastrointestinal AEs showed an overall trend of a decrease in the proportion of patients reporting AEs over time across treatment groups. This observation could be made both from Pool A and Pool B.

Table 20. Exposure-adjusted incidence of AEs by preferred term (&gt;2% in any group) - Entire treatment period (Pool A: Phase 3 PsA trials - Safety set)

| Preferred Term                    | Any AIN457 75mg N=391 n/EX (IR)   | Any AIN457 150mg N=438 n/EX (IR)   | Any AIN457 300mg N=145 n/EX (IR)   | Any AIN457 dose N=974 n/EX (IR)   | Placebo N=300 n/EX (IR)   |
|-----------------------------------|-----------------------------------|------------------------------------|------------------------------------|-----------------------------------|---------------------------|
| - Any AE                          | 296/158.7 (186.5)                 | 342/147.0 (232.6)                  | 94/42.3 (222.3)                    | 732/348.0 (210.3)                 | 181/56.6 (319.6)          |
| Upper respiratory tract infection | 59/384.2 (15.4)                   | 69/399.0 (17.3)                    | 18/84.1 (21.4)                     | 146/867.2 (16.8)                  | 18/102.3 (17.6)           |
|                                   | 64/370.4                          | 61/396.1                           | 15/85.1                            | (16.4)                            | (18.7)                    |
| Nasopharyngitis                   | (17.3)                            | (15.4)                             | (17.6)                             | 140/851.6                         | 19/101.4                  |

<div style=\"page-break-after: always\"></div>

| Preferred Term                   | Any AIN457 75mg N=391 n/EX (IR)   | Any AIN457 150mg N=438 n/EX (IR)   | Any AIN457 300mg N=145 n/EX (IR)   | Any AIN457 dose N=974 n/EX (IR)   | Placebo N=300 n/EX (IR)   |
|----------------------------------|-----------------------------------|------------------------------------|------------------------------------|-----------------------------------|---------------------------|
| Headache                         | 30/394.3 (7.6)                    | 29/421.2 (6.9)                     | 8/84.9 (9.4)                       | 67/900.5 (7.4)                    | 12/102.7 (11.7)           |
| Back pain                        | 28/400.7 (7.0)                    | 18/431.1 (4.2)                     | 3/89.2 (3.4)                       | 49/921.0 (5.3)                    | 5/104.1 (4.8)             |
| Diarrhoea                        | 18/406.5 (4.4)                    | 21/426.7 (4.9)                     | 6/88.1 (6.8)                       | 45/921.3 (4.9)                    | 9/103.4 (8.7)             |
| Bronchitis                       | 11/411.8 (2.7)                    | 22/430.1 (5.1)                     | 5/88.1 (5.7)                       | 38/930.0 (4.1)                    | 8/103.7 (7.7)             |
| Hypertension                     | 21/405.4 (5.2)                    | 13/435.7 (3.0)                     | 4/87.6 (4.6)                       | 38/928.7 (4.1)                    | 8/103.5 (7.7)             |
| Arthralgia                       | 17/407.8 (4.2)                    | 16/435.5 (3.7)                     | 4/88.4 (4.5)                       | 37/931.7 (4.0)                    | 7/104.5 (6.7)             |
| Psoriatic arthropathy            | 18/410.4 (4.4)                    | 17/435.7 (3.9)                     | 2/89.6 (2.2)                       | 37/935.7 (4.0)                    | 3/104.7 (2.9)             |
| Nausea                           | 18/407.3 (4.4)                    | 12/435.7 (2.8)                     | 5/87.2 (5.7)                       | 35/930.2 (3.8)                    | 6/103.9 (5.8)             |
| Sinusitis                        | 11/413.1 (2.7)                    | 15/437.1 (3.4)                     | 9/87.2 (10.3)                      | 35/937.4 (3.7)                    | 6/104.6 (5.7)             |
| Urinary tract infection          | 10/413.8 (2.4)                    | 21/427.2 (4.9)                     | 3/88.6 (3.4)                       | 34/929.6 (3.7)                    | 6/104.1 (5.8)             |
| Cough                            | 10/412.5 (2.4)                    | 20/429.3 (4.7)                     | 3/88.0 (3.4)                       | 33/929.8 (3.5)                    | 8/103.7 (7.7)             |
| Psoriasis                        | 18/409.5 (4.4)                    | 11/440.2 (2.5)                     | 2/88.7 (2.3)                       | 31/938.4 (3.3)                    | 5/104.2 (4.8)             |
| Gastroenteritis                  | 9/413.9 (2.2)                     | 17/432.5 (3.9)                     | 3/88.8 (3.4)                       | 29/935.1 (3.1)                    | 3/105.1 (2.9)             |
| Pharyngitis                      | 10/413.2 (2.4)                    | 13/433.8 (3.0)                     | 5/88.9 (5.6)                       | 28/935.9 (3.0)                    | 0/105.6 (0.0)             |
| Hypercholesterolaemia            | 13/406.8 (3.2)                    | 12/432.2 (2.8)                     | 2/89.2 (2.2)                       | 27/928.2 (2.9)                    | 6/104.0 (5.8)             |
| Oropharyngeal pain               | 11/411.8 (2.7)                    | 10/437.1 (2.3)                     | 4/88.2 (4.5)                       | 25/937.2 (2.7)                    | 8/104.1 (7.7)             |
| Oral herpes                      | 7/415.5 (1.7)                     | 12/434.2 (2.8)                     | 5/87.4 (5.7)                       | 24/937.2 (2.6)                    | 4/104.4 (3.8)             |
| Vomiting                         | 15/409.0 (3.7)                    | 7/441.0 (1.6)                      | 2/88.4 (2.3)                       | 24/938.5 (2.6)                    | 3/104.8 (2.9)             |
| Fatigue                          | 11/409.0 (2.7)                    | 10/439.4 (2.3)                     | 2/89.5 (2.2)                       | 23/937.9 (2.5)                    | 7/103.8 (6.7)             |
| Dyspepsia                        | 6/416.3 (1.4)                     | 14/434.3 (3.2)                     | 1/89.5 (1.1)                       | 21/940.0 (2.2)                    | 4/105.0 (3.8)             |
| Pruritus                         | 8/415.1 (1.9)                     | 10/435.3 (2.3)                     | 3/88.5 (3.4)                       | 21/938.9 (2.2)                    | 4/104.9 (3.8)             |
| Rash                             | 7/413.9 (1.7)                     | 9/438.0 (2.1)                      | 5/88.9 (5.6)                       | 21/940.9 (2.2)                    | 11/103.3 (10.7)           |
| ALT increased                    | 5/414.5 (1.2)                     | 12/436.8 (2.7)                     | 3/88.1 (3.4)                       | 20/939.4 (2.1)                    | 4/105.0 (3.8)             |
| Gastrooesophageal reflux disease | 7/413.2 (1.7)                     | 9/440.7 (2.0)                      | 3/88.7 (3.4)                       | 19/942.6 (2.0)                    | 2/104.9 (1.9)             |
| Dyslipidaemia                    | 7/412.4 (1.7)                     | 11/433.2 (2.5)                     | 0/90.1 (0.0)                       | 18/935.7 (1.9)                    | 7/103.1 (6.8)             |
| Influenza                        | 8/413.5 (1.9)                     | 8/440.1 (1.8)                      | 2/89.9 (2.2)                       | 18/943.6 (1.9)                    | 2/105.1 (1.9)             |

<div style=\"page-break-after: always\"></div>

| Preferred Term                          | Any AIN457 75mg N=391 n/EX (IR)   | Any AIN457 150mg N=438 n/EX (IR)   | Any AIN457 300mg N=145 n/EX (IR)   | Any AIN457 dose N=974 n/EX (IR)   | Placebo N=300 n/EX (IR)   |
|-----------------------------------------|-----------------------------------|------------------------------------|------------------------------------|-----------------------------------|---------------------------|
| Pain in extremity                       | 12/412.4 (2.9)                    | 6/442.2 (1.4)                      | 0/90.1 (0.0)                       | 18/944.7 (1.9)                    | 5/104.7 (4.8)             |
| Laceration                              | 8/415.4 (1.9)                     | 9/440.9 (2.0)                      | 0/90.1 (0.0)                       | 17/946.3 (1.8)                    | 3/104.9 (2.9)             |
| Depression                              | 10/413.6 (2.4)                    | 4/441.0 (0.9)                      | 2/89.2 (2.2)                       | 16/943.8 (1.7)                    | 8/103.1 (7.8)             |
| Mouth ulceration                        | 5/415.3 (1.2)                     | 9/439.2 (2.0)                      | 2/89.0 (2.2)                       | 16/943.5 (1.7)                    | 0/105.6 (0.0)             |
| Insomnia                                | 7/415.5 (1.7)                     | 5/441.5 (1.1)                      | 3/88.8 (3.4)                       | 15/945.8 (1.6)                    | 5/104.6 (4.8)             |
| Viral upper respiratory tract infection | 5/417.7 (1.2)                     | 9/437.6 (2.1)                      | 1/89.7 (1.1)                       | 15/945.0 (1.6)                    | 8/103.7 (7.7)             |
| Tooth abscess                           | 8/415.4 (1.9)                     | 5/441.2 (1.1)                      | 1/89.4 (1.1)                       | 14/945.9 (1.5)                    | 0/105.6 (0.0)             |
| Abdominal pain upper                    | 3/417.6 (0.7)                     | 7/441.9 (1.6)                      | 3/89.7 (3.3)                       | 13/949.2 (1.4)                    | 3/104.9 (2.9)             |
| Excoriation                             | 4/415.9 (1.0)                     | 9/437.5 (2.1)                      | 0/90.1 (0.0)                       | 13/943.5 (1.4)                    | 1/105.6 (0.9)             |
| Fall                                    | 4/417.9 (1.0)                     | 6/441.3 (1.4)                      | 3/89.4 (3.4)                       | 13/948.6 (1.4)                    | 0/105.6 (0.0)             |
| Toothache                               | 6/416.5 (1.4)                     | 4/443.4 (0.9)                      | 3/88.9 (3.4)                       | 13/948.9 (1.4)                    | 2/105.3 (1.9)             |
| Conjunctivitis                          | 3/417.9 (0.7)                     | 6/439.3 (1.4)                      | 3/89.0 (3.4)                       | 12/946.1 (1.3)                    | 0/105.6 (0.0)             |
| Alopecia                                | 1/418.6 (0.2)                     | 4/441.2 (0.9)                      | 3/89.2 (3.4)                       | 8/949.0 (0.8)                     | 2/104.9 (1.9)             |
| Palpitations                            | 1/419.1 (0.2)                     | 4/441.7 (0.9)                      | 3/88.9 (3.4)                       | 8/949.7 (0.8)                     | 1/105.4 (0.9)             |

<div style=\"page-break-after: always\"></div>

| Preferred Term   | Any AIN457 75mg N=391 n/EX (IR)   | Any AIN457 150mg N=438 n/EX (IR)   | Any AIN457 300mg N=145 n/EX (IR)   | Any AIN457 dose N=974 n/EX (IR)   | Placebo N=300 n/EX (IR)   |
|------------------|-----------------------------------|------------------------------------|------------------------------------|-----------------------------------|---------------------------|
| Epistaxis        | 0/420.0 (0.0)                     | 1/444.8 (0.2)                      | 3/89.7 (3.3)                       | 4/954.6 (0.4)                     | 3/104.8 (2.9)             |

Preferred terms are sorted in descending order of frequency in the Any AIN457 column. ALT=alanine aminotransferase; EX = exposure in patient years. Percentage cut-off refers to percentages for crude incidence rates. IR=incidence rate per 100 patient years. For patients with event, exposure time is censored at time of first event

The exposure adjusted incidence rates of these AEs did not show dose-related differences for the 150 mg and 300 mg groups with sc-loading (in study F2312) with the exception of headache (IR=8.6 vs. 11.8), sinusitis (IR=5.6 vs. 8.4), oral herpes (IR=0 vs. 5.7), pharyngitis (IR=0 vs. 5.5), and epistaxis (IR=1.4 vs. 4.1).

In Pool B, the overall exposure-adjusted incidence of AEs were similar for the 150 mg and 300 mg groups (IR=247.1 and 250.4, respectively), suggesting the absence of a dose-response. AE rates were highest for  the  placebo  group  (IR=329.6),  reflecting  the  lower  exposure  in  this  group.  Exposure-adjusted incidence rates of AEs for most SOCs were similar for the 150 mg and 300 mg groups. A higher rate of respiratory, thoracic and mediastinal disorders for the Any 300 mg group compared to the Any 150 mg group (IR=21.0 vs. 13.9, respectively) reflected higher rates of cough (IR=6.7 vs. 4.3) and oropharyngeal pain (IR=5.8 vs. 3.5).

In Pool B the majority of AEs by preferred term were reported with comparable exposure-adjusted rates for the 150 mg and 300 mg secukinumab dose groups ( Table 21 ).

## Table 21. Exposure-adjusted incidence of the most frequent AEs by preferred term (≥2% in any group) - Entire treatment period (Pool B: Phase 3 PsA and psoriasis trials - Safety set)

<div style=\"page-break-after: always\"></div>

| PreferredTerm                   | AnyAIN457 150mg N=1919 n/EX (IR)   | AnyAIN457 300mg N=1618 n/EX (IR)   | AnyAIN457 N=3928 n/EX (IR) 2944/1223.9   | Placebo N=994 n/EX(IR)   |
|---------------------------------|------------------------------------|------------------------------------|------------------------------------------|--------------------------|
| -Any preferred term             | 1438/581.9 (247.1)                 | 1210/483.3(250.4)                  | (240.5)                                  | 537/162.9(329.6)         |
| Nasopharyngitis                 | 343/1368.6(25.1)                   | 301/1076.8 (28.0)                  | 708/2815.7 (25.1)                        | 80/272.3 (29.4)          |
| Upperrespiratorytract infection | 173/1472.1 (11.8)                  | 115/1180.1 (9.7)                   | 347/3036.4 (11.4)                        | 25/282.6 (8.8)           |
| Headache                        | 139/1481.2(9.4)                    | 129/1152.8(11.2)                   | 298/3028.4 (9.8)                         | 53/277.1 (19.1)          |
| Diarrhoea                       | 86/1519.7 (5.7)                    | 81/1184.5 (6.8)                    | 185/3110.7 (5.9)                         | 21/282.5 (7.4)           |
| Arthralgia                      | 83/1532.8 (5.4)                    | 69/1202.3 (5.7)                    | 169/3142.9 (5.4)                         | 25/282.6 (8.8)           |
| Hypertension                    | 75/1526.4 (4.9)                    | 71/1201.3 (5.9)                    | 167/3133.0 (5.3)                         | 20/284.0 (7.0)           |
| Backpain                        | 72/1532.4 (4.7)                    | 62/1202.4 (5.2)                    | 162/3135.5 (5.2)                         | 15/284.5 (5.3)           |
| Cough                           | 66/1533.3 (4.3)                    | 80/1192.7 (6.7)                    | 156/3138.5 (5.0)                         | 17/283.5 (6.0)           |
| Pruritus                        | 72/1528.0 (4.7)                    | 58/1192.5 (4.9)                    | 138/3135.5 (4.4)                         | 23/283.3(8.1)            |
| Oropharyngealpain               | 54/1542.7 (3.5)                    | 69/1197.6 (5.8)                    | 134/3152.1 (4.3)                         | 20/284.3 (7.0)           |
| Bronchitis                      | 57/1541.8 (3.7)                    | 56/1211.1 (4.6)                    | 124/3164.7 (3.9)                         | 15/284.3 (5.3)           |
| Influenza                       | 49/1546.4 (3.2)                    | 46/1217.3 (3.8)                    | 103/3177.2 (3.2)                         | 9/285.8 (3.1)            |
| Pharyngitis                     | 46/1545.0 (3.0)                    | 46/1211.8 (3.8)                    | 102/3170.0 (3.2)                         | 0/287.7 (0.0)            |
| Gastroenteritis                 | 51/1544.7 (3.3)                    | 39/1213.6 (3.2)                    | 99/3172.2 (3.1)                          | 9/286.1 (3.1)            |
| Nausea                          | 42/1546.8 (2.7)                    | 32/1211.9 (2.6)                    | 92/3165.9 (2.9)                          | 22/283.3 (7.8)           |
| Fatigue                         | 41/1549.5(2.6)                     | 32/1216.0(2.6)                     | 84/3174.5 (2.6)                          | 14/284.4 (4.9)           |
| Sinusitis                       | 37/1557.3 (2.4)                    | 35/1221.1 (2.9)                    | 83/3191.5 (2.6)                          | 9/286.3 (3.1)            |
| Psoriasis                       | 32/1559.7 (2.1)                    | 29/1223.5 (2.4)                    | 79/3192.7 (2.5)                          | 25/283.1(8.8)            |
| Painin extremity                | 34/1555.5 (2.2)                    | 32/1215.7 (2.6)                    | 78/3183.6 (2.5)                          | 13/285.4 (4.6)           |
| Folliculitis                    | 36/1554.4 (2.3)                    | 32/1218.4 (2.6)                    | 72/3189.3 (2.3)                          | 6/286.5 (2.1)            |
| Urinarytractinfection           | 37/1548.6 (2.4)                    | 25/1223.1 (2.0)                    | 72/3185.5(2.3)                           | 9/285.8 (3.1)            |
| Rhinitis                        | 31/1554.3 (2.0)                    | 33/1215.7 (2.7)                    | 71/3184.0 (2.2)                          | 5/287.0 (1.7)            |
| Hypercholesterolaemia           | 38/1544.4 (2.5)                    | 17/1224.0 (1.4)                    | 68/3175.1 (2.1)                          | 15/283.3 (5.3)           |
| Vomiting                        | 23/1562.5 (1.5)                    | 29/1212.8 (2.4)                    | 67/3184.3 (2.1)                          | 8/285.3 (2.8)            |
| Eczema                          | 26/1560.7 (1.7)                    | 37/1217.5 (3.0)                    | 66/3197.2 (2.1)                          | 1/287.5 (0.3)            |
| Psoriaticarthropathy            | 32/1559.4 (2.1)                    | 15/1226.5 (1.2)                    | 65/3196.3 (2.0)                          | 8/285.8 (2.8)            |
| Laceration                      | 20/1565.4 (1.3)                    | 12/1231.4 (1.0)                    | 40/3212.2(1.2)                           | 5/286.9 (1.7)            |
| Depression                      | 18/1563.6 (1.2)                    | 11/1229.4 (0.9)                    | 39/3206.6 (1.2)                          | 12/284.4 (4.2)           |
| Toothabscess                    | 16/1566.1(1.0)                     | 10/1230.9 (0.8)                    | 34/3212.4 (1.1)                          | 2/287.3 (0.7)            |

PreferredtermsaresortedindescendingorderoffrequencyintheAnyAiN457column.

forcrudeincidencerates（preferredtermswith&gt;=2%inAnyAIN45775mg（notshown),AnyAlN457150mg,or AnyAIN457300mg.

Forpatientswithevent,exposuretimeiscensoredattimeoffirstevent.

## Adverse Drug Reactions

During the first 16 weeks (Pool A), the incidence of treatment related AEs in the 300 mg secukinumab dose group was higher compared to placebo (25.0%, 18.0%, and 21.2% for 300 mg, 150 mg and 75 mg, respectively, vs. 20.7% for placebo), due to a higher rate of infections and infestations (13.0%, 12.0%, and 11.1% for 300 mg, 150 mg and 75 mg, respectively, vs. 9.0% for placebo). This was driven by small differences between treatment groups for individual treatment-related infections, in particular respiratory tract infection (2.0% for 300 mg vs. 0% for 150 mg, 75 mg and placebo groups) and oral herpes (2.0% for  300  mg  vs.  0%  for  150  mg,  1.0%  for  75  mg  and  0%  for  placebo  groups).  A  small  increase  in treatment-related AEs in the 300 mg secukinumab dose group was also seen for skin and subcutaneous

<div style=\"page-break-after: always\"></div>

tissue  disorders  (5.0%,  1.0%,  and  2.0%  for  300  mg,  150  mg,  and  75  mg,  respectively,  vs.  3.3%  for placebo), although this was not driven by individual events.

During the entire treatment period for Pool A, there was a higher overall incidence of treatment-related AEs in the secukinumab dose groups compared to placebo (29.0%, 31.7% and 28.9% for Any 300 mg, Any 150 mg and 75 mg groups, respectively, vs. 21.3% for placebo), due to a higher rate of infections and infestations (16.6%, 20.8%, and 17.9% for 300 mg, 150 mg and 75 mg, respectively, vs. 9.7% for placebo). Upper respiratory tract infection and nasopharyngitis, the most common infections, as well as respiratory  tract  infections,  urinary  tract  infections,  sinusitis,  oral  herpes,  bronchitis,  and  pharyngitis occurring at low rates, contributed to this imbalance. No dose response for secukinumab was seen in the total rate or in any event considered possibly related to study treatment.

## AEs causing dose interruption or adjustment

As for Pool A, the overall incidence of patients with AEs causing dose interruption in Pool B did not show a dose increase across the secukinumab dose groups (5.3% and 6.0% for the Any 300 mg and Any 150 mg,  respectively,  and  3.3%  for  placebo).  The  most  common  AEs  causing  dose  interruption  were  for infections and infestations and did not show a dose increase across the secukinumab dose groups (3.2% and 3.5%, respectively, for the Any 300 mg and Any 150 mg groups vs. 1.6% for placebo). Individual AEs  causing  dose  interruption  were  reported  for  few  patients  and  were  comparable  across  treatment groups.

For the entire treatment period of Pool A, the overall incidence of AEs requiring concomitant medication was lowest for  the  secukinumab  sc  dose  groups  compared  to  the  iv  dose  groups  (57.0%,  62.0%  and 47.5%, respectively, for the 300 mg, 150 mg and 75 mg sc groups vs. 74.3-76.7% for the iv loading groups, 45.3% for placebo). This difference was due to infections and infestations (38.0%, 42.0% and 29.3%,  respectively,  for  the  300  mg,  150  mg  and  75  mg  vs.  51.0-54.5%  for  the  iv  loading  groups, 20.7% for placebo), mainly as a result of a higher rate of upper respiratory tract infections.

## Crohn´s disease

Of the 4 cases of IBD in pool A ( Table 22 ), 2 cases were Crohn's disease (1 placebo patient - on baseline - and 1 patient on 75 mg).

Table 22. Exposure-adjusted incidence of inflammatory bowel disease - Entire treatment period (Pool A: Phase 3 PsA trials - Safety set)

| Level1 Preferredterm                 | AnyAIN457 75mg N=391 n/EX(IR)   | AnyAIN457 150mg N=438 n/EX(IR)   | AnyAIN457 300mg N=145 n/EX（IR)   | AnyAIN457 dose N=974 n/EX(IR)   | Placebo N=300 n/EX(IR)   |
|--------------------------------------|---------------------------------|----------------------------------|----------------------------------|---------------------------------|--------------------------|
| BasedonallAEs                        |                                 |                                  |                                  |                                 |                          |
| Inflammatoryboweldisease (narrowNMQ) | 2/418.9 (0.5)                   | 0/444.9(0.0)                     | 1/89.3(1.1)                      | 3/953.1(0.3)                    | 1/105.5 (0.9)            |
| Diamheahemorrhagic(PT)               | 1/418.9(0.2)                    | 0/444.9(0.0)                     | 1/89.3(1.1)                      | 2/953.2(0.2)                    | 0/105.6(0.0)             |
| Crohn'sdisease(PT)                   | 1/420.0(0.2)                    | 0/444.9(0.0)                     | 0/90.1 (0.0)                     | 1/955.0(0.1)                    | 1/105.5(0.9)             |
| BasedonSAEs                          |                                 |                                  |                                  |                                 |                          |
| Inflammatoryboweldisease (narrowNMQ) | 1/420.0(0.2)                    | 0/444.9(0.0)                     | 0/90.1(0.0)                      | 1/955.0(0.1)                    | 1/105.5(0.9)             |
| Crohn'sdisease（PT)                   | 1/420.0(0.2)                    | 0/444.9(0.0)                     | 0/90.1 (0.0)                     | 1/955.0(0.1)                    | 1/105.5(0.9)             |

NMQ=NovartisMedDRAquery:PT=preferredtem

PreferredtermsaresortedindescendingorderoffrequencyintheAnyAiN457dosecolumn

## Infections and infestations

Consistent with the psoriasis program, there was a small increase in the risk of localized (non-invasive) clinically  manageable candidiasis, which was expected due to the role of IL-17A in immunity to fungal infections. A dose effect was apparent only in the entire treatment period (Pool A). Candida cases were all mild  or  moderate  in  severity,  responsive  to  standard  treatment  and  did  not  lead  to  discontinuation. Esophageal  candidiasis  was  reported  in  2  PsA  patients,  one  in  each  of  the  150  mg  and  300  mg secukinumab dose groups. Both cases of esophageal candidiasis were mild or moderate in severity, non-

<div style=\"page-break-after: always\"></div>

serious and resolved upon treatment with standard antifungal medication without requiring discontinuation of secukinumab.

In  Pool  A,  herpes  viral infections  (HLT)  occurred  in  a  higher  proportion of  patients in  the  Any  300  mg group (4.8%) than in the other secukinumab dose groups (3.1% and 3.4% for Any 75 mg and Any 150 mg, respectively). Crude incidence of herpes viral infections (HLT) for the placebo group was 1.3%. The higher rate in the Any 300 mg group was due to oral herpes (3.4% for Any 300 mg vs. 1.8% and 2.7%, respectively, for Any 75 mg and Any 150 mg groups). All cases of oral herpes were of mild or moderate severity, were not SAEs and did not require study drug discontinuation. There was one case of herpes zoster cutaneous disseminated, also an event in the opportunistic infections NMQ, in a patient on iv-75 mg secukinumab.

There  were  no  serious  opportunistic  infections,  and  no  cases  of  reactivation  of  either  tuberculosis  or Hepatitis B.

The most common infections of skin structures reported in pool A are presented in Table 23 .

Table 23. Exposure-adjusted incidence rate of adverse drug reactions (Pool A entire treatment period: Phase 3 PsA trials - Safety set)

| HighLevelTenm Preferredtem             | AnyAIN457 75mg N=391 n/EX(IR)   | AnyAIN457 150mg N=438 MEX(IR)   | AnyAIN457 300mg N=145 n/EX(IR)   | AnyAIN457 dose N=974 n/EX (IR)   | Placebo N=300 n/EX (IR)   |
|----------------------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|---------------------------|
| Upperrespiratorytract infections (HLT) | 136/322.2 (42.2)                | 149/336.3 (44.3)                | 4275.6 (55.6)                    | 327/734.1 (44.5)                 | 48/96.2 (49.9)            |
| Upperrespiratory tract infeclions (PT) | 59/384.1 (15.4)                 | 89/398.9 (17.3)                 | 18/84.1 (21.4)                   | 146/867.2 (16.8)                 | 18/102.3 (17.6)           |
| Na sopharyngitis (PT)                  | 64/370.3 (17.3)                 | 61/306.1 (15.4)                 | 15/85.1 (17.6)                   | 140/851.6 (16.4)                 | 19/101.4 (18.7)           |
| Pharyngitis (PT)                       | 10/413.2 (2.4)                  | 13/433.8 (3.0)                  | 5/88.9 (5.8)                     | 28/935.8 (3.0)                   | 0/105.8 (0.0)             |
| Rhinitis (PT)                          | 7413.9 (1.7)                    | 7/441.0 (1.6)                   | 1/89.8 (1.1)                     | 15/944.8 (1.6)                   | 0/105.8 (0.0)             |
| Conjunctivitis (PT)                    | 3/417.8 (0.7)                   | 6/439.2 (1.4)                   | 3/89.0 (3.4)                     | 12/946.1(1.3)                    | 0/105.6 (0.0)             |
| Oral herpes (PT)                       | 7415.5 (1.7)                    | 12434.2 (2.8)                   | 5/87.4 (5.7)                     | 24/937.2 (2.6)                   | 4/104.4 (3.8)             |
| Tinea pedis (PT)                       | 4/415.4 (1.0)                   | 2442.2 (0.5)                    | 2/89.3 (2.2)                     | 81048.9 (0.8)                    | 0/105.6 (0.0)             |
| Urticaria (PT)                         | 2419.4 (0.5)                    | 1/444.8 (0.2)                   | 2/89.3 (2.2)                     | 5/953.5 (0.5)                    | 0/105.6 (0.0)             |

## Malignancies and skin tumours

Results  from  the  PsA  population  continue  to  support  the  conclusion  from  the  psoriasis  program  that secukinumab does not confer an increased risk for malignancy. The incidence of malignancies including skin tumours was low and comparable across the secukinumab dose groups and placebo.

Malignancy  SAEs  occurred  at  a  low  and  comparable  exposure-adjusted  incidence  rate  in  the  Any secukinumab dose and placebo groups (IR: 0.3 vs. 0.9) ( Table 24 ).

## Table 24. Exposure-adjusted incidence rates for malignancies and skin tumors Entire treatment period (Pool A: Phase 3 PsA trials - Safety set)

<div style=\"page-break-after: always\"></div>

| Level1 Preferredterm                         | AnyAIN457 75mg N=391 n/EX(IR)   | AnyAIN457 150mg N=438 n/EX (IR)   | AnyAIN457 300mg N=145 n/EX (IR)   | AnyAIN457 dose N=974 n/EX (IR)   | Placebo N=300 n/EX(IR)   |
|----------------------------------------------|---------------------------------|-----------------------------------|-----------------------------------|----------------------------------|--------------------------|
| BasedonallAEs                                |                                 |                                   |                                   |                                  |                          |
| Malignantorunspecifiedtumors (SMQ)           | 4/418.1 (1.0)                   | 1/444.8 (0.2)                     | 0/90.1 (0.0)                      | 5/953.0 (0.5)                    | 1/105.5 (0.9)            |
| Skintumorsmalignantand unspecified（broadNMQ) | 4/418.1 (1.0)                   | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 4/953.1 (0.4)                    | 0/105.6 (0.0)            |
| Basalcellcarcinoma（PT)                       | 3/418.3 (0.7)                   | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 3/953.3 (0.3)                    | 0/105.6 (0.0)            |
| Squamouscellcarcinoma(PT)                    | 1/419.9 (0.2)                   | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 1/954.9 (0.1)                    | 0/105.6 (0.0)            |
| BasedonallSAEs                               |                                 |                                   |                                   |                                  |                          |
| Malignantorunspecifiedtumors (SMQ)           | 2/419.4 (0.5)                   | 1/444.8 (0.2)                     | 0/90.1 (0.0)                      | 3/954.3 (0.3)                    | 1/105.5 (0.9)            |
| Skintumorsmalignantand unspecified（broadNMQ) | 2/419.4 (0.5)                   | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 2/954.5 (0.2)                    | 0/105.6 (0.0)            |
| Basal cellcarcinoma(PT)                      | 1/419.6 (0.2)                   | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 1/954.6 (0.1)                    | 0/105.6 (0.0)            |
| Squamouscellcarcinoma(PT)                    | 1/419.9 (0.2)                   | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 1/954.9 (0.1)                    | 0/105.6 (0.0)            |

PT=preferredterm;SMQ=StandardMedDRAquery

EX=exposureinpatient-years;IR=incidencerateper100patient-years;NMQ=NovartisMedDRA Query;

New malignancies from the psoriasis studies are from the ongoing studies A2308 and A2309, reported in the Week 52 study reports provided in the present submission, and include the following:

- Two uncomplicated cases of basal cell carcinoma
- One case of adenosquamous cell carcinoma, confounded by relevant medical history
- One case of B-cell lymphoma for which the investigator reported the event as suspected to be related to study treatment but also suspected to be related to past treatment of tofacitinib and ustekinumab.

## Major adverse cardiovascular events (MACE)

Data from the Phase 3 program in PsA do not suggest an increased risk of MACE in PsA patients treated with secukinumab. In the psoriasis submission, secukinumab was comparable to placebo in the incidence of MACE in the first 12 weeks of treatment as well as over the entire treatment period. All MACE cases were associated with prior or active cardiovascular disease or risk factors at Baseline. There was no dose dependence for secukinumab.

Consistent with the psoriasis program, the Phase 3 studies in PsA did not exclude patients with stable cardiovascular risk factors from secukinumab treatment. A total of 7 (0.7%) adjudicated and confirmed MACE cases were reported in Pool A of PsA studies (6 cases for the 75 mg dose, and 1 case for the 150 mg dose) ( Table 25 ).  No MACE cases were reported for the 300 mg dose or for placebo.

<div style=\"page-break-after: always\"></div>

Table 25. MACE adjudication results in PsA patients - Entire treatment period (Pool A: Phase 3 PsA trials - Safety set)

| MACEcategory Adjudicationoutcome   | Any AIN457 75mg N=391 n (%)   | AnyAIN457 150 mg N=438 n (%)   | Any AIN457 300 mg N=145 n (%)   | Any AIN457 dose N=974 n (%)   | Placebo N=300 n (%)   |
|------------------------------------|-------------------------------|--------------------------------|---------------------------------|-------------------------------|-----------------------|
| Myocardialinfarction               |                               |                                |                                 |                               |                       |
| Yes                                | 2 (0.5)                       | 1 (0.2)                        | 0                               | 3 (0.3)                       | 0                     |
| Indeteminate                       | 0                             | 0                              | 0                               | 0                             | 0                     |
| Stroke                             |                               |                                |                                 |                               |                       |
| Yes                                | 4 (1.0)                       | 0                              | 0                               | 4 (0.4)                       | 0                     |
| Indeteminate                       | 0                             | 0                              | 0                               | 0                             | 0                     |
| Cardiovasculardeath                |                               |                                |                                 |                               |                       |
| Cardiovascular                     | 0                             | 0                              | 0                               | 0                             | 0                     |
| Indeterminate                      | 1 (0.3)                       | 0                              | 0                               | 1 (0.1)                       | 0                     |
| Total no. MACE (Yes)#              | 6 (1.5)                       | 1 (0.2)                        | 0                               | 7 (0.7)                       | 0                     |

OnlyconfirmedandindeterminateadjudicatedMACEeventswereincluded.

#Total MACE(Yes)isthe sumofpatientsintheMyocardialinfarction(Yes)andStroke(Yes)rows;the indeteminatecardiovasculardeathisalsocountedintheStroke(Yes)row.

In the present PsA submission, the rate of MACE on secukinumab across multiple indications was stable despite increased exposure in comparison to the psoriasis submission. Pooling across 42 studies including 8 new studies reported here for the first time, the exposure-adjusted incidence of potential MACE AEs over the entire treatment period of all secukinumab trials (Pool C) was 0.40 (n=30, CI: 0.26 - 0.59) for the Any secukinumab dose group and 0.39 (n=2, CI: 0.05 - 1.40) for placebo, Figure 14 .

Figure 14. Exposure adjusted incidence rate for adjudicated and confirmed MACE by studies and data pools

<!-- image -->

Studies A2302 and A2303 inchude mmtemsion data.Pool Psoriasis include additicemal studies A2102, A2103, A2204 A2211, A2212, A2220, A2223, A2225, and A.2307

## Hepatotoxicity

<div style=\"page-break-after: always\"></div>

Consistent with the conclusions from the psoriasis program, the safety data in the PsA population do not suggest an increased risk for drug-induced liver injury (DILI) from secukinumab treatment. Despite small imbalances  in  the  incidence  of  mild  hepatic  transaminase  elevations  (CTCAE  Grade  1)  vs.  placebo, secukinumab at any dose in the PsA program was not associated with any cases of combined elevations in  hepatic  transaminases  and  serum  bilirubin.  Discontinuations  due  to  hepatotoxicity  were  rare  in secukinumab  treated  patients  and  all  cases  were  confounded  by  either  a  previously  reported  medical condition or concomitant treatment with isoniazid and methotrexate.

## QTC-prolongation

A search for cases of QT prolongation yielded a total of 3 AEs in the PsA population, one case in each of the 75 mg, 150 mg, and placebo groups. No cases were reported for the 300 mg group. All 3 events were non-serious,  mild  or  moderate  in  severity  and  considered  unrelated  to  study  medication.  No  patient discontinued study medication due to the event. There were no further events of QT prolongation in the expanded PsA population in Pool B1 or among the psoriasis patients included in Pool B. QT prolongation is being monitored as a routine risk.

## Serious adverse events and deaths

Four deaths were reported across data pools A, B1 and B: one death was reported for the PsA trials (Pool A) due to an intracranial haemorrhage in a patient receiving iv-75 mg. One further death occurred in Pool B1  of  unknown  cause  (300  mg  secukinumab).  Two  additional  deaths  occurred  in  psoriasis  patients contributing  to  Pool  B  as  a  result  of  cardiopulmonary  arrest  (150  mg  secukinumab),  and  of  alcohol poisoning  (placebo-secukinumab  300  mg),  respectively.  None  of  these  deaths  was  considered  by  the investigator to be related to study treatment.

For Pool A studies CAIN457F2306 and CAIN457F2312, one further death was reported between the data cut-off for Pool A (9-Oct-2013 for study F2306 and 12-May-2014 for study F2312) and the data cut-off used for the submission (10-Oct-2014).

In  studies  F2305  and  F2310  on  ankylosing  spondylitis,  there  were  three  additional  deaths  (1  in  the placebo group (suicide), 1 in the iv-75 mg group due to respiratory failure, and 1 in the 75 mg sc group due  to  an  acute  myocardial  infarction).  None  of  these  deaths  was  considered  by  the  respective investigators to be related to study treatment.

Overall exposure adjusted rates of SAEs ( Table 26 ) were similar for the secukinumab dose groups and no higher than placebo. The exposure adjusted rates of infections and infestations were slightly higher for the 'Any 300 mg group compared to the Any 150 mg and Any 75 mg groups (IR=4.5 vs. 2.5 and 2.2, respectively). This difference (based on few events) was also seen when comparing the two sc loading doses of 150 mg (n=1, IR=1.4) and 300 mg (n=3, IR=4.2).

## Laboratory findings

## Haematology

Most  newly  occurring  or  worsening  haematology-related  abnormalities  observed  for  PsA  patients  were CTCAE  Grade  1  or  Grade  2  abnormalities  and  were  consistent  with  findings  from  the  initial  psoriasis submission. The incidence of CTCAE Grade 2 and 3 laboratory abnormalities was higher in secukinumabtreated patients compared to placebo in the initial 16 weeks of treatment. A similar pattern was observed over the entire treatment period and no CTCAE Grade 4 abnormalities were observed as of 10-Oct-2014. In the current submission for PsA, no dose effect for secukinumab was observed in lab results or in AEs.

<div style=\"page-break-after: always\"></div>

Table 26. Exposure-adjusted incidence of the most frequent SAEs by preferred term (&gt;=0.5 per 100 patient-years in any group) - Entire treatment period (Pool A: Phase 3 PsA trials - Safety set)

| PreferredTerm                         | AnyAIN457 75mg N=391 n/EX (IR)   | AnyAIN457 150mg N=438 n/EX (IR)   | AnyAIN457 300mg N=145 m/EX (IR)   | AnyAIN457 dose N=974 n/EX (IR)   | Placebo N=300 n/EX (IR)   |
|---------------------------------------|----------------------------------|-----------------------------------|-----------------------------------|----------------------------------|---------------------------|
| -Any SAE                              | 34/406.7 (8.4)                   | 41/420.3 (9.8)                    | 7/86.6(8.1)                       | 82/913.6 (9.0)                   | 14/102.8 (13.6)           |
| Erysipelas                            | 1/419.8 (0.2)                    | 2/443.5 (0.5)                     | 1/89.6 (1.1)                      | 4/953.0 (0.4)                    | 1/105.4 (0.9)             |
| Non-cardiac chestpain                 | 0/420.0 (0.0)                    | 2/444.7 (0.4)                     | 1/89.6 (1.1)                      | 3/954.4 (0.3)                    | 1/105.4 (0.9)             |
| Osteoarthritis                        | 1/419.9 (0.2)                    | 2/443.3 (0.5)                     | 0/90.1 (0.0)                      | 3/953.2 (0.3)                    | 1/105.5 (0.9)             |
| Sepsis                                | 3/419.5 (0.7)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 3/954.6 (0.3)                    | 1/105.6 (0.9)             |
| Atrial fibrillation                   | 2/419.1 (0.5)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 2/954.1 (0.2)                    | 0/105.6 (0.0)             |
| Cerebrovascularaccident               | 2/419.2 (0.5)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 2/954.2 (0.2)                    | 0/105.6 (0.0)             |
| Coronaryarterydisease                 | 0/420.0(0.0)                     | 2/443.5 (0.5)                     | 0/90.1 (0.0)                      | 2/953.6 (0.2)                    | 1/105.3 (0.9)             |
| Deepveinthrombosis                    | 0/420.0 (0.0)                    | 2/444.1 (0.5)                     | 0/90.1 (0.0)                      | 2/954.2 (0.2)                    | 0/105.6 (0.0)             |
| Diverticulitis                        | 0/420.0 (0.0)                    | 2/444.0 (0.5)                     | 0/90.1 (0.0)                      | 2/954.1 (0.2)                    | 0/105.6 (0.0)             |
| Myocardialinfarction                  | 2/419.6 (0.5)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 2/954.6 (0.2)                    | 0/105.6 (0.0)             |
| Pneumonia                             | 2/419.7 (0.5)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 2/954.7 (0.2)                    | 0/105.6 (0.0)             |
| Psoriaticarthropathy                  | 0/420.0 (0.0)                    | 2/443.5 (0.5)                     | 0/90.1 (0.0)                      | 2/953.6 (0.2)                    | 0/105.6 (0.0)             |
| Septic shock                          | 2/419.8 (0.5)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 2/954.8 (0.2)                    | 1/105.6 (0.9)             |
| Vertigopositional                     | 2/417.8 (0.5)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 2/952.9 (0.2)                    | 0/105.6 (0.0)             |
| Calculus urinary                      | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 1/90.1 (1.1)                      | 1/955.0 (0.1)                    | 0/105.6(0.0)              |
| Cervicalradiculopathy                 | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 1/89.4 (1.1)                      | 1/954.3 (0.1)                    | 0/105.6 (0.0)             |
| Crohn'sdisease                        | 1/420.0 (0.2)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 1/955.0 (0.1)                    | 1/105.5 (0.9)             |
| Dehydration                           | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 1/89.2 (1.1)                      | 1/954.2 (0.1)                    | 0/105.6 (0.0)             |
| Intervertebraldisc protrusion         | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 1/89.4 (1.1)                      | 1/954.3 (0.1)                    | 0/105.6 (0.0)             |
| Limbtraumaticamputation               | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 1/89.3 (1.1)                      | 1/954.3 (0.1)                    | 0/105.6(0.0)              |
| Migraine                              | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 1/89.4 (1.1)                      | 1/954.4 (0.1)                    | 0/105.6(0.0)              |
| Nephrolithiasis                       | 0/420.0 (0.0)                    | 1/444.8 (0.2)                     | 0/90.1 (0.0)                      | 1/954.9 (0.1)                    | 1/105.3 (0.9)             |
| Osteomyeliis                          | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 1/89.3 (1.1)                      | 1/954.3 (0.1)                    | 0/105.6 (0.0)             |
| Sinusitis                             | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 1/89.8 (1.1)                      | 1/954.7 (0.1)                    | 1/105.4 (0.9)             |
| Subcutaneousabscess                   | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 1/89.4 (1.1)                      | 1/954.4 (0.1)                    | 0/105.6 (0.0)             |
| Cholecyslilisacute                    | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 0/955.0 (0.0)                    | 1/105.5 (0.9)             |
| Depression                            | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 0/955.0 (0.0)                    | 1/105.4 (0.9)             |
| Haematomainfection                    | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 0/955.0 (0.0)                    | 1/105.6 (0.9)             |
| Hypertensivecrisis                    | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 0/955.0 (0.0)                    | 1/105.2(1.0)              |
| Inguinalhemia                         | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 0/955.0(0.0)                     | 1/105.4 (0.9)             |
| Intraductalproliferative breastlesion | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 0/955.0 (0.0)                    | 1/105.5 (0.9)             |
| Pleuraleffusion                       | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 0/955.0 (0.0)                    | 1/105.1 (1.0)             |
| Rectalhaemorrhage                     | 0/420.0 (0.0)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 0/955.0 (0.0)                    | 1/105.6 (0.9)             |

PreferredtermsaresortedindescendingorderoffrequencyintheAnyAlN457column

EX=exposureinpatientyears.IR=incidencerateper100patientyears.

Forpalientswithevent,exposuretimeiscensoredattimeoffirstevent

Among the 4 patients with CTCAE Grade 3 neutropenia, none experienced an infection any time during the  reporting  period.  Further,  neutropenia  reported  as  AEs  were  transient  (lasting  only  1  visit  and normalizing at the next subsequent visit) and did not result in permanent discontinuation of study drug.

<div style=\"page-break-after: always\"></div>

These events are presented in Table 27 .  The overall incidence of neutropenia was similar between the different loading regimens.

Table 27. Neutropenia events - Entire treatment period (Pool A: Phase 3 PsA trials Safety set)

| Level1 Preferredterm               | Any AIN457 75mg N=391 n/EX(IR)   | AnyAIN457 150mg N=438 n/EX (IR)   | AnyAIN457 300mg N=145 n/EX (IR)   | Any AIN457 dose N=974 n/EX (IR)   | Placebo N=300 n/EX (IR)   |
|------------------------------------|----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|---------------------------|
| BasedonallAEs                      |                                  |                                   |                                   |                                   |                           |
| Neutropenia(narrowNMQ)             | 9/412.1 (2.2)                    | 5/440.1 (1.1)                     | 2/88.6 (2.3)                      | 16/940.9 (1.7)                    | 7/103.9 (6.7)             |
| Leukopenia (PT)                    | 6/415.5 (1.4)                    | 3/443.4 (0.7)                     | 0/90.1 (0.0)                      | 9/949.0 (0.9)                     | 3/105.0 (2.9)             |
| Neutropenia (PT)                   | 1/418.3 (0.2)                    | 3/441.9 (0.7)                     | 1/89.2 (1.1)                      | 5/949.5 (0.5)                     | 3/104.6 (2.9)             |
| Whitebloodcellcount decreased (PT) | 3/418.1 (0.7)                    | 1/443.3 (0.2)                     | 1/89.5 (1.1)                      | 5/950.8 (0.5)                     | 1/105.5 (0.9)             |
| Neutrophilcountdecreased (PT)      | 1/419.3 (0.2)                    | 0/444.9 (0.0)                     | 0/90.1 (0.0)                      | 1/954.3 (0.1)                     | 0/105.6 (0.0)             |
| BasedonSAEs                        |                                  |                                   |                                   |                                   |                           |
| Neutropenia(narrowNMQ)             | 0                                | 0                                 | 0                                 | 0                                 | 0                         |

PreferredtermsaresortedindescendingorderoffrequencyintheAnyAlN457column

EX=exposure inpatient-years;IR=incidencerateper100patient-years;PT=preferred term;NMQ=Novartis MedDRA query

Apatientwithmultipleoccurrencesofalevelunderonetreatmentiscountedonlyonceforthesameriskforthat treatment.

Forpatientswithevent.exposuretimeiscensoredatthetimeofthefirstevent.

## Clinical chemistry

Secukinumab at any dose showed a higher rate of Grade 1 ALT elevations and of Grade 1-2 abnormalities in cholesterol and triglycerides compared with placebo. Rates of Grade 1 or 2 elevations in ALT, alkaline phosphatase, bilirubin, creatinine and GGT for secukinumab were lower than or similar to placebo. Across the secukinumab dose groups, higher rates were not observed with the 300 mg dose, with the possible exception of Grade 1 values in bilirubin. The rates of Grade 1 or 2 elevations in the iv loading groups were comparable to or lower than the rates in the sc loading groups, suggesting no increase with higher exposure.

Grade 3 elevations in ALT, AST, GGT, increased fasting serum glucose and triglycerides were noted for a small  number  of  patients  in  both  secukinumab  and  placebo  groups,  with  no  meaningful  difference between secukinumab and placebo treatments or across secukinumab doses. Grade 4 abnormalities in decreased fasting glucose were reported for 1 (1.0%) patients on 150 mg secukinumab and 1 (0.3%) patient  on  placebo.  Grade  4  elevations  in  triglycerides  were  observed  in  3  (0.4%)  patients  on secukinumab (all with iv loading) and none on placebo.

Grade 2 elevations in cholesterol were infrequent, but rates were slightly higher in the Any secukinumab dose group compared to placebo (1.6% vs. 0.3% respectively); the highest rate (4.0%) was reported in the iv-150 mg group. Grade 3 and 4 cholesterol abnormalities were not reported.

## Safety in special populations Baseline BSA

Rates of total AEs and most SOCs were higher in patients with &lt;10% BSA than in those with ≥10% BSA in all treatment groups, including the placebo group ( Table 28 ).

<div style=\"page-break-after: always\"></div>

Table 28. Exposure-adjusted incidence of AEs by baseline BSA - Entire treatment period (Pool A: Phase 3 PsA trials - Safety set)

| Primary SOC                                   | Subgroup   | Any AIN457 75mg n/EX (IR)   | Any AIN457 150mg n/EX (IR)   | Any AIN457 300mg n/EX (IR)   | Any AIN457 dose n/EX (IR)   | Placebo n/EX(IR)   |
|-----------------------------------------------|------------|-----------------------------|------------------------------|------------------------------|-----------------------------|--------------------|
| Totalofpatients-N                             | BSA≥10%    | 118                         | 145                          | 34                           | 297                         | 98                 |
| Totalofpatients-N                             | BSA<10%    | 265                         | 288                          | 106                          | 659                         | 198                |
| Any AEs                                       | BSA≥10%    | 77/60.9 (126.5)             | 96/61.3 (156.5)              | 18/12.3 (146.1)              | 191/134.5 (142.0)           | 46/23.0 (200.4)    |
| Any AEs                                       | BSA<10%    | 213/95.6 (222.9)            | 241/85.1 (283.2)             | 71/29.0 (244.6)              | 525/209.7 (250.4)           | 133/33.1 (402.1)   |
| Infections and infestations                   | BSA≥10%    | 54/89.9 (60.1)              | 55/100.6 (54.7)              | 9/16.8 (53.4)                | 118/207.3 (56.9)            | 22/29.9 (73.5)     |
| Infections and infestations                   | BSA<10%    | 140/180.9 (77.4)            | 175/160.1 (109.3)            | 47/44.3 (106.2)              | 362/385.3 (93.9)            | 59/56.0 (105.3)    |
| Musculoskeletaland connectivetissue disorders | BSA≥10%    | 23/111.7 (20.6)             | 30/124.1 (24.2)              | 3/20.9 (14.4)                | 56/256.7 (21.8)             | 7/34.0 (20.6)      |
| Musculoskeletaland connectivetissue disorders | BSA<10%    | 80/233.4 (34.3)             | 61/252.5 (24.2)              | 16/58.3 (27.5)               | 157/544.2 (28.8)            | 37/ 61.1 (60.5)    |
| Gastrointestinal disorders                    | BSA≥10%    | 17/116.9 (14.5)             | 24/130.3 (18.4)              | 3/19.9 (15.1)                | 44/267.1 (16.5)             | 9/33.6 (26.8)      |
| Gastrointestinal disorders                    | BSA<10%    | 70/231.6 (30.2)             | 75/237.8 (31.5)              | 24/54.4 (44.1)               | 169/523.9 (32.3)            | 29/61.7 (47.0)     |
| Skin and subcutaneoustissue disorders         | BSA≥10%    | 13/119.9 (10.8)             | 18/135.9 (13.2)              | 2/21.5 (9.3)                 | 33/277.3 (11.9)             | 5/34.1 (14.7)      |
| Skin and subcutaneoustissue disorders         | BSA<10%    | 52/247.1 (21.0)             | 55/253.2 (21.7)              | 15/58.3 (25.7)               | 122/558.6 (21.8)            | 24/64.1 (37.4)     |
| Nervoussystem disorders                       | BSA≥10%    | 16/115.5 (13.9)             | 20/132.6 (15.1)              | 3/20.3 (14.8)                | 39/268.4 (14.5)             | 4/34.2 (11.7)      |
| Nervoussystem disorders                       | BSA<10%    | 43/249.5 (17.2)             | 48/255.1 (18.8)              | 14/56.9 (24.6)               | 105/561.5 (18.7)            | 24/ 63.4 (37.9)    |

Mostfrequentlyreportedprimarysystemorganclasses(&gt;15per100-patient-yearsintheAnyAIN457groupinthe overallpopulation)arepresentedindescendingorderofIRinAnyAlN457groupofTable2-3

EX=exposureinbatient-vears.IR=incidencerateDer100patient-vears

## Body weight

No specific weight-related trends in total AEs or in the most frequently affected SOC of infections and infestations were observed. There were no meaningful differences by weight observed in the incidence of cardiac  disorders,  skin  and  subcutaneous  tissue  disorders  or  gastrointestinal  disorders  or  other  SOCs compared to the overall population. The incidence of SAEs was low and no weight-related trends among the treatment groups were observed. Serious infections and infestations were reported in a slightly higher proportion of patients weighing &lt; 90 kg (n=8, 1.8% in the Any secukinumab group vs. 0% in the placebo group), with no meaningful difference across dose groups, than in the patients weighing &gt; 90 kg (n=1, 0.4% in the Any secukinumab group vs. n=1, 1.1% in the placebo group).

## 10-year CHD risk category

The majority of patients across all treatment groups were in the low risk category for 10-year CHD risk (&lt;10%). AEs by CHD risk  category  in  the  initial  treatment  period  of  Pool  A  were  consistent  with  the profile observed in the overall population. There was no increase in the incidence of AEs in the SOCs of cardiac disorders, nervous system disorders and vascular disorders among patients in the high 10-year

<div style=\"page-break-after: always\"></div>

CHD risk category (&gt;20%) compared with patients in the medium (10-20%) or low (&lt;10%) CHD risk category. There were no clinically meaningful differences across the treatment groups in any subgroups of  CHD  risk.  Similar  findings  were  observed  for  SAEs  by  CHD  risk  category,  which  showed  no  specific trends for any event and few SAEs among the small number of patients in the high risk category. The profile of AEs for Pool A over the entire treatment period by CHD risk category was consistent with those observed for the overall population. Similar results were seen for SAEs in Pool A over the entire treatment period.

## Immunological events

In  the  PsA  studies,  the  overall  incidence  of  immune/administration  reactions  in  the  initial  16-week treatment  period  was  comparable  across  the  secukinumab  and  placebo  groups.  Some  specific  events were more common in placebo patients (mainly cough and rash), while other events ( e.g., peripheral edema,  conjunctivitis,  mouth  ulceration,  urticaria  and  injection  site  erythema)  were  reported  with  low rates  in  secukinumab  patients  only.  There  were  no  reports  of  anaphylactic  reaction  in  a  secukinumab treated patient. With longer exposure over the entire treatment period, the overall incidence was higher with the 300 mg dose compared with the 150 mg dose, mainly driven by rash, pruritus and conjunctivitis. Results from the expanded PsA population and from the pooled PsA and psoriasis population supported these findings.

One case of angioedema (PT) was reported. The event was non-serious, moderate in severity, lasted for 13 days and was considered related to study medication. The patient discontinued study medication and recovered  from  the  event  without  requiring  treatment.  No  systemic  features  of  anaphylaxis  were reported.

The  exposure  adjusted  incidence  of  the  most  frequent  immunological  AEs  over  the  entire  treatment period, are presented in Table 29 .

Table 29. Exposure-adjusted incidence rate of the most frequent AEs of immune/administration reactions (&gt;2% in any treatment group) - Entire treatment period (Pool A: Phase 3 PsA trials - Safety set)

| Level1 Preferredterm                 | AnyAIN457 75mg N=391 n/EX(IR)   | AnyAIN457 150mg N=438 n/EX(IR)   | AnyAIN457 300mg N=145 n/EX(IR)   | AnyAIN457 dose N=974 n/EX(IR)   | Placebo N=300 n/EX(IR)   |
|--------------------------------------|---------------------------------|----------------------------------|----------------------------------|---------------------------------|--------------------------|
| BasedonallAEs                        |                                 |                                  |                                  |                                 |                          |
| Immune/administration reactions(NMQ) | 98/354.8 (27.6)                 | 117/354.7 (33.0)                 | 30/76.4 (39.3)                   | 245/785.8 (31.2)                | 43/95.4 (45.1)           |
| Cough (PT)                           | 10/412.5(2.4)                   | 20/429.3 (4.7)                   | 3/88.0 (3.4)                     | 33/929.7(3.5)                   | 8/103.7 (7.7)            |
| Pruritus (PT)                        | 8/415.0 (1.9)                   | 10/435.3 (2.3)                   | 3/88.5 (3.4)                     | 21/938.9(2.2)                   | 4/104.9 (3.8)            |
| Rash (PT)                            | 7/413.9 (1.7)                   | 9/438.0 (2.1)                    | 5/88.9 (5.6)                     | 21/940.9 (2.2)                  | 11/103.2(10.7)           |
| Conjunctivitis(PT)                   | 3/417.8 (0.7)                   | 6/439.2 (1.4)                    | 3/89.0 (3.4)                     | 12/946.1(1.3)                   | 0/105.6 (0.0)            |
| Mouthulceration（PT)                  | 5/415.3 (1.2)                   | 9/439.2(2.0)                     | 2/89.0 (2.2)                     | 16/943.4 (1.7)                  | 0/105.6 (0.0)            |
| BasedonSAEs                          | 2/419.8 (0.5)                   | 3/443.4 (0.7)                    | 0/90.1 (0.0)                     | 5/953.2 (0.5)                   | 1/105.5 (0.9)            |
| Psoriaticarthropathy(PT)             | 0/420.0 (0.0)                   | 2/443.5 (0.5)                    | 0/90.1 (0.0)                     | 2/953.6 (0.2)                   | 0/105.6(0.0)             |
| Crohn'sdisease(PT)                   | 1/420.0 (0.2)                   | 0/444.9 (0.0)                    | 0/90.1 (0.0)                     | 1/955.0 (0.1)                   | 1/105.5 (0.9)            |
| Local swelling(PT)                   | 0/420.0 (0.0)                   | 1/444.8 (0.2)                    | 0/90.1 (0.0)                     | 1/954.9 (0.1)                   | 0/105.6 (0.0)            |
| Ocularmyasthenia(PT)                 | 1/419.8(0.2)                    | 0/444.9 (0.0)                    | 0/90.1 (0.0)                     | 1/954.8 (0.1)                   | 0/105.6 (0.0)            |

EX=exposureinpatientyears;IR=incidencerateper100patientyears;NMQ=NovartisMedDRAquery; PT=preferredterm;

MostfrequentlyoccurringpreferredtermsforAEs(&gt;=2%inanytreatmentgroup)arepresentedandsortedin descendinaorderoffreauencyintheAnvAiN457dosecolumn

Exposure-adjusted  incidence  rates  for  hypersensitivity  AEs  were  higher  in  the  Any  300  mg  group compared with the Any 150 mg and Any 75 mg groups (IR=14.0 vs. 9.6 and 7.7, respectively), but all secukinumab doses showed numerically lower rates than the placebo group (IR=21.7). The imbalance was mainly driven by the higher rate of rash and urticaria.

<div style=\"page-break-after: always\"></div>

In  the  time  interval  of  0-8  weeks,  the  absolute  incidence  of  immune/administration  reactions  was comparable  between  the  sc  loading  (11.0%,  8.0%  and  8.1%  for  300  mg,  150  mg  and  75  mg, respectively) and iv loading regimens (7.9% and 10.9% for iv-75 mg and iv-150 mg, respectively), and slightly  lower  for  the  no-load  regimens  (6.7%,  5.1%  and  8.9%  for  75  mg,  150  mg  and  300  mg, respectively).

The  profile  of  immune/administration  reactions  in  the  Phase  3  PsA  and  psoriasis  studies  (Pool  B)  was similar  to  that  observed  in  PsA  populations  of  Pools  A  and  B1,  also  showing  no  new  or  unexpected reactions with secukinumab treatment.

## Immunogenicity

Treatment-emergent ADA are defined as ADA that developed post-treatment in patients with negative ADA screens at Baseline  (ie,  seroconversion  to  ADA  positivity  from  a  seronegative  state).  Across  both Phase 3 PsA trials, treatment-emergent ADA were detected in one patient only (1/996, 0.1%) who was receiving  75  mg  secukinumab  at  the  time  of  the  positive  result  at  Week  24.  A  subsequent  sample collected at Week 52 was negative for ADA. There was no loss of efficacy, no immunogenicity-related AEs and no altered PK profile in this single case of treatment-emergent ADA.

Non-treatment emergent ADA were also observed in both Phase 3 PsA trials. A total of 16/996 (1.6%) patients were ADA positive at Baseline. This includes 10 patients who were ADA positive at Baseline only and  reverted  to  a  seronegative  state  while  on  secukinumab  treatment,  and  6  patients  who  had  both baseline  and  post-baseline  ADA  positive  samples.  Overall,  the  non-treatment  emergent  positive  ADA responses were mostly transient and of low titer. The MSD-based assay is highly sensitive and therefore capable of detecting very low levels of antibodies which can bind to secukinumab. Consequently, nontreatment related, naturally  occurring  ADA  may  lead  to  a  confirmed  positive  response  in  this  assay  in either  predose  samples  or samples  derived from patients  not  exposed  to  secukinumab.  These observations  were  not  considered  to  be  clinically  relevant,  as  the  ADA  were  not  associated  with secukinumab treatment. Of the 17 patients who tested positive for ADA at any time point in either Phase 3 PsA trials, 10 (58.8%) reverted to a seronegative state at a later time point with no detectable ADA while on secukinumab treatment. This total includes the single patient with treatment-emergent ADA who also reverted to a seronegative state while on treatment.

ADA were also not associated with altered PK profiles. Secukinumab concentrations in all patients with ADA and more than one evaluable PK sample fit into the observed range for all patients without ADA at Weeks 4, 16, 24 and 52. There was also no correlation between ADA titers and alteration in PK profile in Phase 2 or 3 patients.

Across all secukinumab-exposed patients evaluated for ADA in the 2 Phase 3 PsA trials, 8/996 (0.8%) patients tested positive for both ADA and neutralizing antibodies. PK profiles were normal and therapeutic efficacy was maintained in these patients with neutralizing antibodies, although one of these patients  had only one PK sample available and another patient  had too few evaluable visits while on active treatment to  fully  assess  the  impact  on  efficacy.  The  patient  with  possible  loss  of  efficacy  had  no  neutralizing antibodies associated with the positive ADA.

## Drug interactions and other interactions

## Prior anti-TNF-alpha exposure

The  exposure-adjusted  AE  profile  over  the  entire  treatment  period  by  prior  anti-TNF-α  exposure  was similar to that observed in the overall population of Pool A. The incidence per 100 patient-years of total AEs and of the most frequently occurring SOCs including infections and infestations showed the same pattern as seen in the overall population, with numerically higher rates in the placebo group compared

<div style=\"page-break-after: always\"></div>

with the Any secukinumab dose group. A dose dependency could be noted for infections and infestations as well as for gastrointestinal disorders, which appeared to be more pronounced and consistent in TNFaIR patients.

Overall the incidence of exposure-adjusted incidence of total AEs was higher in TNFa-IR patient than in anti-TNFα naïve patients in all treatment groups).

The exposure-adjusted incidence rate of total SAEs was low and showed no trends by prior anti-TNF-α exposure  ( Table  30 ).  Among  the  TNFa-IR  patients,  serious  infections  were  more  frequent  with secukinumab vs. placebo (IR=2.9 for Any secukinumab dose vs. 0 for placebo), driven by a higher rate with the 300 mg dose (7.2 for Any 300 mg vs. 2.4 for Any 150 mg and 2.5 for Any 75 mg). However, similar to the overall population, the rate was higher with placebo vs. secukinumab among the anti-TNF-α naïve patients (IR=4.1 for placebo vs. 2.4 for Any secukinumab dose), with no meaningful dose effect across  the  secukinumab  groups  (IR=3.3,  2.6  and  2.0  for  Any  300  mg,  Any  150  mg  and  Any  75  mg, respectively).

Table 30. Exposure-adjusted incidence of AEs by previous TNF-alpha exposure Entire treatment period (Pool A: Phase 3 PsA trials - Safety set)

| PrimarySoc                          | Subgroup         | Any AIN457 75mg n/EX(IR)         | Any AIN457 150mg n/EX(IR)         | Any AIN457 300mg n/EX(IR)      | Any AIN457 so n/EX(IR)            | Placebo n/EX(IR)               |
|-------------------------------------|------------------|----------------------------------|-----------------------------------|--------------------------------|-----------------------------------|--------------------------------|
| Totalofpatients-N                   | TNF-naive TNF-IR | 273 118                          | 302 136                           | 96 49                          | 671 303                           | 206 94                         |
| AnyAE                               | TNF-naive        | 204/111.2 (183.4)                | 234/107.1 (218.4)                 | 59/29.8 (198.1)                | 497/248.2 (200.3)                 | 121/40.1 (301.4)               |
| Infectionsand infestations          | TNF-IR TNF-naive | 92/47.5 (193.8) 139/190.2 (73.1) | 108/39.9 (270.7) 165/186.8 (88.3) | 35/12.5 (280.2) 40/43.3 (92.3) | 235/99.8 (235.4) 344/420.3 (81.8) | 60/16.5 (363.9) 58/61.2 (94.8) |
| Musculoskeletaland                  | TNF-IR           | 59/85.2 (69.2)                   | 68/75.9 (89.6)                    | 20/19.7 (101.3)                | 147/180.9 (81.3)                  | 24/25.8 (93.0)                 |
| connectivetissue                    | TNF-naive        | 68/247.5 (27.5)                  | 55/276.6 (19.9)                   | 10/57.4 (17.4)                 | 133/581.5 (22.9)                  | 29/67.9 (42.7)                 |
| disorders                           | TNF-IR           | 37/102.9 (36.0)                  | 38/103.9 (36.6)                   | 10/25.6 (39.1)                 | 85/232.4 (36.6)                   | 16/27.9 (57.4)                 |
| Gastrointestinal disorders          | TNF-naive        | 60/251.3 (23.9)                  | 61/268.9 (22.7)                   | 16/53.2 (30.1)                 | 137/573.4 (23.9)                  | 30/66.7 (45.0)                 |
|                                     | TNF-IR           | 28/103.1 (27.2)                  | 38/104.9 (36.2)                   | 12/24.2 (49.7)                 | 78/232.1 (33.6)                   | 9/29.5 (30.5)                  |
| Skinandsubcutaneous tissuedisorders | TNF-naive        | 51/257.4 (19.8)                  | 46/284.2 (16.2)                   | 16/55.2 (29.0)                 | 113/596.8 (18.9)                  | 17/70.6 (24.1)                 |
|                                     | TNF-IR           | 15/115.0 (13.0)                  | 28/109.1 (25.7)                   | 4/26.9 (14.9)                  | 47/251.0 (18.7)                   | 13/28.3 (45.9)                 |
| Nervoussystem disorders             | TNF-naive        | 32/269.3 (11.9)                  | 46/279.2 (16.5)                   | 9/56.0 (16.1)                  | 87/604.4 (14.4)                   | 21/69.3 (30.3)                 |

overallpopulation)arepresentedindescendingorderofIRinAnyAIN457groupofTable2-3 EX=exposureinpatient-years.IR=incidencerateper100patient-years;TNF-IR=anti-TNF-alphaincomplete responders

Mostfrequentlyreportedprimarysystemorganclasses(&gt;15per100-patient-yearsintheAnyAiN457groupinthe

## Concomitant methotrexate use

There  were  no  additional  trends  in  total  AEs  or  in  the  most  frequently  affected  SOC  of  infections  and infestations  compared  to  the  overall  population.  No  clinically  meaningful  differences  were  seen  in  the incidence of AEs in any SOC across subgroups of concomitant use of methotrexate.

## Concomitant corticosteroid use

Exposure-adjusted  incidence  rates  showed  similar  trends  for  total  AEs  and  for  the  most  frequently affected SOC of infections and infestations as compared to the overall population. No clinically meaningful

<div style=\"page-break-after: always\"></div>

differences were seen in the incidence of safety risks based on SAEs between subgroups of concomitant use of corticosteroids

## 2.5.1. Discussion on clinical safety

The  secukinumab  development  program  studied  7048  patients,  including  6200  patients  exposed  to  at least one dose of secukinumab in any indication, and 6267 patient-years of secukinumab exposure, are included  in  the  safety  pooling.  The  safety  data  in  the  present  submission  provided  an  additional  2679 patient-years of secukinumab exposure (75% increase), including 955 patient-years of exposure in PsA patients, beyond the 3588 patient-years of exposure reported previously for the psoriasis development program.

Pool A consisted of 2 pivotal placebo-controlled Phase 3 trials (F2306 and F2312) in PsA with placebo and dose  comparisons  that  allow  risks  to  be  evaluated  in  the  PsA  population  during  the  first  16  weeks  of treatment, which was the placebo-controlled phase, and during the entire treatment period (median 48 weeks of exposure to secukinumab, interim analyses on week 52 in study F2306 and on week 24 in study F2312).

Pool B1 (an expanded PsA population with PsA patients from the 2 Phase 3 PsA trials, F2306 and F2312, and psoriasis patients with concomitant PsA from 3 Phase 3 psoriasis trials, A2302, A2303, and A2304).

Pool B (a mixed population of PsA patients from the 2 Phase 3 PsA trials, F2306 and F2312, and psoriasis patients  from  the  5  Phase  3  psoriasis  trials  A2302,  A2303,  A2304,  A2308,  and  A2309)  increased  the probability of observing less common events over long-term treatment for the target doses of 150 mg sc and 300 mg sc.

Pool C, the largest data pool, included all patients treated with secukinumab in 42 studies and maximized the probability of observing rare events in patients receiving secukinumab.

Deaths, overall AEs and SAEs were examined for Pools A, B1 and B. The severity of AEs, the relationship of  AEs  to  study  treatment,  AEs  causing  permanent  discontinuation  of  study  treatment,  laboratory parameters,  vital  signs,  and  electrocardiogram  (ECG)  data  were  examined  for  patients  in  PsA  and psoriasis studies (Pools A and B). Risk categories (AEs of special interests, corresponding to potential and identified  risks  in  the  RMP)  were  examined  for  Pools  A,  B1  and  B.  Pool  C  was  used  to  examine malignancies and major adverse cardiovascular events (MACE) only.

Pooling was done in a rational manner to 1) investigate the specific safety concerns during the induction period in the PsA studies (related to either iv or sc loading regimen), 2) to enable comparisons against placebo during the initial 16 weeks of PsA studies, 3) to find out about long term tolerability in psoriasis and PsA indications, and 4) to investigate the overall critical safety features of secukinumab pooled from all  exposed patients (longest follow-up to date of reporting over 212 weeks in 1 subject and over 132 weeks in 108 subjects).

The AE profile of induction and placebo controlled study phases resembles closely the AE profile observed in  the  initial  submission  of  psoriasis  indication,  where  up  to  week  12,  the  most  common  AEs:  were nasopharyngitis (placebo 8.6% vs. secukinumab 11.9%), headache (5.2% vs. 6.0%), diarrhoea (1.4% vs. 3.3%), pruritus (2.6% vs 3.2%), URTI (0.7% vs. 2.82%), oropharyngeal pain (1.7% vs. 2.3%), and arthralgia (2.4% vs. 2.1%).

In PsA patients it appeared that nasopharyngitis was slightly more common in patients receiving the ivloading. Oral herpes was observed more in patients receiving 300 mg sc-doses (n=4) or iv-loading and 150 mg sc-doses (n=5).  However, none of the herpes cases were severe or led to discontinuation from the  study.  Eight  cases  of  rhinitis,  6  cases  of  conjunctivitis,  and  6  cases  of  mouth  ulcerations  were

<div style=\"page-break-after: always\"></div>

reported from patients receiving secukinumab, but not from patients who had received placebo. Mouth ulcerations were not associated with candidiasis. These observations supported the use of the sc-loading method and use of lower than 300 mg sc doses in maintenance, when possible, to ensure the greatest safety.

Similarly to weeks 0 to 16, in the entire study period the AE profile closely resembled that seen in the psoriasis studies, where nasopharyngitis, URTIs, arthralgia, hypertension, diarrhoea, back pain, pruritus, cough, psoriasis, and oropharyngeal pain were the top ten preferred terms for AEs.

There appeared to be no dose-dependence during maintenance treatment for most of the reported AEs. However,  a  trend  for  dose-dependence  can  be  observed  in  the  incidences  of  sinusitis  (2.7%,  3.4%, 10.3% for 75 mg, 150 mg, and 300 mg sc doses, vs. 5.7% in the placebo patients), oral herpes (1.7%, 2.8%, 5.7% for 75 mg, 150 mg, and 300 mg sc doses, vs. 3.8% in the placebo patients) pharyngitis (2.4%, 3.0%, 5.6% for 75 mg, 150 mg, and 300 mg sc doses, vs. 0.0% in the placebo patients), and epistaxis  (0%,  0,2%,  3.3%  vs.  2.9%  respectively)  in  the  two  PsA  trials.  In  earlier  psoriasis  trials, headache was more common in patients receiving placebo, with no difference between 150 and 300 mg doses. Oral herpes affected 1.49% of patients receiving placebo, 1.50% of patients receiving 150 mg sc and 1.74% of patients receiving 300 mg sc. Therefore, escalation of the dose to 300 mg sc when needed in accordance with the PsA indication can be justified.

Upper  respiratory  tract  infections,  candida  infections,  and  mainly  oral  herpes  infections  have  been addressed in sufficient manner in the current Cosentyx-PI. There are no new findings in this respect from the PsA-studies. No cases of tuberculosis or viral hepatitis were reported.

Deaths in patients receiving secukinumab were all associated with severe cardiovascular risks and comorbidity  and  do  not  seem  to  be  related  to  the  study  medications  in  the  PsA  studies.  The  same conclusion could be made about deaths in the AS studies.

SAEs in Pool A first 16 weeks consisted of two occurrences of cerebrovascular accident in 10 mg/kg-75 mg sc group, and two occurrences of erysipelas in 150 mg sc and 300 mg sc groups. For rest of the studies,  there  was  also  one  erysipelas  case  in  the  placebo  group.  Incidence  rates  of  erysipelas,  chest pain,  osteoarthritis,  sepsis,  coronary  artery  disease,  and  septic  shock  were  lower  during  secukinumab treatment  compared  to  placebo  treatment.  Atrial  fibrillation,  cerebrovascular  accident,  deep  vein thrombosis,  diverticulitis,  myocardial  infarction,  pneumonia,  psoriatic  arthropathy,  septic  shock,  and positional vertigo were reported two times each during secukinumab treatment and never during placebo treatment.  Most  of  these  cases  were  reported  from  the  75  mg  sc  patients,  thus  no  apparent  dosedependence could be observed. There were no significant findings in Pool B compared to pool A.

Two new diagnoses of Crohn's disease were made during or after secukinumab exposure in AS patients and one new diagnosis similarly in PsA patients. Crohn´s disease has already been addressed in sufficient manner in the product information of secukinumab and no further action was considered necessary in relation to the psoriatic arthritis indication.

Skin  malignancies  as  well  as  other  malignancies  were  rare,  and  not  considered  related  to  study medications in Pool A.

Three cases of lymphomas in psoriasis and ankylosing spondylitis studies were evaluated closely. While the 2 lymphoma cases observed on secukinumab occurred after many months of exposure to the IMP, they  had  quite  different  characteristics  suggesting  a  different  underlying  etiopathogenesis.  Some commonalities in these 2 lymphoma cases would have been expected if they were to be associated to neutralisation of IL-17A.

During  the  induction  period  in  Pool  B,  there  were  10  cardiac  disorders  reported  as  SAEs  in  the  'Any secukinumab dose' group, compared to none in the placebo- and etanercept-groups. Number of patients

<div style=\"page-break-after: always\"></div>

experiencing a serious cardiovascular adverse event (and the incidence rate per 100 patient years) for placebo  0  (0.00),  secukinumab  150  mg  13  (1.14),  secukinumab  300  mg  7  (0.60),  and  etanercept  3 (1.03) would suggest a slightly increased risk for users of secukinumab. However, taking into account the larger and - in particular - longer exposure to secukinumab and that most of the SAEs occurred weeks or months  after  continuous  secukinumab  use  in  patients  with  predisposing  factors  and  cardiovascular morbidity, there was no implication that secukinumab would predispose patients to serious cardiovascular complications. The same conclusions can be drawn from the analyses of the PsA studies. The issue will remain  under  close  review  as  it  is  included  in  the  RMP  as  an  important  potential  risk,  but  the  CHMP considered that no updates to the SmPC would be warranted at this stage based on the available data.

There was a significant decrease in total leukocytes and neutrophils in the pooled secukinumab group during  all  pivotal  studies  in  the  psoriasis  submission.  This  decrease  was  considered  related  to  the pharmacodynamic effects  of  the  drug  (and  it  was  somewhat  more  prominent  in  the  etanercept  group compared to secukinumab patients). In general, the neutropenia cases were not associated with SAEs or treatment discontinuation. There were no new findings in the PsA studies in this respect. There were no observed  effects  attributable  to  use  of  study  medications  in  haemoglobin,  lymphocyte,  and  platelet parameters. In the three cases of severe hepatobiliary AEs, there was concomitant morbidity at baseline or concomitant medications in use.

Mild  elevations  of  ALT  observed  during  induction  period,  with  only  slight  differences  between  different induction regimens, appear not to be a relevant safety issue.

The mild elevations grade I elevation of total cholesterol and triglycerides appear in similar incidences irrespective of route of loading doses and clinically insignificant as well. Grade II elevations of cholesterol were observed in 2/293 (0.68%) in patients receiving sc loading and 9/390 (2.31%) in patients receiving iv loading (during the first 16 weeks). However, as iv loading is not foreseen in the clinical setting, the higher incidence in those patients is not considered a significant finding.

There were no clinically meaningful differences in the AE profile stratified by the baseline BSA (&lt;10%, &gt;10%), body weight (&lt;90 kg, &gt;90 kg), and gender.

AE  profiles  of  patients  having  earlier  taken  biologicals  and/or  currently  taking  immunosuppressants appeared similar. Concomitant immunosuppression should warrant more careful follow up of the patient regarding severe infections and adequate warnings are contained in the SmPC. All immune reactions were non-serious.  One  case  of  angioedema  was  related  to  study  medication  and  resolved  in  13  days  after discontinuation  of  study.  One  case  of  anaphylaxis  was  considered  related  to  a  concomitant  antibiotic treatment.

Milder  forms  of  hypersensitivity  reactions  were  rare.  Urticaria  was  seen  here  less  frequently  (0.5%) compared  to  the  original  psoriasis  submission  (1.85%).  Rash  was  slightly  less  common  here  (2.2%) compared to the earlier submission (2.45%). Overall incidence of hypersensitivity reaction in here Pool A was 9.2% and 11.17% in the original submission in the secukinumab patients.

The  presence  of anti-secukinumab  antibodies  was  scarce, suggesting  that the potential risk of immunogenicity  is  low.  Based  on  the  clinical  trial  data,  the  immunogenicity  to  secukinumab  did  not appear to have a negative impact on the overall safety profile, efficacy, or pharmacokinetic parameters of secukinumab.

## 2.5.2. Conclusions on clinical safety

The safety profile of secukinumab in treatment of PsA in both the induction and maintenance phases of the  studies  resembled  closely  to  the  safety  profile  observed  in  the  psoriasis  indication  of  the  initial submission. ADRs occurring more frequently in the secukinumab group included URTI, nasopharyngitis,

<div style=\"page-break-after: always\"></div>

sinusitis, and diarrhoea. There were no new findings regarding Crohn´s disease or MACEs. There were no new  concerns  about  malignancies.  Hypersensitivity  and  immunological  reactions  remain  rare  and immunogenic potential of secukinumab appeared very low, with no clinical implications.

## 2.5.3. PSUR cycle

The PSUR cycle remains unchanged. The PSUR cycle for the medicinal product should follow a half-yearly cycle until otherwise agreed by the CHMP.

The next data lock point will be 25 December 2015.

The annex II related to the PSUR refers to the EURD list which remains unchanged.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 2.1 is acceptable. The PRAC endorsed PRAC Rapporteur assessment report is attached.

The CHMP endorsed the Risk Management Plan version 2.1 with the following content:

Safety concerns

Table 31. Summary of the Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                      |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Infections and infestations Neutropenia Hypersensitivity                                                                                                                                                                                        |
| Important potential risks    | Malignant or unspecified tumors Major Adverse Cardiovascular events (MACE) Immunogenicity Crohn's disease Hepatitis B reactivation Interaction with live vaccines                                                                               |
| Missing information          | Fetal exposure in utero Long-term safety data Long-term efficacy data Use in pediatric patients Patients with severe hepatic impairment Patients with severe renal impairment Patients with severe cardiac disease or uncontrolled hypertension |

Pharmacovigilance plan

Table 32. Table of on-going and planned additional PhV studies/activities in the Pharmacovigilance Plan

<div style=\"page-break-after: always\"></div>

| Activity/Study Type, title and category (1-3)   | Objectives                                                                                                                                                                                                  | Safety concerns addressed                         | Status   | Date for submission of interim or final reports (planned or actual)                                                                                                                |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Psoriasis Registry Category 3                   | The primary goal of the registry is to assess the incidence and nature of malignancies in a real-world population of moderate-to-severe psoriasis patients (including PsA patients) on secukinumab therapy. | Malignant or unspecified tumours Long-term safety | Started  | Progress reports including data presentation to be included in DSUR/PSUR according to the regulated timelines No additional Interim reports planned Final study report in Q2 2030. |

The MAH proposed to update the RMP to change the due date of the Psoriasis registry (category 3 study). The revision in the final report date of the Psoriasis Registry resulted in an increase in the sample size from 2000 to 3000 secukinumab treated subjects and in the follow-up period from 5 to 8 years. These changes required a revision in the study duration and final report date which is now at Q2 2030.

Risk minimisation measures

Table 33. Summary table of Risk Minimisation Measures

| Safety concern                             | Routine risk minimisation measures                                                                                                                                              | Additional risk minimisation measures   |
|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Important Identified Risks                 | Important Identified Risks                                                                                                                                                      | Important Identified Risks              |
| Infections and infestations                | Labeling SmPC section 4.3 (Contraindications), SmPC section 4.4 (Special warnings and precautions for use), and section 4.8 (Undesirable effects-summary of the safety profile) | None                                    |
| Neutropenia                                | Labeling SmPC section 4.8 (Undesirable effects-summary of the safety profile)                                                                                                   | None                                    |
| Hypersensitivity                           | Labeling SmPC section 4.3 (Contraindications), section 4.4 (Special warnings and precautions for use), and section 4.8 (Undesirable effects-summary of the safety profile)      | None                                    |
| Important Potential Risks                  | Important Potential Risks                                                                                                                                                       | Important Potential Risks               |
| Malignant or unspecified tumors            | No specific measures are required for patients receiving secukinumab - standard of care is adequate                                                                             | None                                    |
| Major Adverse Cardiovascular Events (MACE) | No specific measures are required for patients receiving secukinumab - standard of care is adequate.                                                                            | None                                    |
| Immunogenicity                             | Labeling SmPC Section 4.8 (Undesirable effects-                                                                                                                                 | None                                    |

<div style=\"page-break-after: always\"></div>

|                                                                   | summary of the safety profile)                                                                                                                                      |      |
|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Crohn's disease                                                   | Labeling SmPC section 4.4 (Special warnings and precautions for use)                                                                                                | None |
| Hepatitis B reactivation                                          | No risk minimization measure is considered necessary at this time.                                                                                                  | None |
| Interaction with live vaccines                                    | Labeling SmPC section 4.4 (Special warnings and precautions for use) and section 4.5 (Interaction with other medicinal products and other forms of interaction)     | None |
| Missing information                                               |                                                                                                                                                                     |      |
| Fetal exposure in utero                                           | Labeling SmPC section 4.6 (Fertility, pregnancy and lactation)                                                                                                      | None |
| Long-term safety data                                             | No risk minimization measure is considered necessary at this time. Routine risk minimization (standard of care for the target population) is considered sufficient. | None |
| Long-term efficacy data                                           | No risk minimization measure is considered necessary at this time. Routine risk minimization (standard of care for the target population) is considered sufficient. | None |
| Use in pediatric patients                                         | Labeling SmPC section 4.1 (Therapeutic indications)                                                                                                                 | None |
| Patients with severe hepatic impairment                           | No risk minimization measure is considered necessary at this time.                                                                                                  | None |
| Patients with severe renal impairment                             | No risk minimization measure is considered necessary at this time.                                                                                                  | None |
| Patients with severe cardiac disease or uncontrolled hypertension | No risk minimization measure is considered necessary at this time.                                                                                                  | None |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC have been updated as detailed in the appended product information. The package leaflet has been updated accordingly.

In addition, changes in relation to the study duration and the final report date of the study in the psoriasis registry which is included in the RMP were also made.

## 2.7.1. User consultation

The results of the user consultation with target patient groups on the package leaflet for Cosentyx prefilled syringe submitted by the MAH show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use. No full user consultation with target patient groups on the package leaflet for Cosentyx pre-filled pen and Cosentyx powder for solution for injection has been performed on the basis of a bridging report making reference to Cosentyx pre-filled syringe. The bridging report submitted by the applicant has been found acceptable.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

Rapid and clinically meaningful efficacy of secukinumab in the treatment of PsA has been demonstrated. Both  phase  III  studies  met  the  primary  endpoint  of  ACR20  response  rates  at  Week  24.  The  response rates in Study F2306 were 50.5% for secukinumab 10 mg/kg-75 mg, 50.0% for 10 mg/kg-150 mg and 17.3% for placebo (p&lt;0.0001 for each comparison vs. placebo). The response rates in Study F2312 were 29.3% for  secukinumab  75  mg,  51.0%  for  secukinumab  150  mg,  54.0  for  secukinumab  300  mg  and 15.3%  for  placebo  (p&lt;0.0001  for  secukinumab  150  mg  and  300  mg  vs.  placebo,  p=0.0200  for secukinumab 75 mg vs. placebo). The efficacy was also maintained up to Week 52.

Results of the secondary efficacy endpoints were in general consistent with those of the primary efficacy endpoint.  Secondary  efficacy  endpoints  related  to  signs  and  symptoms  of  PsA,  such  as  DAS28-CRP change, ACR50 response, SF-36 PCS, HAQ-DI,  and the presence of dactylitis and enthesitis, as well as those related to concomitant psoriasis such as PASI75 and PASI90 were generally met for secukinumab doses  150  mg  and  300  mg.  As  an  exception,  HAQ-DI  response  at  Week  24  was  not  statistically significantly different to placebo in Study F2312 in the secukinumab 150 mg dose group.

Overall, efficacy endpoints related to joint and skin disease, physical function, health-related quality of life consistently showed robust and clinically relevant efficacy of secukinumab in the treatment of PsA.

In Study F2306, statistically significant inhibition of progression of structural damage based on the vdHmTSS  at  Week  24  was  shown  for  both  secukinumab  doses.  The  lower  dose  of  10  mg/kg-75  mg demonstrated somewhat better efficacy vs. placebo compared to the higher dose of 10 mg/kg-150 mg (p-values 0.0132 and 0.0212, respectively).

The pivotal studies were stratified according to previous use of TNFα inhibitors. Based on results of Study F2312, in TNFα-IR patients at Week 24, ACR 20 response rates in the secukinumab 75 mg, 150 mg and 300 mg dose groups were 14.7%, 29.7% and 45.5%, respectively, compared with 14.3% in the placebo group.  The  difference  vs.  placebo  was  statistically  significant  for  the  300  mg  dose  level  (p=0.0077). Higher PASI75 and PASI90 rates were also observed with secukinumab 300 mg dose compared to the 150 mg dose, consistent with the phase III psoriasis program. Week 52 efficacy data was consistent with the results obtained at Week 24. Therefore, the recommended dose is 150 mg sc, while the 300 mg dose is  more appropriate for TNFα-IR patients and for patients with concomitant moderate to severe plaque psoriasis. No dose adjustment based on body weight is needed.

## Uncertainty in the knowledge about the beneficial effects

The data in Study F2306 was generated with an iv secukinumab loading regimen that resulted in greater initial exposure.  The role of induction regimen appears however limited in the prevention of progression of structural damage. Nevertheless, Section 5.1 of the SmPC includes a statement that the inhibition of progression of structural damage in PsA has not yet been demonstrated using the subcutaneous loading regimen which is approved for clinical use.

Neither  of  the  pivotal  studies  in  PsA  had  an  active  control  arm.  The  lack  of  active  control  is  partly compensated by the etanercept-controlled psoriasis Study A2303 with a subset of PsA patients, as well as by the responses reported for other biologics studied in similar clinical study settings.

<div style=\"page-break-after: always\"></div>

There  is  also  a  lack  of  dedicated  assessment  of  axial  inflammation,  as  recommended  in  the  EMA  PsA guideline. Considering the overall weight of evidence on the efficacy of secukinumab in both PsA and AS, extrapolation of the clinical benefit in axial involvement in AS to PsA is however considered meaningful.

## Risks

## Unfavourable effects

Infections  were  more  commonly  reported  in  secukinumab-treated  patients  compared  to  placebo.  The imbalance  with  secukinumab  vs.  placebo  was  mainly  due  to  upper  respiratory  tract  infections.  Also candida  infections  and  oral  herpes  infections  were  more  commonly  reported  compared  to  placebo. Infections are included in the RMP as an important identified risk with appropriate warnings also included in the SmPC.

The  increased  incidence  of  candida  infections  was  mainly  due  to  oral  candidiasis  and  vulvovaginal candidiasis  and  consistent  with  the  mechanism  of  action  of  secukinumab  and  knowledge  on  the  IL-17 biology. All candida infections were  mild to moderate  in severity and none  led to treatment discontinuation.

Neutropenia  was  more  common  in  secukinumab-treated  patients  compare  to  placebo.  In  general,  the neutropenia cases were not associated with SAEs or discontinuations. Majority of the neutropenia cases were associated with iv loading regimen, which will not be used in the clinical practice. Neutropenia is included in the RMP as an important identified risk with appropriate warnings in the SmPC.

## Uncertainty in the knowledge about the unfavourable effects

## Effects Table

## Effects Table for Cosentyx in the treatment of psoriatic arthritis (data cut-off: 12 May 2014)

| Effect             | Short Description                                                                                   | Unit               | Active 150mg       | Active 300 mg      | Plac ebo           | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                       | References         |
|--------------------|-----------------------------------------------------------------------------------------------------|--------------------|--------------------|--------------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Favourable Effects | Favourable Effects                                                                                  | Favourable Effects | Favourable Effects | Favourable Effects | Favourable Effects | Favourable Effects                                                                                                                                                                                                                                                                                                        | Favourable Effects |
| ACR 20 1           | %achieving response at Week 24 (primary endpoint) (sc loading regimen as proposed for clinical use) | %                  | 51.0               | 54.0               | 15.3               | Significant effect in the primary endpoint with all secukinumab doses compared to placebo after sc loading (p=0.0200 for 75 mg dose; p<0.0001 for 150/300 mg doses), 150/300 mg doses supported by the secondary endpoints. Study F2312 provides the most relevant efficacy data (posology as proposed for clinical use). | Study F2312        |

## Unfavourable Effects

<div style=\"page-break-after: always\"></div>

| Effect        | Short Description                                           | Unit       | Active 150mg   | Active 300 mg   | Plac ebo   | Uncertainties/ Strength of evidence                                                                                                                                                                                                         | References              |
|---------------|-------------------------------------------------------------|------------|----------------|-----------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| Infections    | Overall rate of infections, SOC Infections and infestations | % 2) IR 3) | 30.0 88.7      | 29.0 95.1       | 25.7 94.2  | Increased incidence of infections during the first 16 weeks, mainly upper respiratory tract infections. No imbalance in the long- term using exposure- adjusted IR. No increased rate of mycobacterial or serious opportunistic infections. | Studies F2306 and F2312 |
|               | Candida infections (HLT)                                    | % 2) IR 3) | 1.0 1.6        | 1.0 3.4         | 0.0 0.0    | Candida infections consisting mainly of oral candidiasis and vulvovaginal candidiasis. All cases mild/moderate in severity. None led to discontinuation.                                                                                    | Studies F2306 and F2312 |
|               | Oral herpes infections (PT)                                 | % 2) IR 3) | 0.0 2.8        | 4.0 5.7         | 1.0 3.8    | Increased incidence of herpes viral infections. No cases of disseminated or CNS herpes.                                                                                                                                                     | Studies F2306 and F2312 |
| Neutro- penia | Neutropenia (PT)                                            | % 2) IR 3) | 0 0.7          | 1.0 1.1         | 1.0 2.9    | Cases of grade 2, and 3 (n=5) neutropenia were not associated with severe/serious infections.                                                                                                                                               | Studies F2306 and F2312 |

1)  ≥20% improvement in the American College of Rheumatology criteria (ACR)

2) % rate (first 16 weeks, only patients with sc loading in study F2312, placebo patients from both studies)

3)  IR = exposure adjusted incidence rate (entire treatment period, from both studies F2306 and F2312), expressed as number of subjects with event per 100 patient-years

SOC = System Organ Class

HLT = High Level Term

PT = Preferred Term

## Benefit-Risk Balance

## Importance of favourable and unfavourable effects

Statistically significant efficacy of secukinumab in the treatment of PsA has been shown with respect to joint  and  skin  disease,  physical  function,  health-related  quality of  life  and  prevention  of progression of structural damage. These results are considered robust and clinically relevant.

Secukinumab provides a novel treatment option for PsA, including the hard-to-treat patients, i.e., TNFαIR population.

The  most  relevant  safety  concerns  of  secukinumab  identified  so  far  are  related  to  mild  infections. Appropriate measures to minimise this risk are included in the SmPC and further information on this issue will be collected as described in the RMP.

## Benefit-risk balance

Efficacy of secukinumab in the treatment of PsA has been demonstrated. The safety profile is favourable based on the data currently available.

<div style=\"page-break-after: always\"></div>

## Discussion on the Benefit-Risk Balance

Clinically relevant efficacy has been shown for secukinumab in the treatment of PsA. These results are considered  robust.  The  overall  safety  profile  of  secukinumab  appears  favourable.  Unfavourable  effects typical  for  biologic  therapies  have  been  observed,  including  infections  and  mild  neutropenia,  but  no increase was observed in the rate of mycobacterial or serious opportunistic infections.

Based on the data available, secukinumab alone or in combination with methotrexate (MTX) is approvable for  the  treatment  of  active  psoriatic  arthritis  in  adult  patients  when  the  response  to  previous  disease modifying anti rheumatic drug (DMARD) therapy has been inadequate is approvable.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following group of variations acceptable and therefore recommends the variations to the terms of the Marketing Authorisation, concerning the following changes:

| Variations accepted   | Variations accepted                                                                                                                           | Type    | Annexes affected   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                | Type II | I and IIIB         |
| C.I.11.z              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | Type IB | None               |

Extension of Indication to include new indication for Cosentyx in the treatment alone or in combination with methotrexate (MTX) of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, and 5.2 of the SmPC are updated in order to update the safety and efficacy information. The Package Leaflet and RMP have been updated accordingly. Furthermore, the due of the final report for the psoriasis registry in the RMP has been amended and minor editorial changes have been introduced throughout the PI.

The group of variations leads to amendments to the Summary of Product Characteristics, Package Leaflet and the Risk Management Plan (RMP).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this group of variations. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of Indication to include new indication for Cosentyx in the treatment alone or in combination with methotrexate (MTX) of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, and 5.2 of the SmPC are updated in order to update the safety and

<div style=\"page-break-after: always\"></div>

efficacy information. The Package Leaflet and RMP have been updated accordingly. Furthermore, the due of the final report for the psoriasis registry in the RMP has been amended and minor editorial changes have been introduced throughout the PI.

## Summary

Please refer to the Scientific Discussion Cosentyx-H-C-3729-II-01 G

## Attachments

1. SmPC, Package Leaflet (changes highlighted) as adopted by the CHMP on 22 October 2015.
2. Rapporteurs initial Assessment Report dated 26 May 2015.
3. Co - Rapporteurs initial Assessment Report dated 26 May 2015.
4. PRAC Assessment Report as endorsed by PRAC on 11 June 2015.
5. CHMP Request for supplementary information as agreed by the CHMP on 25 June 2015.
6. Rapporteur's response Assessment Report dated 28 September 2015.
7. PRAC Assessment Report as endorsed by PRAC on 8 October 2015.
8. Joint Rapporteur/Co-Rapporteur Assessment Report on the responses provided by the applicant, dated 16 October 2015.